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ABSTRACT 
 
MicroRNAs (miRNAs) are small, non-coding RNAs that function as guide molecules in RNA 
silencing. They target both non-coding and protein-coding transcripts, thus, being involved in 
virtually all homeostatic and pathological processes. The biogenesis of miRNAs is under tight 
temporal and spatial control, and their deregulation is associated with multiple human 
diseases. 
Each miRNA targets hundreds of transcripts and most protein-coding genes are miRNA 
targets. Therefore, fine-tuning the expression of hundreds of genes is critical to cells’ 
physiology. Indeed, miRNAs’ confer precision to protein expression, thus offering an 
explanation for the generally observed combinatorial targeting of endogenous genes by 
multiple miRNAs, as well as the preferential targeting of lowly expressed genes. Although, 
the average level of repression induced by miRNAs is modest, the repression amongst 
individual cells varies considerably, which is a direct consequence of gene expression as a 
stochastic process.  
MiRNAs have emerged as key gene regulators in diverse biological pathways involved in 
Prostate Cancer (PCa). PCa is the most common non-cutaneous cancer and a leading 
cause of cancer-related death in the Western World. Due to the clinical and molecular 
heterogeneity of the PCa, the role of miRNA remains elusive. Although deregulation of 
miRNA expression has been implicated in the development and progression of PCa, its 
precise role in prostate carcinogenesis is mostly unknown. Nevertheless, miRNAs have been 
envisaged as putatively useful for PCa management, specifically as diagnostic and 
prognostic biomarkers, as well as targets for miRNA-based therapeutics.  
Globally, this Thesis aimed to: 1) understand the extension of miRNA deregulation in PCa, 2) 
investigate whether there is specific miRNAs’ methylation-repression patterns, 3) understand 
the role of specific miRNAs in PCa biology and 4) identify potential PCa-specific biomarkers 
based on miRNAs methylation aberrations. 
The results obtained in this Thesis proved that miRNAs are globally down-regulated in PCa 
compared to morphologically normal prostate tissues, due to: (i) decreased expression (and, 
arguably, activity) of the core genes involved in miRNA biogenesis (DROSHA, DGCR8, 
DICER); (ii) aberrations in the DNA methylation landscape of miRNA promoters; (iii) altered 
chromatin conformation in the loci of certain miRNAs.  
Moreover, in vitro studies showed that restoration of miRNAs expression caused attenuation 
of the malignant phenotype of PCa cell lines, indicating that miR-130a, miR-130b~301b 
cluster and miR-152 as new PCa tumor-suppressor miRNAs. Furthermore, this Thesis 
showed that miR-130a and miR-152 seems to act by fine-tuning target genes’ expression, 
whereas the cluster miR-130b~301b controls specifically cellular senescence signaling 
x 
pathways. Interestingly, miR-130a and miR-130b~301b cluster are part of the same miRNA 
family. The phenotype obtained by their in vitro manipulation was rather similar, suggesting 
that they might act as cooperative functional units. These results support the functional 
cooperation and specialization of the members of this family, as exemplified by the co-
regulation of DNA Damage and Senescence-related genes.  
Taking advantage of the DNA methylation dataset and a miRNA profile, an integrative 
approach was conceived. Thus, miR-152 was found to be downregulated and 
hypermethylated in PCa. Restoration of miR-152 reverted the malignant phenotype of PCa 
cell lines and, importantly, promoted cell cycle arrest at S and G2/M. TMEM97 and NOL4 
were identified as targets of miR-152. 
Finally, the value of miRNAs promoter methylation as PCa biomarkers was also evaluated. 
Using several patients’ cohorts, miR-193b’s hypermethylation was unveiled as a promising 
biomarker for non-invasive detection of PCa in urine samples. In parallel, higher miR-34b/c 
or miR-129-2 methylation levels independently predicted worse outcome.  
Overall, the work presented in this Thesis provides evidence that miRNAs are dynamically 
regulated in PCa carcinogenesis, and may serve as biomarkers for non-invasive or minimally 
invasive diagnosis and prognostication of PCa patients. Furthermore, the multiple pathways 
regulated by miRNA restoration described in this Thesis not only proved the functional 
relevance of specific miRNAs in PCa but also set the stage for a future miRNA-based 
therapeutic strategy. Finally, the datasets generated will help to understand the complex 
biological functions of miRNAs in PCa.  
 
Keywords: microRNA, Non-coding RNAs, Prostate Cancer, Senescence, DNA Damage, 
Cell Cycle, Senescence-Associated Secretory Phenotype, Epigenetics, DNA Methylation. 
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RESUMO 
 
Os microRNAs (miRNAs) são uma classe de RNAs não codificantes, de cadeia simples com 
cerca de 22 nucleótidos de tamanho que actuam como “guias” no silenciamento de genes 
através da degradação de moléculas de RNA mensageiro. Os miRNAs têm como alvo 
transcritos com capacidade de codificar proteína e transcritos não codificantes. Desta forma, 
os miRNAs estão envolvidos – virtualmente – em todos os processos homeostáticos e 
patológicos. O processo de maturação dos miRNAs é regulada de forma muito complexa e, 
quando desregulados, estão associados com diferentes patologias.  
Cada miRNA tem a capacidade de regular um grande número de transcritos, sendo que a 
maioria dos genes que codificam proteína são alvos de miRNAs. Funcionalmente, estes 
controlam a expressão génica através de pequenos ajustes nos transcritos alvo, sendo o 
seu papel fundamental para a fisiologia celular. Os miRNAs conferem precisão à expressão 
proteica, oferecendo assim uma explicação para a abordagem combinatória comummente 
observada de genes regulados por múltiplos miRNAs, bem como uma acção preferencial 
sobre genes pouco expressos. Todavia, o nível de repressão induzido por miRNAs é 
modesto, sendo que a repressão inter-celular varia consideravelmente, o que é uma 
consequência direta da expressão génica como um processo estocástico. 
Os miRNAs posicionam-se como reguladores genéticos fundamentais em diversas vias de 
sinalização envolvidas no cancro da próstata (CaP). O CaP é o cancro não cutâneo mais 
comum em homens e uma das principais causas de morte por cancro no mundo ocidental. 
Devido à sua heterogeneidade clínica e molecular, o papel dos miRNAs permanece 
impreciso. Embora a desregulação da expressão dos miRNAs esteja implicada no 
desenvolvimento e progressão do CaP, o seu papel preciso na carcinogénese da próstata é 
em grande parte desconhecida. No entanto, os miRNAs parecem apresentar valor na prática 
clínica em doentes com CaP, especificamente como biomarcadores de diagnóstico e 
prognóstico, bem como podem ser potenciais alvos para terapêutica.  
Globalmente, os objectivos desta Tese foram: 1) compreender a extensão da desregulação 
dos miRNAs no CaP; 2) investigar se a metilação do DNA é uma das principais causas da 
alteração de expressão dos miRNAs em CaP; 3) caracterizar a função de alguns miRNAs na 
biologia das células de CaP; e 4) identificar potenciais biomarcadores específicos para o 
CaP baseados nos padrões de metilação nos promotores de alguns miRNAs.  
Os resultados obtidos nesta Tese demonstraram que os níveis de miRNAs estão 
globalmente diminuídos em CaP em comparação com tecidos morfologicamente normais da 
próstata, devido a: (i) diminuição da expressão (e, discutivelmente, actividade) dos genes 
envolvidos no processamento dos miRNAs (DROSHA, DGCR8, DICER); (ii) aberrações ao 
xii 
nível da metilação do DNA nos promotores dos miRNAs; (iii) alteração da conformação da 
cromatina nos loci de miRNAs. 
Adicionalmente, estudos in vitro mostraram que a restauração da expressão de miRNAs 
causou atenuação do fenótipo maligno das linhas celulares representativas de CaP, 
indicando o miR-130a, o cluster miR-130b~301b e o miR-152 como novos miRNAs com 
função onco-supressora em CaP. Além disso, os resultados indicam que o miR-130a e miR-
152 actuam como moduladores da expressão de genes-alvo, enquanto o cluster miR-
130b~301b controla especificamente as diferentes vias de sinalização envolvidas na 
senescência celular. 
Curiosamente, o miR-130a e o cluster miR-130b~301b fazem parte da mesma família de 
miRNAs. O fenótipo obtido com a sua manipulação in vitro foi bastante semelhante, 
sugerindo que eles podem actuar como unidades funcionais cooperativas. Estes resultados 
suportam a cooperação funcional e a especialização dos membros desta família, como 
exemplificado pela co-regulação dos genes relacionados com a reparação danos no DNA e 
senescência. 
Aproveitando o conjunto de dados gerados para a metilação do DNA e o perfil de expressão 
dos miRNAs, foi concebida uma abordagem integrativa desta informação. Deste modo, 
verificou-se que o miR-152 estava sistematicamente sub-expresso em CaP e parte deste 
resultado é mediado pela hipermetilação do seu promotor. A restauração de miR-152 
reverteu o fenótipo maligno das células de CaP e, importantemente, promoveu a paragem 
do ciclo celular em S e G2/M. Os genes TMEM97 e NOL4 foram identificados como alvos do 
miR-152, sugerindo, assim, que o miR-152 é capaz de controlar o desenvolvimento e 
progressão de CaP em diferentes etapas da carcinogénese. 
Finalmente, foi avaliado se a metilação do promotor de alguns miRNAs tem potencial para 
identificar novos biomarcadores de CaP. Usando várias coortes de doentes, a 
hipermetilação do promotor do miR-193b revelou bastante potencial como biomarcador para 
a detecção não invasiva de CaP em amostras de urina. Paralelamente, níveis elevados de 
metilação de miR-34b/c ou de miR-129-2 revelaram ser factores independentes de mau 
prognóstico. 
Em suma, o trabalho apresentado nesta Tese fornece evidências de que os miRNAs são 
dinamicamente regulados na carcinogénese prostática e podem servir como biomarcadores 
para o diagnóstico não invasivo ou minimamente invasivo e prognóstico dos doentes de 
CaP. Além disso, as múltiplas vias reguladas pelos miRNAs descritos nesta Tese não só 
provou a relevância funcional dos miRNAs no CaP, mas também pode ajudar definir uma 
futura estratégia terapêutica baseada em miRNAs. Finalmente, os conjuntos de dados 
gerados ajudarão a um melhor entendimento das complexas funções biológicas dos 
miRNAs em CaP. 
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PART I – INTRODUCTION 
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CHAPTER 1 – AN OVERVIEW OF THE TRANSCRIPTIONAL DYNAMICS OF 
MAMMALIAN CELLS 
 
 
1. Challenging the Central Dogma of Molecular Biology 
In the 50 years following the discovery of DNA in the 1950s, Molecular Biology was based on 
a unifying principle: the central dogma of Molecular Biology. Francis Crick framed the central 
dogma in 1958, only 5 years after the basic structure of DNA was reported (1, 2). This model 
explained the relationship between the two nucleic acids and proteins. The Central Dogma 
postulated that once information has passed into protein it cannot get-out again, flowing uni-
directionally. Essentially, this concept advocates that information’s transfer from nucleic acid 
to protein, but transfer from protein to protein, or from protein to nucleic acid cannot occur. 
Herein, information means the precise sequence’s determination of nucleic acid’s bases or 
protein’s aminoacid residues (1). Thus, the central dogma of biology postulates that DNA is 
transcribed into RNA and that RNA is translated protein. 
This initial model shortly was improved. In addition to DNA and proteins, RNA, the carrier of 
genetic information was also added (2, 3). The Enzymatic Synthesis of Ribonucleic Acid 
gave the Noble Prize of Medicine to Severo Ochoa in 1959. Thus, transfer of genetic 
information was possible from DNA to RNA, RNA to protein, RNA to DNA, and DNA to 
protein (2), although Crick believed that transfer of genetic information from RNA to DNA or 
DNA directly to protein was unlikely (1, 2, 4).  
However, the advent of high-throughput sequencing methods has assisted the exploration of 
transcriptomes in unprecedented depth and in an unbiased way. It is now evident that 
whereas less than 2% of the genome encodes proteins, at least 75% is actively transcribed 
into non-coding RNAs (5). Across all domains of life, a profusion of non-canonical transcripts 
has been detected in the transcriptome. They are clearly distinguished as they are non-
coding, are not demarked by gene boundaries and are, for instance, recurrently antisense. 
As the occurrence of these transcripts is widespread, this phenomenon has been described 
as pervasive transcription. Thus, transcription is not restricted by the position of annotated 
protein-coding genes but can be initiated in almost any genomic context, i.e., the majority of 
its bases are associated with at least one primary transcript, mostly ncRNAs (6). However, it 
should be noticed that pervasive transcription is also subjected to skepticism: whether the 
detected RNAs are artifacts of the technologies used to identify them; simply inevitable 
byproducts of transcription from accessible, activated chromatin; and the biological 
significance of such transcripts (7). Nonetheless, multiple evidence from loss- and gain-of-
function studies has demonstrated that ncRNAs reproducibly perturb in vitro physiology (8, 
9). Although the functions of these transcripts, is largely unknown (10, 11), they seem to be 
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critical regulators of cell and developmental biology (10). RNA has been a powerful 
regulatory molecule, with numerous classic examples of RNA-mediated roles in splicing, 
translation, and genomic imprinting (10). Therefore, the pervasive transcription is unveiling a 
vast catalog of transcribed non-coding genes representing a wealth of different regulatory 
RNA elements that contribute to a physiological function primarily mediated through an RNA-
based mechanism.  
 
2. Non-coding RNAs 
The biggest surprise of the postgenomic era has been the massive number and diversity of 
transcriptional products arising from the previously presumed ‘dark matter’ portion of the 
genome. This pervasive impact of genome structure is now emerging. It includes an 
overabundance of small regulatory RNAs and a plethora of polyadenylated and 
nonpolyadenylated long non-coding RNAs (lncRNAs) that are antisense, intronic, intergenic 
and overlapping with respect to protein-coding loci (12). The ncRNAs are classified by an ad 
hoc size threshold cutoff. The distinction of two separate classes is somewhat arbitrary and 
might reflect technical bias rather than a true biological bimodal length distribution. LncRNA 
refers to a transcript >200 nucleotides in length that does not appear to contain a protein-
coding sequence, while a small RNA is a transcript of 20 to 200 nucleotides. The abundance 
of lncRNA genes outnumbers protein-coding gene (13), and more than 90% have no 
significant peptide products (14). However, a tiny percentage of transcripts originally 
annotated as lncRNAs, are able to encode cryptic micropeptides (15, 16). The catalog of 
non-coding transcripts has grown enormously over the past few years, in large part due to 
the identification of extensive lncRNA genes (17). These lncRNAs elicit functional outcomes 
through interactions with DNA, chromatin, signaling and regulatory proteins, and a variety of 
cellular RNA species. Mechanistically, lncRNAs can act at neighboring intrachromosomal 
genes in cis (18) or targeting of genes in trans (19) on different chromosomes. 
Several dozen classes of small ncRNAs have been proposed (20). These include well-
characterized housekeeping ncRNAs (e.g. transfer RNA and some ribosomal RNA) essential 
for fundamental aspects of cell biology or splicing RNAs (21). Moreover, other small 
infrastructural and regulatory RNAs are now being characterized. A significant proportion of 
coding and non-coding transcripts are processed into steady-state stable RNAs shorter than 
200 nucleotides (5). These precursors include transfer RNA, microRNA, small nuclear RNA 
and small nucleolar RNA (tRNA, miRNA, snRNA and snoRNA, respectively).  
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2.1 Small RNAs 
Currently, more than 7,000 small RNAs are annotated by GENCODE, 85% of which 
correspond to four major classes: small nuclear (sn)RNAs, small nucleolar (sno)RNAs, micro 
(mi)RNAs and transfer (t)RNAs (5). The distribution of annotated small RNAs varies 
markedly between cytosolic and nuclear compartments (22). The small RNA classes 
enriched in each compartment depend on their functions. Thus, whereas miRNAs and tRNAs 
are in the cytosol, snoRNAs are in the nucleus. Interestingly, snRNAs are equally abundant 
in both the nucleus and the cytosol (4). Apart from this abundant small ncRNAs, the diversity 
of small ncRNAs has, perhaps, grown the most. Several dozen classes of small ncRNAs 
have been proposed, including splicing RNAs (small nuclear RNA (snRNAs)), and a variety 
of recently-observed RNAs associated with protein-coding gene transcription. It includes tiny 
transcription-initiation RNAs, promoter-associated short RNAs, termini-associated short 
RNAs, 3’UTR-derived RNAs, and antisense termini-associated short RNAs (5, 21).  
The use of small RNA sequencing allowed the identification of previously unannotated small 
RNAs (5). These newly, low copy numbers, small RNAs are associated with promoter and 
terminator regions of annotated genes (promoter-associated short RNAs (PASRs) and 
termini-associated short RNAs (TASRs)), and their position relative to transcription start sites 
(TSS) and transcription termination sites.  
The transcriptome resolution obtained from RNA-sequencing detected an accumulation of 
reads at the start of snoRNAs and at the guide and passenger sequences of annotated 
miRNAs, both in the nucleus and cytoplasm (23).  
The ENCODE project was also able to establish short RNAs’ genealogy. Globally, 27% of 
annotated small RNAs are mapped within 8% of protein-coding and 5% within 3% of lncRNA 
genes (23). Overall, about 6% of all annotated long transcripts overlap with small RNAs and 
are probably precursors to these small RNAs (23). Although most of these small RNAs 
reside within introns, exons from lncRNAs are comparatively enriched as hosts for snoRNAs 
(23). Additionally, 8.4% of GENCODE annotated small RNAs map are within novel intergenic 
transcripts derived from non-polyadenylated RNAs, with most overlapping annotated tRNAs 
(23). As expected, several long RNAs, both novel and annotated, seem to have dual roles, 
as functional (protein coding) RNAs, and as precursors for many important classes of small 
RNAs (23). To date, the most extensively studied small RNAs in cancer are microRNAs.  
 
2.1.1 microRNAs  
Numerous forms of small non-coding RNAs (sncRNAs) have evolved in eukaryotes to 
suppress undesirable genetic elements and transcripts, in order to maintain cell and genome 
integrity (24). SncRNAs are RNA sequences from 20-30 nucleotides in length that are 
intimately associated with Argonaute family proteins (AGO), acting as guides of AGO 
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proteins to RNA targets (24). Although the number of AGO proteins varies across species, 
four paralogues thought to have overlapping activities are known in human and mice. The 
current model, classify these sncRNAs into three different classes: miRNA, small interfering 
RNAs (siRNA) and PIWI-interacting RNA (piRNA). MiRNAs were discovered by Victor 
Ambros in 1993 (25). The first to be discovered were the lin-4 and lethal-7 (let-7), which are 
components of the gene regulatory network that controls the timing of Caenorhabditis 
elegans larval development (25-27). Both lin-4 and let-7 were found to bind the 3’ 
Untranslated Region (3’UTR) of their respective targets, lin-14 and lin-41, respectively. 
Furthermore, several studies demonstrated that the recruitment of the miRNA-induced 
silencing complex (miRISC) to messenger RNA (mRNA) targets reduced the output of the 
target proteins, thus impacting in cell homeostasis. The discovery of let-7 and its 
conservation from worms, flies and humans, emphasized the functional significance of 
miRNA-dependent gene regulation. 
It is now estimated that miRNA genes comprise from 0.5-2% of all genes in worms, flies, and 
mammals (28). MiRNAs function as guide molecules in RNA silencing, targeting both protein-
coding transcripts and lncRNAs (24). MiRNAs repress gene expression by binding (mostly) 
to complementary sequences in the mRNAs 3ʹUTR to target them for degradation and 
thereby prevent their translation (24).  
The human genome comprises more than 2000 hairpin structures that generate detectable 
small RNAs, although the genuineness and functional importance of several miRNAs 
candidates remains to be proved (29). Selective pressure during evolution not only selected 
miRNAs with a critical role in sculpting gene regulatory networks, but apparently have 
maintained the paring between miRNAs and the vast majority of all human transcripts (30). 
Considering that more than 500 bona fide individual miRNA genes have been identified (31), 
that an individual miRNA can target hundreds or thousands of different mRNAs and that an 
individual mRNA can be simultaneously suppressed by multiple different miRNAs, support 
that biological processes are subject to miRNA dependent regulation (32). 
The last years have witnessed the acknowledgment that miRNAs are cancer genes (33). The 
biogenesis of miRNAs is under tight cellular, temporal and spatial control, and their 
deregulation was associated with several human diseases, particularly cancer (24, 32). They 
often are classified as oncomiRNA (an over-expressed miRNA with oncogenic activities) or 
tumor-suppressor miRNAs (when a miRNA expression is down-regulated and unable to 
repress a oncogene) (33). Using disease models, both loss-of-function and gain-of-function 
experiments in human cancer cells, mouse xenografts, transgenic mouse models and 
knockout mouse models demonstrated that miRNAs have key roles in cancer initiation, 
progression and metastasis (32, 33), including in Prostate Cancer (PCa).  
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The data available supports a model in which miRNA expression is globally suppressed in 
cancer compared with normal tissue, suggesting that when miRNA biogenesis is disrupted it 
accelerates neoplastic transformation (32, 34). Indeed, miRNAs may control cell proliferation, 
differentiation, apoptosis, metabolism, genome stability, inflammation, invasion and 
angiogenesis to affect tumor development (28, 32, 33). These pathways might also represent 
putative therapeutic strategies for different types of cancer.   
Comparative genomics studies indicate that a miRNA binds to hundreds of miRNA Response 
Elements (MRE) across the transcriptome (as well a given RNA is targeted by multiple 
miRNAs) (35). However, when the expression of the miRNA is perturbed most predicted 
miRNA targets undergo small changes at mRNA and protein levels (36, 37). Taking together 
these observations generated the idea that rather than acting as genetic switches – where 
strong repression of one or few targets results in a clear phenotypic outcome – most miRNA 
act as rheostats, fine tuning the expression of hundreds of genes (36, 37) to reinforce cell 
fate decisions brought about through other mechanisms (28).  
Most of the miRNA targets show evidence that they are regulated by depletion of mRNA 
levels. Thus, mRNA destabilization is the major effect of miRNAs by the time that substantial 
target gene repression arises (30). Interestingly, functionally critical genes that are spatially 
or temporally expressed are stringently regulated by miRNAs. Longer 3'UTRs are preferred 
as they have a higher average density of MRE, suggesting that their evolutionary selection. 
In its turn, housekeeping genes, however conserved, are selected to have shorter 3'UTRs 
and therefore less subjected to miRNA-mediated regulation (28).  
Globally, miRNAs shape the dynamics of target gene expression in an intricate, tight 
process, involving multistep processing and requiring multi-protein complexes responsible for 
accurate miRNA function. Any disruption in miRNA biogenesis will impair cell homeostasis 
and leading to disease (28, 32).  
Moreover, cancer-associated changes in miRNA’s expression patterns are evolving as 
promising diagnostic markers that often correlate with clinical and pathological parameters 
used in clinical practice (32, 33). 
 
2.1.2 microRNAs as fine tuners of gene expression 
Gene expression is a stochastic process. Predictions indicate that each miRNA targets 
hundreds of genes and the majority of protein-coding genes are miRNA targets. Some 
miRNAs are expressed as high as 50,000 copies per cell; and by their sequence 
conservation, with some miRNAs conserved from sea urchins to humans (31). Therefore, 
miRNAs can regulate a large variety of cellular processes, from differentiation and 
proliferation to apoptosis. MiRNAs also confer robustness to systems by stabilizing gene 
expression during stress and in developmental transitions (31, 37). MiRNAs can generate 
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thresholds in target gene expression and mediate feedforward and feedback loops in gene 
networks (38). 
However, miRNAs only marginally decrease the mean expression of most targeted proteins, 
leading to speculation about their role in the variability, or noise, of protein expression. It is 
now accepted that miRNAs decrease protein expression noise for lowly expressed genes but 
increase noise for highly expressed genes (37). Therefore, genes that are regulated by 
multiple miRNAs show more marked noise reduction. These observations suggest that 
miRNAs confer precision to protein expression and thus offer plausible explanations for the 
commonly observed combinatorial and overlapping targeting of endogenous genes by 
multiple miRNAs, as well as the preferential targeting of lowly expressed genes (37). 
It is accepted that inactivation of a miRNA results in very modest de-repression of its direct 
targets, typically less than two fold even for highly abundant miRNAs (36). These differences 
are well within the range that could be attributed to fluctuations of gene expression between 
two genetically identical cells or between individuals (39). For most genes, such modest 
changes in expression can be well tolerated by the organism, which might explain why 
genetic inactivation of miRNAs often does not have obvious phenotypic consequences (28). 
Globally, these observations suggest that rather than acting as genetic switches - i.e. robust 
repression of one or few targets results in a strong phenotypic outcome (40, 41) – most 
miRNA act as rheostats, fine-tuning the expression of hundreds of genes to reinforce cell fate 
decisions caused through other mechanisms (39, 42, 43). Altered miRNA levels might lead to 
widespread de-repression of target genes and an unbuffering of gene expression. In cancer 
biology, such deregulation might be associated in increased genomic noise and an 
associated increase in the clonal heterogeneity of cancer cells. 
 
2.1.3 Functional redundancy among family members 
One notable aspect of miRNA genes is that a large number display paralogs in the genome. 
Paralog miRNAs arise both from tandem and nonlocal gene duplication events, which give 
rise to either duplication of sequences in the same transcript – thus originating miRNA 
clusters – or on distant loci, typically on different chromosomes (31, 44). These miRNAs not 
only retain a high degree of sequence homology, but also share the same seed sequence. 
Hence, and by convention, they are grouped into ‘miRNA seed families’ (45). Notably, 
roughly one third of human miRNA genes are categorized into families based on sequence 
similarity (46). As paralog miRNAs share the same seed sequence, they are likely to have 
similar correspondences to target genes. When expressed in the same cells, these 
associated miRNAs can co-regulate targets, leading to higher levels of repression than those 
that could be achieved by each miRNA individually (28). Thus, the existence of miRNAs with 
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redundant functions suggests that, in particular conditions, numerous members of the family 
need to be deleted to obtain a clear phenotypic alteration (28).  
Polycistronic miRNA clusters are a common feature of vertebrate genomes. Up to two-thirds 
of the genome are encoded in polycistroninc clusters, i.e., they are co-transcribed with their 
cluster partners. Such co-regulated miRNAs seem to have a propensity to target the same 
gene or different genes in the same pathways. Overall, this emphasizes the pathway-
regulating roles of these miRNAs (e.g. miR-200 family targeting of actin cytoskeleton). 
Moreover, in a recent study, it was exposed evidence that strong functional specialization 
and cooperation can coexist among members of the same polycistronic cluster (47).  
 
2.1.4. The transcriptional landscape aberrations of prostate cancer 
The complex eukaryotic transcriptome is dynamically transcribed [16]. Indeed, there are 
many different RNA species generated by pervasive transcription, including mRNAs, 
lncRNAs and sncRNAs [16]. The coding potential defines a mRNA as able to translate the 
DNA sequence information into an aminoacid sequence, forming a protein. This is the 
boundary used to distinguish between a protein-coding gene (PCG) and ncRNAs. 
MiRNAs have been characterized either as tumor-suppressors or oncogenes, varying on the 
deregulated downstream targets. A growing frame of literature has investigated the biology of 
miRNA deregulation in PCa. Comparative genomics analyses and high-throughput 
experimental studies indicate that a miRNA binds to a multitude of sites across the 
transcriptome, in an intricate regulatory mechanism. Advances in experimental and 
computational approaches are revealing not just cancer pathways controlled by single 
miRNAs but also interlinked regulatory networks controlled by multiple miRNAs, which often 
engage in reciprocal feedback interactions with the targets that they regulate. Thus, miRNAs 
can establish thresholds and increase the coherence of the expression of their target genes, 
as well as reduce the cell‑ to‑ cell variability in target gene expression. Owing to recent 
developments in sequencing technologies, surveying other ncRNAs’ molecular mechanisms 
are now providing the tools to functionally interpret these cancer-associated transcripts, 
making these genes attractive targets for therapeutic intervention in PCa management.  
The following review, entitled “Deciphering the function of non-coding RNAs in prostate 
cancer”, summarizes and compares the multitude of ncRNA aberrations in PCa. This is an 
attempt to characterize the most relevant ncRNA elements, and provide evidence that the 
non-coding transcriptome is functionally relevant, especially miRNAs, for PCa 
carcinogenesis. 
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Abstract  
The advent of next-generation sequencing methods is fuelling the discovery of multiple 
noncoding RNA transcripts with direct implication in cell biology and homeostasis. This new 
layer of biological regulation seems to be of particular importance in human pathogenesis, 
including cancer. The aberrant expression of ncRNAs is a feature of Prostate cancer, as they 
promote tumor-suppressive or oncogenic activities, controlling multicellular events leading to 
carcinogenesis and tumor progression. From the small RNAs involved in the RNAi pathway 
to the long noncoding RNAs controlling chromatin remodeling, alternative splicing and DNA 
repair, the noncoding transcriptome represents the significant majority of transcriptional 
output. As such, ncRNAs appear as exciting new diagnostic, prognostic, and therapeutic 
tools. However, additional work is required to characterize the RNA species, their functions, 
and their applicability to clinical practice in Oncology. In this review, we summarize the most 
important features of ncRNA biology, emphasizing its relevance in prostate carcinogenesis 
and its potential for clinical applications.  
Key Words: ncRNA, microRNA, lncRNA, Prostate Cancer, Transcription. 
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1. Introduction 
Following the central dogma of Molecular Biology, DNA is transcribed into messenger RNAs, 
which in turn serves as the guide for protein synthesis (1, 2). Although exceptions to this rule 
were known to occur, in the form of transfer RNAs and ribosomal RNAs for a long time (3, 4), 
only over the last few years’ evidence emerged that RNA displayed functional roles beyond 
the messenger between DNA and protein. It is now widely accepted that RNA plays a key 
role in the regulation of genome organization and gene expression (5, 6). Multiple studies 
have demonstrated that the vast majority of the human genome is dynamically and 
differentially transcribed to produce multiple and complex non-coding RNAs (ncRNAs), i.e., 
RNA transcripts that do not encode for a protein but rather act as regulatory RNAs, in a 
phenomenon called pervasive transcription (2, 7-9).  
The human genome comprises more than 3.2 billion nucleotides that unfolded correspond to 
more than 2 meters of linear DNA, which is packed into three-dimensional structures in the 
nucleus of each cell (10). However, the part of the genome that represents protein-coding 
genes is approximately only 2-3%, while a vast and diverse plethora of ncRNAs originate 
from the remaining nucleotides in the genome (5, 10). Current ENCODE predictions suggest 
that ~80% of the genome's DNA is transcribed into RNA, and contribute to the overall 
estimates of 80% of the genome being biochemically active/functional (11). Although these 
include some functionally well characterized small and long ncRNAs (11-15), it has been 
hypothesized that their abundance and sheer complexity alone is reason enough to believe 
that they must play major regulatory roles in complex organisms. Furthermore, because such 
complexity is not the result of the amount of synthesized proteins, it should represent the 
extent and nature of genome regulation (12, 16). However, caution should be taken when 
considering those transcribed DNA elements as functional players. Multiple lines of evidence 
indicate that this genome wide transcription is a stochastic process rather than a sign of 
function per se (17, 18). Indeed, any given DNA element can be transcribed when it is 
associated with specific histone marks, binds to transcription factors and is located in an 
open chromatin area (11). Transcription is certainly a prerequisite for a genetic element to be 
functional but it is not synonymous of that condition (18). Further, if one looks at the term 
‘function’ from an evolutionary standpoint and assumes that a putative undetected function of 
98% of the human genome is not a human specific trait, it might be argued that a given DNA 
element with an important function would possibly show significant signs of selective 
pressure (i.e., sequential conservation in related organisms) to maintain this functionality 
over evolutionary time as demonstrated for a very limited number of long ncRNAs (lncRNAs) 
(19). Comparative studies showed that broadly conserved lncRNAs share a short and 5’-
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biased patches of conserved sequence (20). Moreover, lncRNA structure is considerably 
renewed during evolution, in part due to exonization of transposable elements (20).  
Nevertheless, an ever-increasing number of novel classes of small and long ncRNAs are 
being described, regardless of its homology to that of any related organism or demonstrated 
function. Driven by recent paradigm shifts in the appreciation of genomic architecture, 
regulation and transcriptional output, this seems a valid approach to many researchers. 
Many of these novel ncRNAs are able to interact with DNA, RNA and proteins. Some take 
part in diverse structural, functional and regulatory activities, controlling nuclear organization 
and transcription, post-transcriptional and epigenetic regulation (10, 16). This expanding 
inventory of ncRNAs is implicated in a broad spectrum of processes including organ 
homeostasis and pathogenesis. This growing index of ncRNAs is fuelled by the discoveries 
of large-scale consortia aiming to dissect the functional genomic elements such as ENCODE 
and FANTOM (5). These projects exposed the complexity and plasticity of the genome: it 
encompasses not only protein-coding genes with multiple transcription start sites, alternative 
promoter and enhancer elements, splicing initiation and donor sites, as well as variable 3ʹ-
untranslated regions (UTRs), but also an unpredictably large number of ncRNAs (5). These 
display numerous regulatory functions and similarly serve as substrates for transcriptional 
and post-transcriptional diversification (12, 16). The advent of sequencing technologies 
revealed that the vast majority of the genome is transcribed either in sense or antisense and 
it is also expressed in a highly cell type-, subcellular compartment-, and developmental 
stage-specific manner (21). The current view of RNA transcription is that each nucleotide can 
contribute to context-dependent transcription, mediated by specific RNA polymerases, 
ultimately giving rise to numerous and overlapping transcripts (21).  
Several reports shed light on the global deregulation of noncoding transcriptome that occurs 
in cancer cells. One of the best examples is the overexpression of lncRNA HOTAIR in breast 
cancer. HOTAIR reprograms breast cells’ epigenome in a Polycomb repressive complex 2 
(PRC2)-dependent manner, contributing to increased invasiveness and metastasization (22). 
Recently, it was shown that intronic RNA may serve as molecular scaffold for epigenetic 
regulation through recruitment of PRC2 proteins to specific gene loci (23). This misregulation 
of RNA-protein interactions ultimately leads to tumor formation (23). Interestingly, R-loop-
formation and head-to-head antisense transcription are known to be involved in 
transcriptional activation in cancer (24). However, one the first hints on ncRNAs involvement 
in cancer was the deletion and concomitant down-regulation of miR-15 and miR-16 in chronic 
lymphocytic leukemia (25). The de-regulation of some PIWI-interacting RNAs may also 
contribute to breast cancer-specific biology, possibly by remodeling the cancer epigenome 
(26). Taken together, these body of evidence sets ncRNA as critical components of cancer 
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biology: ncRNAs are cancer-related genes due to their potential tumor suppressive and/or 
oncogenic functions (27).  
 
2. The diversity of non-coding RNAs in humans  
 
According to its size, ncRNAs are classified in two main families: lncRNAs, corresponding to 
transcripts with over 200nt that does not appear to contain a protein coding sequence, and 
small ncRNAs (sncRNAs), when the RNA sequence contains less than 200nt (12). The 
ncRNAs localize both to the nucleus and cytoplasm, and may be found in exosomes and 
other microvesicles, present in bodily fluids such as urine, blood, and seminal fluid, although 
the abundance and activity of ncRNAs in exosomes remains unclear (28). Exosomes are 
released from tumor cells and may transfer proteins and RNA across cells. Thus, it is 
tempting to speculate whether in the PCa microenvironment, miRNAs (the most commonly 
studied ncRNA in exosomes) may be transferred among stromal cells and cancer stem cells, 
although it is not clear how miRNAs reassemble into a functional miRISC upon import into 
other cells.  
Moreover, circulating ncRNAs in serum, plasma or urine, although at low levels, may provide 
new opportunities for biomarker development (29).  
 
a. Small non-coding RNAs 
Small ncRNAs differ from lncRNAs by its length and are typically classified according to 
different biogenesis pathways and genomic origins (Table1). Classically, sncRNAs include all 
transfer RNAs (tRNAs), some ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs), 
small nucleolar RNAs and its derivatives, microRNAs (miRNA), short interfering RNAs and 
piwi-interacting RNAs (30). More recently, several other small RNAs associated with protein-
coding gene transcription and splicing regulation, such as transcription initiation RNAs 
(tiRNAs), promoter-associated short RNAs, termini-associated short RNAs, 3’-untranslated 
region-derived RNAs and antisense termini-associated short RNAs have been added to this 
class (30, 31).  
 
i. microRNAs 
Presently, sncRNAs involved in post-transcriptional regulation of target RNAs via the RNAi 
pathway, such as miRNA, siRNA and piRNA, are considered the most biologically relevant 
(32). Owing to its involvement in human diseases such as cancer and its potential as disease 
biomarkers, miRNAs are undoubtedly the best-studied sncRNA class. Mature miRNAs are 
typically ~22 nucleotide single-stranded RNAs (ssRNA), canonically derived from longer 
primary transcripts (pri-miRNAs) which are processed to intermediate precursor-miRNAs 
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(pre-miRNAs) by DROSHA-DGCR8 microprocessor complex (33). These hairpin-precursors 
are exported from the nucleus to the cytoplasm, via exportin 5 (XPO5), where the terminal 
loop region of the hairpin is removed by DICER/TRBP2 (34), resulting in a double-stranded 
mature/star RNA molecule (dsRNA) (Figure 1) (35). Both Drosha and Dicer are RNase-Type 
III proteins and leave characteristic 2nt offsets on their substrate that can be used for 
bioinformatics description of miRNAs (36). While the canonical microRNA biogenesis and 
action model is being constantly refined, Drosha (37) and Dicer (38) independent biogenesis 
mechanism have been described, but they represent rare exceptions. After the canonical, 
multistep processing, typically only one of the strands (mature miRNA) is loaded by 
Argonaute proteins and coupled with diverse components of the RNA-induced silencing 
complex (RISC). Constrained by the structure of the Argonaute protein, only 7 nucleotides 
(Position 2-8) of the mature miRNA are exposed (39). This so-called “seed region” defines 
the range of potential target RNAs, by usually perfect complementarity of these few 
nucleotides. In the vast majority of cases, target-interaction of miRNAs occurs at the 3’UTR 
of protein coding genes (40). 
  
 
 
Figure 1. MicroRNA biogenesis in human cells. 
In the canonical miRNA biogenesis pathway, primary transcripts are processed by Drosha in 
the nucleus and by Dicer in the cytoplasm. Both Drosha and Dicer are RNAse III enzimes 
and produce a hairpin precursor with 2-nt offsets at the 5p and 3p arm. The lncRNA pri-
miRNA displays a 7- methylguanosine cap (m7Gppp), ends with a 3 poly(A) tail, and is 
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transcribed by RNA polymerase II (Pol II). The pri-miRNA contains a stem–loop structure that 
is cleaved in the nucleus by the endonuclease Drosha together with its double-stranded RNA 
(dsRNA)-binding protein parner DGCR8, forming a complex called Microprocessor. The 
output of this trimming is a precursor miRNA (pre-miRNA). It is then exported to the 
cytoplasm by exportin 5 and further cleaved by the endonuclease Dicer, together with its 
dsRNA-binding partner TRBP, to produce a miRNA-miRNA* duplex. Further maturation 
steps reject miRNA* and incorporate the mature miRNA strand into the miRNA-induced 
silencing complex (miRISC). Alternative biogenesis pathways are also acknowledged. 
Mirtrons are short introns with hairpin potential that are spliced and disbranched into pre-
miRNAs and bypass the Drosha cleavage of the canonical miRNA pathway. It lacks a lower 
stem and basal single-stranded segments, which are structural features of primiRNA and 
mediate recognition/cleavage by the DGCR8/Drosha complex. In this pathway, pri-miRNA is 
generated from a branched mirtron structure that undergoes lariat debranching. Another 
alternative biogenesis pathway involves pre-miRNA escaping to Dicer processing after 
nuclear export that is directly loaded into AGO2 protein. AGO2 is responsible for processing 
the pre-miRNA into a single-stranded miRNA (hsa-miR-451) 
 
 
 
Figure 2. miRNA-mediated gene regulation. 
Most plant and a few animal miRNAs direct endonucleolytic cleavage of their mRNA targets 
by perfect complementarity. However, highly complementary sites in animals’ transcriptomes 
are infrequent. Accordingly, miRNA-directed translational repression is indistinguishable from 
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mRNA destruction via decapping and 5 -to-3 decay. Thus, it was suggested that miRNAs 
mainly direct target mRNAs for decay. Nonetheless, the predominant mode of miRNA-
mediated repression may be context-dependent. The core RISC complex is formed by 
Argonaute proteins (1–4 in mamals) and GW182. If mRNA decay and subsequent target 
mRNA destabilization is observed, it suggests that miRISC interacts with the CCR4–NOT 
and PAN2 deadenylase complexes to facilitate deadenylation of the poly(A) tail. Following 
deadenylation, the 5- terminal cap (m7G) is removed by decapping the DCP1–DCP2 
complex, and mRNA decay is affected by an exonuclease. The miRISC inhibits translation 
initiation by interfering with eIF4E-cap recognition and 40S small ribosomal subunit 
recruitment or by antagonizing 60S subunit joining and preventing 80S ribosomal complex 
formation. Furthermore, miRISC might inhibit translation at post-initiation steps by inhibiting 
ribosome elongation. MicroRNA-target interactions might be additionally mapped by 
Ribosome profiling, providing a “snapshot” of all the ribosomes active in a cell at a specific 
time point. MicroRNA manipulation would allow systematic monitoring of cellular translation 
processes and prediction of protein abundance. Coupled with bioinformatic target 
predictions, this would help determine which mRNA is being translated and which region of 
the mRNA is being targeted by the miRNA. 
 
 
miRNA:mRNA interactions that include the RISC-complex then lead to repression or 
degradation of those transcripts and, ultimately, to a moderate downregulation of the 
corresponding proteins (Figure 2) (35).  
While this seemed a straight forward model when miRNA-function was first discovered, 
complexity was quickly added when researchers realized that multiple copies of nearly 
identical and evolutionarily related miRNAs might be found in the genome, that share seed 
sequences and, consequently, the range of targets (miRNA families). Moreover, single 
miRNAs have not only one but hundreds of target RNAs and single protein coding genes are 
targeted by multiple miRNAs (Figure 3).  
Consequently, there is redundancy in microRNA targeting. Indeed, one miRNA may have 
different MRE in the same target RNA. It is, thus, likely that most miRNA act as rheostats, 
fine tuning the expression of hundreds of genes, in intricate gene networks (41). miRNAs 
may, in fact, establish thresholds and increase the coherence of the expression of its targets, 
as well as reduce the cell-to-cell variability in target gene expression (42). miRNAs 
themselves are also subject to modifications, including post-transcriptional RNA editing 
(methylation, uridylation and adenylation) (27, 43) and miRNA tailing (35). 
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Figure 3. Magnitude of microRNA-mediated gene regulation. 
(A) Redundancy of microRNA targeting. Most miRNA act as rheostats, fine tuning the 
expression of hundreds of genes, in intricated gene networks. A single miRNA can target 
multiple transcripts and one specific mRNA is able to be targeted by several miRNAs. 
Indeed, one microRNA may have different MRE in the same target mRNA (miRNA binds to 
the specific MRE in the same color). (B) Competing endogenous RNAs: natural occurring 
miRNA decoys. Linear or circular lncRNAs may function as miRNA decoys to sequester 
miRNAs from their target mRNAs of functionally relevant lncRNAs. Base pairing is also the 
mode of action of ceRNAs. Those lnc-ceRNAs can mask miRNA-binding sites on a target 
mRNA to block miRNA-induced silencing through the RNAinduced silencing complex (RISC). 
The ceRNA comprises both circular RNA (circRNA), lncRNAs, and pseudogenes competing 
for the complementarity with miRNAs. The ultimate impact of these interactions is that 
protein-coding RNAs and non-coding RNAs may crosstalk by competing for miRNA binding 
through their miRNA recognition motifs impairing cell homeostasis. (ORF, open reading 
frame) 
 
 
Deep sequencing data revealed that the majority of miRNAs show length and sequence 
isoforms (isomiRs) with largely unknown functions in cancer biology (43) although it has 
been shown that they can selectively associate with specific RNA-binding proteins (e.g., 
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Argonaute) or exosomes (44) implying context-dependent functional roles. These alterations 
may, thus, affect miRNA maturation and de-regulate target-genes:miRNA interactions 
stoichiometry. 
Despite growing knowledge on miRNAs biology and the ever-increasing amount of sncRNA 
sequencing data, defining what is and what is not a miRNA has become a challenge. This 
uncertainty led to descriptions of several hundreds to several thousands miRNAs in the 
human genome (45, 46). Remarkably, when structural criteria (Box 1) for annotation and 
nomenclature of human miRNA genes were recently updated, only a small proportion of the 
previously reported human miRNAs was recognized, constituting about one third of the 1881 
putative miRNA entries in the widely used online repository miRBase (last updated June 
2014) were considered bona fide miRNAs (36). Consequently, the 523 currently accepted 
human miRNAs represent a solid foundation for future studies but a reassessment of all 
published (but not yet in miRBase listed) miRNAs is desirable to further expand our 
understanding of the human microRNAome. 
 
Box 1. miRNA structural features 
• miRNAs are between 20-26nt long 
• They are genome-encode and derive from hairpin precursor that shows imperfect 
complimentarity (~16 nts)  
• Mature products of both hairpin arms are expressed (mature, co-mature or star 
sequence)  
• Show a 5’ read homogeneity in 90% of the reads 
• Display a 2nt offset on both ends which is a consequence of Drosha/Dicer processing 
• Mature miRNA sequences usually start with A or U. 
• Flanking region upstream shows UG motif at Position 14, loop shows UGU motif at 
the 3’ end of the 5’ arm, and flanking region downstream shows CNNC motif at 
Position 17-18. 
• At least some miRNAs of any higher animal taxon are representatives of 
phylogenetically conserved miRNA families and show very high sequence similarities. 
 
 
ii. siRNAs 
Endo-siRNAs are double-stranded, 21–26 nt, RNAs (dsRNA) that are cleaved from longer 
dsRNA intermediates precursors derived from repetitive sequences, sense–antisense pairs 
(derived from transposons) or long stem-loop structures (47, 48). Endo-siRNAs biogenic 
pathway in humans is DICER-dependent (although Drosha-independent) and involves 
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Argonaute proteins (AGO2) (47, 49). Endo-siRNAs originate from diverse genomic locations 
and have been implicated in post-transcriptional (mRNA cleavage) and epigenetic silencing 
of protein-coding genes and transposon-derived ncRNAs, respectively, as well as other 
unclear functions (49). Contrasting with miRNAs, endo-siRNAs bind only RNA molecules 
containing perfectly complementary sequences (32). 
 
iii. PIWI-interacting RNAs 
Another important family of RNAi comprises piRNAs (50), 24–30 nucleotide ssRNAs, derived 
from single-stranded RNA precursors transcribed from intergenic repetitive elements, 
transposons or large piRNA clusters (47). The biogenesis is Drosha-/DICER-independent 
and requires Piwi proteins of the Argonaute/Piwi family (50, 51). During piRNAs biogenesis, 
piRNA precursors undergo nuclear processing and export, primary or cyclic secondary 
processing (the ping-pong cycle, catalyzed by PIWI proteins MILI and MIWI2) and PIWI 
ribonucleoprotein complex (piRNP) assembly (21, 52). The ping-pong amplification cycle 
generates antisense piRNAs capable of suppressing the transcript of origin (52). The 
assembly of the piRNP is essential to establish post-transcriptional regulation and 
transposon modulation. The piRNAs functions are connected to its origin: if derived from 
transposons, piRNAs are implicated in regulating cognate transposon activity, whereas 
piRNAs resulting from piRNA clusters are involved in gene expression control (52, 53). 
piRNAs were primarily found in germ cells, but recent studies have recognized that piRNAs 
are expressed in somatic cells, including non-tumorous and tumourous tissues from 11 
organs (54). 
Current views suggest that both endo-siRNAs and piRNAs are defensive mechanisms 
against nucleic acid-based parasites, acting as genome’s guardian. However, both endo-
siRNAs and piRNAs are not considered cancer-related genes and, consequently, additional 
data is need to ascertain the true relevance of these ncRNA families in tumorigenesis (54, 
55). Remarkably, these three major families of sncRNAs associate with different AGO protein 
subclades to perform sequence-specific gene silencing (35). 
 
iv. snoRNAs 
Small non-coding RNAs exert far more biological regulation rather than just RNAi-silencing. 
One of the firstly described classes of small ncRNAs was snoRNAs. SnoRNAs are 60-300 nt 
long, mainly localized in the nucleolus, which are encoded by introns of coding and non-
coding genes (56, 57). Their function is to guide RNA for post-transcriptional modification of 
ribosomal RNAs and some spliceosomal RNAs, with a few others involved in nucleolytic 
processing of the original rRNA transcript (57, 58). Two subdivisions of snoRNAs are known 
to exist and are involved in two different types of RNA post-transcriptional modification. The 
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C/D box snoRNAs define the target sites for 2′-O-ribose methylation and H/ACA box 
snoRNAs demarcate the target sites for pseudouridylation (57, 59). C/D box and H/ACA box 
snoRNAs are structurally distinct and those differences make the connection with the binding 
of specific proteins to form the small nucleolar ribonucleoprotein (snoRNP) complexes that 
identify and modify the cognate targets (60). During processing of rRNA, snoRNA guide 
sequences hybridize to the target rRNA and lead the snoRNP to direct the modification of 
ribose 2’-hydroxyl groups or the isomerization of uredines to pseudouridines within pre-
rRNAs (58, 61). Dyskerin is the enzyme recruited by H/ACA box snoRNAs to catalyze 
pseudouridylation at specific ribonucleotides, whereas C/D box snoRNAs activity requires the 
methyltransferase fibrillarin, to mediate the 2′-O-methylation (59). The reactions occur 
generally at conserved sites in nascent rRNAs (58, 61). In addition to catalyze nucleotide 
modification, snoRNP association with pre-rRNAs may also serve to chaperone correct RNA 
folding for rRNA processing and ribosome assembly (28) 
Additionally, snoRNAs have other functions (e.g., Small Cajal body RNAs (62)) and it has 
recently been found that snoRNA loci may also produce miRNA-like small RNAs (63, 64), 
uncovering a putative complex crosstalk between snoRNA-guided RNA processing and RNAi 
pathways. Strikingly, novel evidences implicate snoRNA as controllers of cell homeostasis 
and snoRNA dysregulation may thus contribute to carcinogenesis (57, 65). 
 
v. smallRNAs incertae sedis 
Although the previously described sncRNA families are relatively well understood from a 
biological standpoint, others are still poorly characterized. These include sncRNAs resulting 
from gene regulatory regions and gene boundaries [subclasses of promoter-associated small 
RNAs, such as transcription initiation RNAs (tiRNAs)], termini-associated short RNAs, 
antisense termini-associated short RNAs and splice-site RNA (spliRNA) (66). Others are 
structural components of chromosomes – the centromere-associated RNAs and telomere 
small RNAs. Additionally, some small RNAs are cleavage sub-products of other ncRNAs 
[e.g., transfer RNA-derived RNA fragments (tRFs)] or are derived from different sources 
(mitochondrial ncRNAs and miRNA-offset RNAs) (12, 66). TRFs are one of the most 
abundant sncRNAs, thought to be present in most organisms and generated by 
ribonucleolytic processing of tRNAs by Dicer and RNAse Z (67). The definition of the multiple 
tRFs classes is made according to the position of the tRNA cleavage site that gives rise to 
tRFs. Among the known classes, the most prominent includes 5’- and 3’-tRNA halves 
(cleaved in the anti-codon loop), 5’- and 3’-tRFs (also known as 3’CCA tRF), and 3’U tRFs 
(68). The stress-induction of tRFs results in stress granule assembly and inhibition of protein 
synthesis, linking tRFS to cell homeostasis through control of cell proliferation and mediating 
RNA inactivation through Argonaute engagement (68). 
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To further ascertain the specific biological roles of these enigmatic small RNAs functional 
studies are needed. For instance, when deleting tiRNAs associated with binding sites for 
RNAPOLII CTCF binding factor, there is a dramatic alteration in CTCF binding and 
nucleosome density at genomic loci proximal to sites of tiRNA biogenesis (69). Further 
research is thus required to dissect the evolution, biogenesis and functions of these small 
ncRNAs classes and explore its potential connections with cancer.  
 
 
b. Long non-Coding RNAs 
According to GENCODE annotation v7, there are 20,687 protein-coding genes and in total, 
GENCODE-annotated exons of protein coding genes cover 2.94% of the genome or 1.22% 
of protein-coding exons (5). These data clearly point out that the vast majority of the human 
genome is transcribed not into a biochemically active RNA but rather into a structural, nc 
RNA. Transcripts lacking the capacity to code for a protein, are uniformly abundant in all 
organisms, from yeast to humans (16). There is growing evidence that ncRNA have biologic 
functions and operate through defined mechanisms. However, this compelling abundance of 
ncRNAs triggered the discussion whether ncRNA transcription is the output of transcription 
or ordinary byproducts of the transcriptional system or simply a methodological artifact (12, 
70). Thanks to global efforts, it has been possible to assign specific features to define 
lncRNAs as distinct transcripts: the vast majority of lncRNAs is generated by the same 
transcriptional machinery, similar to other mRNAs, as emphasized by RNA polymerase II 
occupancy and histone modifications associated with transcription initiation (promoter, 
H3K4me3) and elongation (H3K36me3 in the gene body) (16, 30). lncRNAs possess a 5’ 
terminal methylguanosine cap, are often spliced via canonical genomic splice site motifs and 
some of them are polyadenylated whereas other are not. Alternative pathways also 
contribute to the generation of lncRNAs such as non-polyadenylated lncRNAs, likely 
expressed from RNA polymerase III promoters (16). Not only lncRNA regulation is made by 
well-established transcription factors, but also lncRNA are frequently expressed in a tissue-
specific manner (Table 1) (30).  
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Table 1. mRNA/lncRNA convergent and divergent features 
mRNA lncRNA 
Tissue-specific expression 
Form Secondary structure 
Undergo post-transcriptional processing (e.g. 5’CAP, polyadenylation, splicing) 
Important roles in disease 
Protein-coding transcripts Non-protein coding, regulatory functions 
Well conserved across species Poorly conserved 
Present in both nucleus and cytoplasm Predominately in the nucleus 
Around 20-24,000 mRNAs Predicted 3-100 fold of mRNA in number 
Expression level: low to high Expression level: very low to moderate 
 
 
Generally, lncRNAs are expressed in lower amounts compared to their protein-coding 
counterparts, making it difficult to robustly detect in clinical samples (12, 16). Consistent with 
the many regulatory functions assigned to lncRNAs, the low expression may restrict these 
lncRNAs to subtle or redundant roles, or reflect incomplete repression in nonspecific cells 
(16, 66). By comparison to protein-coding genes, lncRNA expression has higher cell 
specificity than proteins, consistent with their proposed role in architectural regulation in 
which each cell displays a unique transcriptome (16). The organization of lncRNA loci in the 
genome revealed transcriptional complexity as lncRNA genes often display large numbers of 
isoforms. Moreover, lncRNAs are often organized in association with protein-coding genes 
and half of the protein coding genes have complementary non-coding antisense 
transcription, further expanding the complexity of genome transcriptional dynamics. lncRNAs 
may be transcribed from intergenic regions [large intergenic ncRNAs (lincRNAs)]; in 
antisense, overlapping, intronic and bidirectional orientations relative to protein-coding genes 
(Figure 4); from gene regulatory regions – UTR, promoters, and enhancers; from specific 
chromosomal domains (telomere) or derived from the mitochondrial genome (12, 16, 66).  
lncRNAs act by a multitude of regulatory mechanisms according to its specific location in the 
cell. lncRNA play a role as organizing factors in the dynamic nuclear organization that 
shapes the cell nucleus through nucleosome remodeling (71, 72). Nuclear lncRNAs might be 
involved in gene-to-gene interactions either locally or in the context of cross chromosome 
interactions, i.e., cis- and trans-mediated regulatory roles, respectively (6, 10)]. 
26 
 
 
Figure 4. Descriptive structure of a long non-coding RNA loci.  
Normally, lncRNAs are defined by their location accordingly to protein-coding genes in the 
vicinity. Antisense lncRNAs transcription initiate inside or 3′ of a protein-coding gene. They 
are transcribed in the opposite direction of protein-coding genes, overlapping any portion of a 
mRNA. Intronic lncRNAs initiate inside an intron of a protein-coding gene in either direction 
and terminate without overlapping exons. Bidirectional lncRNAs are transcripts that initiate in 
a divergent fashion from the promoter of a protein-coding gene; the precise distance cutoff 
that constitutes bidirectionality is not defined but is generally within ~100 base pairs. 
Intergenic lncRNAs (also termed large intervening noncoding RNAs or lincRNAs) are 
lncRNAs with separate transcriptional units from protein-coding genes. A key structural 
feature is that lincRNAs need to be 5 kb away from protein-coding genes. LincRNA genes 
are preferentially found within 10 kb of protein coding genes. These are defined as lncRNA 
transcripts that encompass a protein-coding gene within the “intron” of a lncRNA or as 
lncRNAs that overlap the intron of a protein coding gene. 
 
 
In most cases, nuclear lncRNAs function by recruiting chromatin-remodeling complexes to 
particular DNA loci (22), as it has been shown to form ribonucleoprotein (RNP) complexes by 
recruiting DNA methyltransferases, the Polycomb repressive complex (PRC) 2 (promotes 
H3K27 trimethylation) (22), and H3K9 methyltransferases, resulting in the formation of 
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repressive heterochromatin and transcriptional inhibition. However, lncRNAs are also 
associated with transcriptional activation through engaging of chromatin-modifying 
complexes, including H3K4 methyltransferases, specific transcription factors and recruiting 
POLII (73-75). Nuclear lncRNAs may also bind and sequester transcription factors away from 
their target chromosomal regions, thus indirectly impairing gene expression (76). 
Nonetheless, a significant number of lncRNAs are transferred to and lodged in the 
cytoplasm. Functions of cytoplasmic lncRNAs include protein localization, mRNA translation 
and stability. By recognition of the target by base pairing, they can modulate mRNA at 
different levels: a) base pairing between BACE1 and BACE1-AS induces stabilization of 
target mRNA and increases the BACE1 protein expression (77); b) repression of translation 
(e.g., lincRNA-p21 suppresses target mRNA translation) (78); and c) competition with 
endogenous RNAs (ceRNAs) for miRNA binding (79). This regulatory system in which 
multiple RNAs (both coding genes, pseudogenes and lncRNA) may crosstalk and compete 
for shared miRNA binding, are thought to be relevant for many processes, including cancer 
(79). Moreover circular RNAs (circRNA) also function as miRNA “sponges” (80), and given 
that linear ceRNAs have a short half-life, it provides superior stability and its turnover can be 
controlled by the occurrence of a perfect miRNA binding site (Figure 3B) (81, 82).  
Another function of cytoplasmic lncRNA is related to protein localization: lncRNA contain 
distinct domains that interact with specific protein complexes and through a combination of 
domains, bring specific regulatory components into proximity, resulting in the formation of a 
specific functional complex to coordinate gene expression (83). Additionally, lncRNAs not 
only act as decoys for sncRNAs but they may also function as precursors of sncRNAs, 
including small nucleolar RNAs (snoRNAs) and miRNAs (84). 
 
i. Natural antisense transcripts 
Natural antisense transcripts (NATs) are endogenous RNAs that partially or totally overlap 
transcripts (either coding or non-coding) originating from the opposite DNA strand (85). NATs 
can be originated from independent promoters, shared bidirectional promoters or cryptic 
promoters that are situated within genes (85). Depending on the orientation of the sense 
transcript, overlapping pairs are classified as: head-to-head (5′-regions overlap, HTH), tail-to- 
tail (3′-regions overlap, TTT), embedded (one transcript is fully contained within the other) 
(EMB), or intronic (INT) pairs (85, 86). NATs function locally (in the nucleus, preferentially) or 
distally (in the cytoplasm) (85), and are usually not abundant (around 10-fold lower 
abundance than associated mRNA) (85).  
Although NATs clearly typify cis regulation, affecting alleles on the DNA strand from which 
they are produced, in a local fashion, they also act in trans because they can interact with 
other loci taking advantage of 3-D organization of chromatin (86). Cis-regulation is due to 
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antisense transcription in a given locus whereas trans-regulation is mediated by the 
antisense transcript corresponding to the RNA being transcribed (85). Cis-acting NATs 
function either locally (e.g., in promoter–gene interactions) or distally (e.g., in enhancer–gene 
interactions). Local cis-regulation comprises epigenetic alterations proximal to a target gene 
(e.g., regulation of transcription initiation by affecting DNA methylation), whereas distal cis-
regulation requires RNA-RNA interactions amid transcripts originated from the same locus 
(85). Moreover, when NATs remain at the loci of origin, they can mediate cis effects due to 
formation of R-loops, triple helices or stalled polymerases. The functional output of cis-
regulation by NATs leads to activation or silencing of the corresponding sense mRNA, via 
transcriptional activation or silencing, mRNA stabilization, alternative splicing or post-
translational regulation (86). Because antisense and sense transcripts are transcribed from 
the same locus, it is suggested that antisense transcripts function recurrently in cis whereas 
other ncRNAs commonly function in trans, although there is evidence for trans-acting 
antisense transcripts. Antisense transcription might be far more extensive than previously 
anticipated, with around 50% of sense transcripts having antisense partners (86). 
Interestingly, NATs’ genomic distribution suggests that they might act as self-regulatory loops 
that control its own expression. 
 
ii. Enhancer elements and RNAs 
Enhancers are non-coding genomic regions that activate transcription of target genes at long 
distances. Mammalian genomes contain hundreds of thousands of putative enhancer 
elements, located upstream and downstream of coding target gene promoters, which are 
critical for cell-specific gene expression programs (87, 88). Enhancers are also considered 
transcription units, giving rise to transcription of a class of lncRNAs, the eRNAs (88). Histone 
modification signatures characterize enhancer-like regions, including enrichment of 
H3K4me1 and H3K4me2 and reduced levels of H3K4me3, compared to promoters (87, 88). 
eRNAs may be either polyadenylated or non-polyadenilated, and are subdivided into 
unidirectional and bi-directional transcripts. eRNAs exhibit a 5’cap, usually are not spliced or 
polyadenylated, and can be produced as unidirectional or bi-directional transcripts. A growing 
body of evidence suggests that eRNAs are functionally important per se, and contribute to 
enhancer-mediated transcriptional activation of target genes. Primed enhancers are marked 
with H3K4me1 and H3K4me2 and lack histone acetylation. The repressive histone 
modification H3K27me3 marks enhancers that are considered to be poised. In contrast, 
active enhancer regions are enriched for H3K27ac and are bound by actively transcribing 
RNA Polymerase II (PolII) (88). eRNA expression is a hallmark of active enhancers and it 
has been used as a signature to identify those regions through transcriptomic profiling. The 
mechanisms by which eRNAs regulate gene expression are not completely clear but it has 
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been hypothesized that it may stabilize enhancer-promoter looping, facilitate PolII 
recruitment and its transition into productive elongation (87). As such, eRNAs are likely to 
have important functions in many regulated programs of gene transcription including those 
mediated by Androgen receptor (89), p53 and ERα (ESR1) (90). 
 
iii. Long intervening noncoding RNAs 
lincRNAs (long intervening noncoding), also called long intergenic noncoding RNAs, are 
lncRNAs that do not overlap exons of either protein-coding or other non-lincRNA types of 
genes (19). They are transcribed from multiple loci in the human genome, are located in 
nucleus although are more frequently reported in cytoplasm. lincRNAs lack defining 
sequence or structure characteristics as they combine multiple classes of noncoding RNAs 
(such as intronic and intergenic genes) (Figure 4). However, a few common features are 
observed, including being composed of few exons (normally 2-3) which makes them shorter 
than mRNAs (19). The average length of lincRNAs exons is no larger than its counterparts in 
PCG. Although the transcriptional regulation, chromatin modifications and splicing signals 
are similar to PCG, lincRNAs seem to be less efficiently spliced. Interestingly, lincRNAs 
significantly overlap repetitive elements, probably due to the fact that lincRNA functions are 
more tolerant to retrotransposon insertions. Repetitive elements were reported to play 
important mechanistic roles in lincRNAs roles, enabling base pairing with other RNAs 
containing repeats from the same family. Finally, the median lincRNA levels are only about a 
tenth of that of mRNAs, as lincRNA expression is typically more variable among tissues and 
enriched in testis and brain. LincRNAs’ functions include co-transcriptional regulation, 
regulation of gene expression (both in cis and trans) by bridging proteins and chromatin, 
scaffolding nuclear and cytoplasmic complexes, and RNA-RNA interactions. Consequently, 
lincRNAs are believed to play a widespread role in gene regulation and maintenance of cell’s 
homeostasis (19). 
 
iv. Pseudogenes 
Pseudogenes are ancestral copies of protein-coding genes that arose from genomic 
duplication or retrotransposition of mRNA sequences into the genome, followed by 
accumulation of deleterious mutations due to loss of selection pressure (91). A pseudogene 
shares an evolutionary history with a functional protein-coding gene but it has been mutated 
through evolution to contain frameshift and/or stop codon(s) that disrupt the open reading 
frame (92). Pseudogenes pervade the genome in close sequence similarity with their 
cognate genes. There are three main types of pseudogenes: (a) unitary pseudogenes - 
species specific unprocessed pseudogene without a parent gene in the same species but 
with an active orthologue in another species; (b) processed pseudogenes – which appear to 
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have been produced by integration of a reverse transcribed mRNA into the genome; and (c) 
unprocessed pseudogene - those that may contain introns as it resulted from gene 
duplication (92). Pseudogenes are of capital importance owing to its competing endogenous 
RNAs (ceRNAs) action as natural miRNA “sponges” (79). Moreover, they may also regulate 
the expression of their parent gene by decreasing mRNA stability of the functional gene 
through its own over-expression (93). Interestingly, pseudogenes are also a source of small 
interfering RNAs, impacting on gene expression by means of RNAi pathway (94) and by 
generating antisense transcripts (95).  
 
3. Non-coding RNAs in Prostate Cancer 
The constantly expanding inventory of ncRNAs has been implicated in a broad spectrum of 
processes including prostate homeostasis and pathogenesis. The emergence of ncRNAs is 
of crucial importance for prostate biology because prostate cells are transcriptionally active 
and numerous reports documented the deregulation of ncRNAs in prostate cancer (PCa) (27, 
30). This is the most commonly diagnosed cancer among men worldwide, and a major cause 
of morbidity and mortality (96). Although radical prostatectomy reduces mortality among men 
with localized prostate cancer, up to 40% of patients experience disease progression and 
recurrence (97). Numerous studies using mRNA-based techniques contributed to a better 
understanding of the molecular pathways involved in prostate carcinogenesis (98). It is likely, 
then that unraveling the biological functions of ncRNAs in PCa will provide new insights into 
their functions, mechanisms of action and potential usefulness as tools for PCa management 
(27). Despite the myriad of ncRNA families described thus far, only a small proportion are 
known to be involved in PCa. The best examples include small RNA families, mainly miRNAs 
and some lncRNAs, including eRNAs and antisense RNAs. Other classes are under active 
investigation, including pseudogenes, lincRNAs and tRNAs. These ncRNAs not only control 
functional pathways of cell biology, but it may also constitute novel therapeutic targets or 
diagnostics biomarkers. In the following sections, we review the rapidly growing knowledge 
on ncRNAs as key players in prostate tumorigenesis and highlight their translational potential 
into the clinics. 
 
a. Small non-coding RNAs  
To date, the most extensively studied sncRNAs in PCa are miRNAs. These are classified as 
oncomirs (when miRNA expression favors tumor development) or tumor suppressor miRNA 
(i.e., when its expression normally counteracts tumor initiation and/or development) and play 
a critical role in PCa [58]. Dysregulation of miRNAs in cancer may occur through epigenetic 
changes (commonly, promoter CpG island hypermethylation) or genetic alterations, as well 
as miRNA biogenesis machinery dysfunction, which subsequently affects transcription of 
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primary miRNA, its processing to mature miRNAs and/or interactions with mRNA targets 
[59]. 
 
i. Dysregulation of microRNAs in PCa 
NGS-based profiling, which enables high-throughput analysis of the miRNAome with single-
base resolution [99], revealed common downregulation of miR-205, miR-143 and miR-145, 
and upregulation of miR-375 and miR-148, among others (Table 2). However, due to the 
inherent heterogeneity of PCa, sample selection and technological platforms used, some 
discrepancies in results are apparent. Down-regulation of miR-15a-miR-16-1 cluster (putative 
tumor suppressors through targeting of BCL2, CCDN1 and WNT3A) in PCa due to 13q14 
deletion is commonly acknowledged [100]. Deletion of this cluster fuels survival, proliferation 
and invasion of PCa cells, whereas in vivo overexpression results in growth arrest, apoptosis 
and marked regression of PCa xenografts [100]. Strikingly, in vitro blockade of miR-15a and 
miR-16-1 promotes survival, proliferation and invasiveness of previously untransformed 
prostate cells, which become tumorigenic in immunodeficient NOD-SCID mice [100]. On the 
other hand, loss of miR-101 contributes to overexpression of EZH2, linking PCa progression 
and altered of epigenetic reprogramming [101]. Indeed, one or both genomic loci encoding 
for miR-101 [located in chromosome 1 (MIR101-1) and in chromosome 9 (MIR101-2)] are 
lost in a sizeable proportion of primary PCa and up to 2/3 of metastatic PCa [101]. In DU145 
cells, forced expression of miR-101 impairs cell invasion and reduces tumor growth in a 
mouse xenograft, whereas miR-101 re-expression globally decreases H3K27me3 histone 
mark levels at PRC2 target genes’ promoters, demonstrating that manipulation of miR-101 
expression may be of therapeutic usefulness [101].  
Mir-34a, a p53 target [103], is downregulated due to promoter methylation [102] and 
underexpressed in CD44+ PCa cells purified from xenograft and primary tumors [104]. Its 
overexpression in cell pool or purified CD44+ PCa cells inhibits clonogenic expansion, tumor 
regeneration, and metastasis, whereas delivery miR-34a antogomirs to CD44- PCa cells has 
the opposite effects [104]. These effects are mediated by CD44, a target of miR-34a, and 
CD44 silencing phenocopied miR-34a overexpression [104]. Additionally, miR-34 cooperates 
with p53 to counteract cancer progression, and jointly regulate prostate stem/progenitor cell 
activity [104]. This action is also mediated by MET, a mutual p53/miR-34 downstream target 
and a critical regulator of stem cell compartment [104]. This suggests a therapeutic potential 
for miR-34a against PCa by directly acting on cancer stem cells [104].  
One of the main focus on miRNA research in PCa is AR-signaling pathway. Not only AR is 
targeted by multiple miRNAs, but it also modulates miRNA expression, mediated by 
androgen-responsive elements within the promoter region [105]. MiR-21 is overexpressed in 
primary PCa and DU145 and PC3 PCa cell lines [107] and AR binding to its promoter 
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enhances transcriptional activity, promoting hormone-dependent and hormone-independent 
PCa growth [106]. miR-21 inhibition using antisense oligonucleotides does not affect 
proliferation although it increases sensitivity to apoptosis and inhibits cell motility and 
invasion by targeting MARCKS, a gene with a role in cell motility [108], whereas miR-21 
overexpression represses BTG2, which induces expression of luminal markers and promotes 
epithelial-mesenchymal transition (EMT) [109]. Increased miR-21 expression is associated 
with shorter biochemical recurrence-free survival and predicts biochemical recurrence in PCa 
patients submitted to radical prostatectomy [110]. The list of AR-regulated miRNA also 
includes miR-27a, miR-141, miR-101 and miR-125b [111]. Conversely, miR-135b, miR-185, 
miR-297, miR-34a, miR-34c, miR-421, miR-634, miR-654-5p, and miR-9 influence androgen 
signalling by targeting AR [105]. Thus, miRNAs are involved in hormone-dependent and 
hormone-independent PCa growth, constituting putative therapeutic strategies to inhibit AR 
function and androgen-dependent cell growth in PCa.  
PTEN is a tumor suppressor that antagonizes PI3K/AKT signalling and its expression is 
frequently abrogated in PCa. Decreased PTEN abundance due to up-regulation of miR-
106b~25 cluster (due to genomic amplification) and miR-22 in PCa is critical for malignant 
transformation of prostate cells [112]. In DU145 cells, stable over-expression of pri-miR-22 
markedly increases colony formation and caused increased proliferation and tumor growth, 
as well as over-stimulation of AKT pathway in xenografts [112]. The same effects are 
apparent when miR-106b~25 cluster is stably expressed in PCa cells, leading to decreased 
PTEN abundance and activity [112]. Strikingly, that miRNA locus also collaborates with its 
host gene, MCM7, to promote malignant transformation. In nude mice, larger tumors were 
formed, compared to control cells, when miR-106b~25 cluster was overexpressed [112]. 
Moreover, miR-22 and miR-106b~25 clusters cooperate with c-MYC, further emphasizing its 
proto-oncogenic properties. Indeed, MCM7, and, consequently, miR-106b~25 cluster 
transcription is enhanced by c-MYC, suggesting that its oncogenic activity may also involve 
transcriptional activation of PTEN-targeting miRNAs [112]. 
MicroRNAs might be also involved in development of PCa bone metastasis, as loss of miR-
15 and miR-16 and increased miR-21 expression stimulate dissemination and bone marrow 
colonization, through aberrant TGF-β and Hedgehog signalling [107]. 
In exosomes derived from PCa bulk and cancer stem cells (CSC), miR-100-5p and miR-21-
5p were the most abundant miRNAs in both cell types, among 1839 miRNAs isolated [113]. 
Strikingly, biological processes controlled by the differentially expressed miRNAs in bulk 
exosomes were related to fibroblast growth, epithelial proliferation, and EMT, through MMPs 
activation, whereas those from CSCs exosomes controlled proliferation, epithelial 
differentiation and angiogenesis [113]. Overexpression of miR-100-5p, miR-21-5p, and miR-
139-5p in a normal prostate fibroblast cell line (WPMY-1) resulted in increased expression of 
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MMPs [113], with a predominant effect of miR-21-5p on MMP9, and of miR-100-5p on MMP2 
and MMP13, whereas miR-139 induced expression of all MMPs. Ultimately, transfection of 
those miRNAs significantly increased RANKL expression, which induces cell proliferation, 
emphasizing that miRNAs contained in exosomes may play a significant role in cancer 
invasion and metastasis [113]. 
 
Table 2. Representative microRNA in PCa biology 
 
It was recently demonstrated that PCa-derived adipose stem cells (pASCs) stimulated with 
conditioned media or exosomes (isolated from PC3, and C4-2B cells) induced prostate-like 
neoplastic lesion in vivo (99). The oncogenic stimulation of pASCs might be a consequence 
of the RNA transfer by PCa-derived exosomes and activation of oncomiRNAs (e.g. miR-
125b, miR-130b, and miR-155), along with oncogenic factors (e.g. H-RAS and K-RAS) (99). 
In fact, expression of miR-125b and miR-130b promoted downregulation of tumor 
suppressors Lats2 and PDCD4 in pASCs exposed to PCa-derived exosomes. Functionally, 
pASC tumors acquire cytogenetic aberrations, mesenchymal-to-epithelial transition features 
and expressed neoplastic markers reminiscent of molecular features of PCa xenografts (99). 
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Due to its plasticity and cargo potential, PCa-derived exosomes might play a critical role in 
clonal expansion of tumors through neoplastic reprogramming of tumor-ASCs in cancer 
patients. This also emphasizes that deregulated expression of oncomiRs cause oncogenic 
transformation of pASCs due to disruption of transcriptional networks of tumor suppressor 
genes (99). Further research on other ncRNA families and different prostate cells (e.g., 
basal, luminal and fibroblasts) might help understand how exosomes are involved in 
crosstalk between tumor and stromal cells to synergistically promote tumor progression and 
drug resistance.  
 
ii. Small nuclear and nucleolar RNAs in PCa 
The role of other small ncRNAs in prostate tumorigenesis has been also investigated. 
SnoRNA U50 is mutated and downregulated in PCa, and a homozygous 2-bp (TT) deletion 
was identified both in PCa cell lines and primary tissues. Ectopic expression of snoRNA U50 
abrogates colony formation, a feature associated with tumor-suppression. (100).  
The nucleolar protein dyskerin (DKC1) catalyzes pseudouridylation of rRNA and it is also 
required for the formation of hTR, the RNA component of telomerase. Compared to benign 
tissues, DKC1 mRNA levels were higher in PCa samples, especially in lymph node 
metastases (101). SiRNA-mediated depletion of DKC1 decreased cell proliferation of 
prostate cells (101), suggesting that deregulation of snoRNA machinery is important for 
prostate carcinogenesis. 
Using a deep sequencing approach to characterized small non-coding RNA transcriptome, 
an increase in both global snoRNAs and tRNA expression in PCa metastatic to lymph node  
compared to that of primary PCa was shown, suggesting a possible oncogenic role for 
snoRNAs, particularly in more advanced tumors (102). In addition, there is a strong 
differential expression of snoRNAs and tRNAs, comparing PCa and normal prostate samples 
(102). Additionally, snoRNA-derived RNAs (sdRNAs) display higher differential expression 
than miRNAs and they are greatly upregulated in PCa. Using qPCR, SNORD44, SNORD78, 
SNORD74 and SNORD81 and sdRNAs were shown to be upregulated in PCa. The higher 
expression levels of SNORD78 and its sdRNA - sd78-3’ – were associated with metastatic 
PCa (102). 
The ribosome biogenesis begins in the nucleolus (103). Here the ribosomal RNA (rRNA) is 
transcribed, processed, and assembled into ribosomal subunits (104). It hosts a 
transcriptional unit encoding a 45S ribosomal RNA precursor that is processed into the 
mature 18S, 5.8S and 28S RNA species (105). 45S percursor rRNA and mature rRNAs 28S, 
18S and 5.8S are overexpressed in PCa samples compared to morphologically normal 
prostate tissues (104). The mechanism leading to the aberrant expression is not well 
characterized, but apparently, overexpression is not associated with rDNA promoter 
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hypomethylation (104). In fact, 45S, 18S and 5.8S rRNA expression levels, altered nucleolar 
structure and function are more closely associated with MYC mRNA levels (104) suggesting 
that MYC might be involved in rRNA biogenesis. In a different report, MYC was found to be 
required for rRNA transcription and processing (106). In PCa cells, MYC binds to the 5′ 
upstream region of Fibrillarin (FBL), a gene required for rRNA production and processing 
(106). FBL is overexpressed in PCa samples and siRNA-mediated depletion of FBL 
suppressed cell proliferation and clonogenic survival. Moreover, FBL knockdown decreased 
the levels of 5.8s, 18s and 28s rRNAs, whereas only a modest reduction in 45S pre-rRNA 
was observed (106). Conversely, MYC knockdown associated with decreased levels of pre-
rRNA as well as of processed rRNAs, indicating that MYC is required for rRNA transcription 
and processing (106). Genome-wide analysis of MYC depletion revealed down-regulation of 
133 nucleolus-associated genes and of 64 genes associated with rRNA processing (106). 
Those comprised fibrillarin, nucleolin, UBF, and nucleophosmin. In addition, overall nucleolar 
size was reduced after MYC depletion in vitro (106). Considering these findings, MYC 
overexpression in PCa cells can drive enhanced de novo nucleolar and ribosomal gene 
expression, thus fostering the malignant phenotype.  
rRNA is crucial for both androgen-dependent and -independent growth of PCa cells. The 
androgen-AR signaling leads to the accumulation of rRNA in androgen-dependent prostate 
cells and angiogenin (ANG) is upregulated in PCa cells, mediating androgen-stimulated 
rRNA transcription (107). In androgen-dependent cells, androgen stimulation promotes ANG 
nuclear translocation, where it binds to rDNA promoter, stimulating rRNA transcription (107). 
Blocking ANG leads to inhibition of androgen-induced rRNA transcription. Moreover, ANG 
signalling is not only critical for androgen-dependent growth but also for the castration-
resistant phenotype. In an androgen-independent context, ANG stimulation leads to 
constitutive nuclear translocation in androgen-insensitive cells, ensuing a continuous rRNA 
overproduction and thereby stimulating cell proliferation (107). 
 
iii. tRNA-derived RNA fragments 
Global expression profile of prostate cell lines revealed that the second most abundant group 
of sncRNA was that of fragments derived from tRNA, the tRNA-derived RNA fragments 
(tRFs) (108). Deep sequencing characterization of LNCaP and C4-2 cell lines, disclosed 17 
tRNA-related small RNAs, including the most abundant: tRF-1, tRF-3, and tRF-5. For 
downstream validation, tRF-1001, a member of tRF-1 series, was selected. tRF-1001 is 
derived from the 3’ end of a Ser-TGA tRNA precursor transcript, which is not retained in the 
mature tRNA (108). 
The tRF-1001 is expressed more abundantly in cell lines than in tissues, but its expression 
decreases either upon starvation or high cell density in DU145 and LNCaP cells. Reduction 
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of cellular metabolism also decreased expression of tRF-1001 precursor but the 
corresponding mature tRNA levels were unaffected. The tRF-1 series of small RNAs are 3′ 
sequences from pre-tRNA, released through a cleavage by tRNA endonuclease ELAC2 
during the 3′-end maturation of tRNA. Knockdown of ELAC2 decreased tRF-1001 
expression, leading to accumulation of the pre-tRNA (108). tRF-1001 and its precursor tRNA 
are exclusively localized in the cytoplasm, providing evidence that biogenesis occurs in the 
cytoplasm, rather than in the nucleus as it happens for tRNAs. These data sustain a 
functional role for tRFs, putting aside the idea of a mere byproduct of tRNA biochemical 
processing (108). 
Recently, RNA-sequencing was used to profile tRFs in fresh frozen tissue samples derived 
from normal adjacent prostate and PCa at different stages (109). A total of 598 unique tRFs 
were identified and several are deregulated in PCa. Strikingly, 5’-tRFs constitute 
approximately 75% of all tRFs detected in prostate tissues. Notably, most of the identified 
tRFs are derived from 5’- and 3’- of mature cytosolic tRNAs. Nonetheless, tRFs derived from 
different segments of tRNAs, including pre-tRNA trailers and leaders, as well as tRFs from 
mitochondrial tRNAs were catalogued. Globally, 110 tRFS were found deregulated (72 
upregulated, 24 downregulated and 13 upregulated in one group but downregulated in the 
other group (109)). Most of the upregulated tRFs were 5’-tRFs and most of downregulated 
were 3’-tRFs. Downstream qPCR validation of 6 different tRFS revealed that 4 tRFs (three 
5’-tRFs and one D-tRF) were upregulated, and 2 tRFs (3’-tRF class) were downregulated in 
PCa. tRF-544 (isotype Phe, anticodon GAA - tRNAPheGAA) is thought to be associated with 
aggressive forms or advanced stages of PCa. Interestingly, high expression level ratio tRF-
315/ tRF-544 significantly associated with poorer progression-free survival and shorter time 
to disease relapse.  
Sex hormone-dependent tRNA-derived RNAs (SHOT-RNAs) are commonly expressed in AR 
positive PCa cancer cell lines (110). In LNCaP-FGC cells, both 5′- and 3′-tRNA halves from 
SHOT-RNAAspGUC and SHOT-RNA HisGUG are detected by northern blot, but not in DU145 or 
PC3 cells, and AR knockdown reduced tRNAs expression levels. One of must abundant 
SHOT-RNAs detected by Honda et al - 5′- SHOT-RNA RNALysCUU – was knocked-down using 
siRNAs in LNCaP-FGC and cell growth rate was decreased compared to control-siRNA 
(110). Because levels of mature tRNA were not changed by siRNA transfection, reduced 
proliferation seems to be solely attributable to the change in SHOT-RNA RNA levels. This 
strategy was also applied to SHOT-RNAAspGUC and SHOT-RNAHisGUG and depletion of each 
SHOT-RNA impaired cell growth, as well. Nevertheless, 3′-SHOT-RNAAspGUC depletion failed 
to impair cell growth (110). Overall, these data support SHOT-RNAs as functional RNA 
molecules and different species of 5′-SHOT-RNA are involved in cell proliferation (110). To 
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determine whether 3′-SHOT-RNA holds functional relevance or not, additional studies are 
required. 
The current understanding of tRFs, however suggests that it are not merely byproducts of 
random cleavage of tRNAs, but might act as mediators of translational and/or gene 
regulation. Although some isolated functions have been indicated, the vast majority of tRFs 
appear to operate via uncharacterized mechanisms. It has been proposed that 5′- but not 3′-
derived tRFs, play a role in stress granule assembly or inhibition of protein synthesis in vitro 
(111). However, 3′-derived tRFs are able to repress their mRNA targets in a miRNA-like 
fashion and may exert tumor suppressive functions (112).  
 
iv. Other short RNAs 
Although no direct involvement of piRNA in PCa has been reported, some genes implicated 
in piRNA biogenesis are deregulated in PCa. Defects in Tudor-domain proteins significantly 
impair piRNA pathway, especially its ping-pong components, although not abolishing it. 
Because multiple Tudor-domain-containing proteins exists, one may argue that it exhibit 
overlapping or redundant roles in the piRNA pathway, explaining the somewhat minor 
phenotypes of the individual mutants (113).  
Tudor domain-containing protein 1 (TDRD1), is a direct target gene of ERG, strongly 
correlating gene with ERG overexpression (114). Mechanistically, ERG is able to disrupt 
tissue-specific DNA methylation pattern at the TDRD1 promoter, resulting in TDRD1 
transcriptional activation (114). Piwil2 has been recently described as an oncogene able to 
modulating invasion and metastasis, as well as EMT (115). Of note, global piRNAs levels 
were not assessed to quantify the deregulation caused by TDRD1 and Piwil2 aberrations.  
 
b. Long non-coding ncRNA  
Although ncRNAs research, and specially lncRNAs, is still in its infancy, significant roles 
have been ascribed to some lncRNAs in PCa and these are summarized in Table 3. 
 
i. Antisense-Regulatory lncRNAs in PCa 
The role of dysregulated antisense transcript expression is under investigation in PCa. The 
polyadenilated antisense transcript ANRIL (encoded by CDKN2B-AS1) is expressed from the 
tumor-suppressor locus INK4b-ARF-INK4a (9q21.3). ANRIL and CBX7 (member of 
Polycomb Repressor Group 1) are both up-regulated in PCa samples (116). Furthermore, 
CBX7 is responsible for maintaining silenced chromatin states through recognition of 
H3K27me3 (116). CBX7 binds to H3K27me3 and interacts with ANRIL at the INK4b-ARF-
INK4a locus. CBX7 employs different regions within its chromodomain for binding to 
H3K27me3 and ANRIL RNA, suggesting that both interactions are important for the 
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sustained cis-repression of the locus (116). Thus, RNA-protein interaction underlies the 
ability of PRC1 to repress the INK4b-ARF-INK4a cluster and its disruption contributes to PCa 
development by reducing senescence (116). Interestingly, these data might indicate that the 
frequent promoter hypermethylation observed at this locus occurs as a secondary event after 
cell differentiation.  
Another NAT with critical impact in PCa cells is CTBP1-AS, an androgen-responsive lncRNA 
that promotes PCa growth through sense-antisense repression of the transcriptional co-
regulator CTBP1 and global epigenetic regulation of tumor suppressor genes (117). The up-
regulation of CTBP1-AS is inversely correlated with CTBP1 in primary and metastatic PCa, 
associating with high AR expression status. Depletion of CTBP1-AS mRNA abolished the 
androgen-dependent reduction of CTBP1, indicating that CTBP1-AS directly regulates 
CTBP1 at RNA level (117). Silencing CTBP1-AS reduced LNCaP cell proliferation, and in 
vivo tumor growth was also reduced, concomitantly with an increased CTBP1 expression. 
Microarray analysis showed that transcriptional activation of androgen-induced genes was 
diminished by siCTBP1-AS (117). Interestingly, CTBP1-AS overexpression stimulated cell 
growth and promoted resistance to growth inhibition by bicalutamide, ultimately rendering in 
vivo tumor growth after castration. Mechanistically, CTBP1-AS coordinates cis-repression of 
CTBP1 promoter, reducing H3Ac and H4K4me levels  but not altering repressive marks 
(117). CTBP1-AS binds to HDAC-Sin3A complex and coordinates HDAC-mediated 
repression by chromatin deacetylation within CTBP1 promoter’s in the AR-dependent 
system. Moreover, CTBP1-AS also interacts with PSF, which binds at CTBP1 promoter to 
induce histone deacetylation by HDACs to promote transcriptional repression of CTBP1. 
Additionally, CTBP1-AS may also act as trans-acting regulator of androgen-regulated genes 
by recruiting the HDAC/Sin3A repressor complex via PSF, prompting cell cycle progression 
by repressing cell cycle regulators and modulating global androgen signaling (e.g., p53, 
SMAD3) (117).  
Another example of antisense gene regulation is the transcriptional control of tumor-
suppressor gene RASSF1A by RASSF1A-antisense RNA 1 (118). RASSF1A-AS1 is 
upregulated is PCa cell lines, inversely correlating with RASSF1A expression (118). 
RASSF1A and RASSF1A-AS1 form a RNA-DNA hybrid at the RASSF1A promoter and 
recruits the polycomb repressor complex PRC2. PRC2 contributes to chromatin compaction 
by catalyzing the methylation of histone H3 at lysine 27, which is enriched at RASSF1A 
promoter, and specifically blocks RASSF1A expression (118).  
 
ii. Enhancers and enhancer RNAs (eRNAs) in PCa 
Cancer cells display altered expression patterns and enhancer usage in comparison with 
their normal counterparts (119). In PCa, eRNAs have been implicated in assisting AR-
39 
mediated signaling, as mediators of enhancer-promoter looping and in altering transcription 
factor binding (Figure 5).  
 
 
Figure 5. Transcription derived from enhancer is important for long-range 
transcriptional control.  
eRNAs are lncRNA derived from short regions of DNA that enhance the expression of genes 
at varying distances. Effects can be mediated by transcription factor binding to these sites, 
such as androgen receptor (AR). AR controls PCa cell-specific gene expression programs 
through interactions with diverse co-activators and the transcription machinery. Gene 
activation may involve DNA loop formation between enhancer-bound AR and the 
transcription machinery at the core promoter. This interaction seems to be mediated by 
mediator complex and cohesin, as they have been reported to interact physically and 
functionally connect the enhancers and core promoters of active genes. The eRNAs 
produced from AR-binding DNA segments, facilitate the spatial interaction between enhancer 
and promoter, ultimately enhancing long-distance transcriptional regulation. Moreover, 
specific eRNA might encompass androgen response elements (ARE), supporting AR and 
mediator interactions. This mechanism is critical for PCa cells, as androgen-induced eRNAs 
scaffolds the AR-associated protein complex that modulate chromosomal architecture and 
selectively enhance AR-dependent gene expression involved in PCa initiation and 
progression 
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FoxA1 has been reported to contribute to the enhancer code in PCa cells, as FoxA1 
regulates AR genomic targeting by simultaneously anchoring AR to cognate loci and 
restricting AR from other ARE-containing loci in the human genome (72). In addition, 
knockdown of FoxA1 markedly elevated di-hydro-testosterone (DHT) response and caused 
AR binding to a distinct cohort of enhancers. Global nuclear run-on sequencing (GRO-seq) 
was applied to understand how differential AR binding is translated into hormonal gene-
response (72). After DHT treatment, GRO-seq detected ncRNA expression from a subset of 
H3K4me1-positive and H3K4me3-negative regions. These differentially expressed eRNAs 
are largely symmetrical and bidirectional (as depicted for the KLK3 enhancer). Moreover, 
these AR-activated enhancers marked by increased eRNA expression are responsible for 
activation of nearby coding transcription units (72). Chromosome conformation capture (3C), 
suggested that eRNA induction per se is the most precise mark of the functional looping 
between an activated enhancer and its regulated gene promoter, rather than p300 or MED12 
binding (72). Moreover, both DHT and FoxA1 knockdown demonstrated a strong H3K4me2-
marked central nucleosome, suggesting that nucleosome remodeling is not required to 
induce specific enhancer-promoter looping and subsequent target gene activation (72).  
Furthermore, it has been reported that PolII binds to a large number of intergenic AR-bound 
enhancers, marked by H3K4me1 and H3K27ac, which produce eRNAs that may regulate 
neighbor or distantly located genes (89). This evidence suggests than eRNAs may contribute 
to AR-driven looping complex that enhances spatial communication of distal enhancers and 
target promoters, leading to transcriptional activation of specific genes (89). The KLK3 
enhancer is marked by AR binding, H3K27ac and H3K4me1, and produces a bidirectional 
eRNA named KLK3e (89). Both KLK3 and KLK3e expression is induced by DHT treatment 
and blocked by bicalutamide, indicating a high correlation of activity-dependent induction 
between eRNAs and adjacent protein coding genes. 
KLK3e sense strand gives rise to a >2kb polyadenylated transcript that is substantially more 
expressed than the antisense transcript. KLK3e facilitates the spatial interaction of the KLK3 
enhancer and the KLK2 promoter, enhancing long-distance KLK2 transcriptional activation 
(89). KLK3e contains the core enhancer element derived from the androgen response 
element III (AREIII) required for the interaction of AR and Mediator 1 (MED1). Suppression of 
either KLK3e or MED1 reduced the interaction of KLK3/2 loci, supporting a role for MED1 as 
a mediator of the long-range chromatin looping and cooperating with KLK3e in the enhancer 
target-promoter interaction. Globally these data suggests that KLK3e forms a functional 
complex with AR and MED1 that facilitates the association of AR-bound enhancers with 
promoters, resulting in transcriptional activation of target genes (89). Supporting this 
hypothesis, KLK3e expression is significantly correlated with KLK3 and KLK2 (R2=0.62; 
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0.59, respectively). Further understanding of how AR-induced eRNAs act as a scaffold for 
AR-associated protein complex that selectively modulate chromosomal architecture and 
gene expression may translate into new RNA-based therapy to improve response to 
androgen deprivation therapy (89).  
Recently, a new role for single-strand nicks was identified, mediated by DNA topoisomerase 
1 (TOP1), in relaxing supercoiled DNA at gene enhancers to promote enhancer dependent 
transcription (120). In LNCaP cells, TOP1 was recruited to AR-regulated enhancers in 
response to androgen treatment. Using ChIP-seq, of the 6,545 putative AR-bound 
enhancers, 96% were occupied by TOP1. Of these, 60% revealed an androgen-stimulated 
increase in TOP1 binding as well as in RNAPOL II occupancy, indicative of active 
transcriptional activity (120). GRO-seq analysis of serum-starved LNCaP cells treated with 
DHT identified 644 putative enhancers (74% of them showed increased TOP1 occupancy) 
with significantly up-regulated eRNA expression. Knockdown of endogenous TOP1 resulted 
in decreased eRNA expression of 79% of AR-regulated enhancer, accompanied by lower 
expression levels of 368 protein-coding mRNAs (including KLK3, KLK2, TMPRSS2 and 
NDRG1) (120). Having proved that TOP1 reduces both eRNA and mRNA production of most 
AR-regulated target genes, the authors found that prior binding by NKX3.1 was required to 
recruit TOP1 to enhancers following androgen treatment. siRNA-depletion of NKX3.1 
inhibited recruitment of TOP1 and reduced DHT-dependent upregulation of eRNA expression 
(120). Strikingly, depletion of both TOP1 and NKX3.1 reduced DHT-mediated eRNA 
upregulation at the same AR-bound enhancers, apparently without affecting AR recruitment. 
This reveals that NKX3.1 and TOP1 occupy the same binding sites at enhancer elements 
and co-regulate an AR transcription program. The Y723F TOP1 mutant did not block 
transcriptional activity in TOP1-depleted cells, suggesting that the nicking activity of TOP1 is 
required for its effects on enhancer activation (120). Given that single-strand nicks might lead 
to the formation of DNA double-strand breaks, several components of the DNA damage 
response pathway - MRE11, RAD50 and ATR – are recruited to AR-regulated enhancers 
after DHT treatment and are required for eRNA and protein-coding mRNA transcription. 
Taken together, these data suggest a common usage of the DNA damage repair machinery 
to regulate AR-mediated gene transcription, highlighting the complexity of PCa (120).   
In a recent study, using Chem-seq (121), a compound that inhibits cell proliferation in vitro 
and tumor growth in vivo – SD70 – was identified. SD70 binds to AR-bound functional 
enhancers, regulating DHT-induced gene transcriptional programs (121). Moreover, it was 
found that KDM4C binds at AR-regulated enhancers and is recruited in a DHT-dependent 
fashion. In vitro, SD70 inhibits KDM4C demethylase activity causing elevated H3K9me2 
levels at enhancer and promoter regions - a plausible component of the inhibitory effects on 
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DHT target gene expression (121). These results suggest that targeting enhancer regions 
has potential therapeutic value for PCa. 
 
iii. lncRNA as master regulators of alternative splicing and translation 
Recently, it has been shown that lncRNA are required to assemble nuclear domains 
specialized in RNA processing, such as the nuclear speckle and the paraspeckle. The 
oncogenic lncRNA MALAT1 (also known as NEAT2, located at 11q13.1) is present within the 
nuclear speckle and spatially re-organizes the actively transcribed genes closed to the 
nuclear speckles, a domain know for its abundance in pre-mRNA splicing factors (10). 
Knockdown of MALAT1 disclosed that this lncRNA regulates alternative splicing of multiple 
genes by controlling the availability of serine/arginine-rich splicing factors in active 
transcription sites (122). Interestingly, during post-transcriptional processing of MALAT1, a 
conserved 3’ tRNA-like sequence generates a short tRNA-like ncRNA called MALAT1-
aasociated small cytoplasmic RNA (MASCRNA), whose function is still unclear. MASCRNA 
is a 61-bp short tRNA-like ncRNA of unknown function, generated by RNase-P cleavage and 
then exported to the cytoplasm (123).  
On the other hand, the lncRNA NEAT1 is an essential structural element to initiate de novo 
assembly of paraspeckles, which are believed to be nuclear domains specialized in retention 
of adenosine-to-inosine edited mRNAs (124). Inducing NEAT1 transcription locus is sufficient 
to form new paraspeckles at the integration locus. However, active transcription of NEAT1 is 
necessary to tether the lncRNA to its own transcription locus and carry out this role (124). 
Taking into account that MALAT1 and NEAT1 are separated by approximately 70kb, it is 
conceivable that coordinated deregulation of both loci may hinder alternative splicing by 
controlling the nuclear localization of splicing factors as well the control of RNA editing and 
export, further contributing to prostate carcinogenesis (10). Indeed, both MALAT1 (125) and 
NEAT1 (126) are overexpressed and possess pro-tumorigenic activity in PCa. MALAT1 
overexpression in primary PCa is associated with higher Gleason score, pathological stage 
and serum PSA >20ng/ml (127). Besides it association with poor prognosis, MALAT1 
expression is significantly increased in castration-resistant PCa (CRPC) compared to 
hormone sensitive PCa (127). Functional assays using siRNA specific to knock down 
MALAT1 expression in 22RV1 and LNCaP-AI cells inhibited cell cycle at G0/G1 phase, 
migration and invasion (127). RNAi silencing of MALAT1 in PCa xenografts of castrated male 
nude mice resulted in significant reduction of tumor volume and metastasis number, 
increasing survival time (127). Whether these alterations are specific of MALAT1 or are the 
combined effect in downstream genes (e.g., RNA splicing deregulation) controlled by 
MALAT1 is still a matter under study. Using EZH2 antibody-based RNA immunoprecipitation 
combined with next generation sequencing (RIP-seq), EZH2 was found to bind to MALAT1 
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(125). Both GST pull-down and RIP assays showed that the 3' end of MALAT1 interacts with 
the N-terminal of EZH2. Moreover, MALAT1 and EZH2 are positively correlated, in CRPC 
samples. Moreover, depletion of MALAT1 impaired EZH2 recruitment to its target loci 
(DAB2IP and BRACHYURY) and caused its upregulation, suggesting that MALAT1 mediates 
EZH2-enhanced migration and invasion in CRPC cell lines (125). Moreover, MALAT1 
enhances expression of PRC2-independent target genes of EZH2 both in vitro and in patient-
derived xenografts (TMEM48 and KIAA0101) (125). 
NEAT1 is an ERα-regulated lncRNA, upregulated in PCa, producing two RNA isoforms that 
overlap completely at the 5’-end. The shorter isoform is 3.7 kB in length and more abundant 
than the longer, 23 kB, isoform (NEAT1_2) (126). NEAT1 expression is a prognostic 
biomarker for aggressive PCa independent of standard clinical and pathologic parameters 
(126). Oestrogen treatment upregulates NEAT1 transcript levels in a time-dependent manner 
and in VCaP cells results in re-distribution of NEAT1 from paraspeckles to an enhanced 
distribution throughout the nucleus (126). Knockout of NEAT1 compromised the expression 
of ERα target genes, suggesting that NEAT1 is not only a downstream target but also a 
mediator of ERα signalling in PCa cells. NEAT1 transcriptionally regulates a compendium of 
genes known to be involved in PCa progression, including PSMA and GJB1 (126). 
Overexpression of NEAT1_1 significantly increased active chromatin marks H3K4Me3 and 
H3AcK9 at the PSMA promoter and induced subsequent recruitment of NEAT1_1 and ERα 
to the same promoter. RNA immunoprecipitation revealed that NEAT1 directly interacts with 
histone H3, favoring a chromatin landscape for active transcription through active histone 
marks (126). Phenotipically, knockdown of NEAT1 in VCaP cells significantly decreased 
proliferation and the invasive properties of cells. Overexpression of NEAT1 resulted in a 
significantly higher number of viable colonies, establishing an oncogenic role for NEAT1 
(126). In athymic nude mice, injection of either VCaP or NCI-H660 overexpressing NEAT1, 
resulted in a significantly higher tumour growth rate, compared to scramble cells. Moreover, 
in vitro NEAT1 expression is inhibited when cells are treated with ERα antagonists in 
combination with E2. Similar results observed with AR antagonists enzalutamide and 
bicalutamide, suggest that NEAT1 is associated with resistance to therapeuty (126). Thus, 
these data suggest a role for paraspeckles in the lncRNA-mediated regulation of gene 
expression in PCa. 
 
iv. lincRNAs deregulation in PCa 
Long intervening noncoding RNAs (lincRNAs) are emerging as key regulators of diverse 
cellular processes but determining their individual function remains a challenge. lincRNAs 
are also called long intergenic noncoding RNAs, although lincRNAs derive from genes and 
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are thus genic, which do not overlap with exons of either protein-coding or other non-lincRNA 
types of genes (19).  
Ab initio transcriptome sequencing of polyA+ RNA from 102 PCa tissues and cell lines 
revealed a total of 1,859 unannotated lincRNAs throughout the human genome (128). A set 
of 121 of those transcripts accurately distinguished benign, localized and metastatic PCa by 
unsupervised clustering. PCAT-1 (located in the 8q24 gene desert) is predominantly 
cytoplasmic and was upregulated in PCa samples especially in high-grade (GS≥7) and 
metastatic tumors. Strikingly, PCAT-1 and EZH2 expression were nearly mutually exclusive, 
suggesting that their expression may define two subsets of high-grade disease. However, 
upregulation of PCAT-1 was not dependent of 8q24 amplification (128). Inhibiting EZH2, 
using either shRNAs or DZNep, caused a dramatic up-regulation of PCAT-1 in VCaP cells. 
ChIP assay showed that SUZ12, a core component of PRC2, directly binds to PCAT-1 
promoter ~1kb upstream of TSS (128). By RNA immunoprecipitation, it was demonstrated 
that PCAT-1 binds to SUZ12 protein in VCaP cells, a feature that was abolished by RNase A, 
RNase H or DNase I treatment. This suggests that PCAT-1 exists primarily as a single-
stranded RNA and secondarily as a RNA/DNA hybrid. Moreover, PCAT-1 stable 
overexpression in RWPE cells promoted cell proliferation, and RNAi silencing decreased cell 
proliferation in LNCaP but not in DU145 (lacks PCAT-1 expression) or VCaP cells (PCAT-1 
is repressed by PRC2) (128). Genomewide expression analysis of LNCaP cells after 
treatment with siRNAs against PCAT-1 disclosed upregulation of 255 genes and repression 
of 115 genes, revealing that PCAT-1 is predominantly repressive. Additionally, the 
upregulated genes showed enrichment for mitosis and cell cycle (128). Specifically, PCAT-1 
targets BRCA2, CENPE and CENPF, whose expression is upregulated upon PCAT-1 
silencing in LNCaP cells. Further research demonstrated that PCAT-1 overexpression 
decreased RAD51 foci formation (a component of homologous recombination, HR) after 
therapy with PARP1 inhibitors and PCAT-1 knockdown increased foci formation upon 
therapy, in PCa cells (129). BRCA2 inactivation impairs both HR and double stranded DNA 
break repair (DSB). PCAT-1 expression is correlated with decreased BRCA2 levels, and in 
vitro, the 5’ end of PCAT-1 is able to directly repress the activity of BRCA2 3’UTR (129). 
PCAT-1 overexpression produces a functional deficiency in HR through post-transcriptional 
repression of BRC2 tumor suppressor, which, in turn, reveals a high sensitivity to small 
molecule inhibitors of PARP1, both in vitro and in vivo (129). Whether PCAT-1 may act as 
predictive biomarker for patient response to PARP1 inhibitor therapy is still to be proved.  
PCAT-1 is located 725kb upstream of the MYC oncogene (130). Overexpression of PCAT-1 
in DU145 and RWPE increased c-MYC protein levels, while silencing of PCAT-1 in LNCaP 
decreased c-MYC protein, suggesting a cis-regulation involving these loci (130). Strikingly, c-
MYC silencing fully abrogated the proliferative effects of PCAT-1 overexpression in DU145 
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and RWPE, indicating that PCAT-1 mediated cell proliferation is dependent of c-MYC 
overexpression. Luciferase assay revealed that PCAT-1 overexpression increased cMYC 
3’UTR activity, whereas silencing of PCAT-1 decreased c-MYC 3’UTR activity. 
Mechanistically, this suggests that PCAT-1 regulates c-MYC in a post-transcriptional manner 
by 3’UTR activation, which can result in gene activation and increased protein abundance 
[95]. 
Another important lincRNA in PCa is SChLAP1 (second chromosome locus associated with 
prostate-1; also designated LINC00913) (131). SChLAP1 is located in a ‘gene desert’ on 
chromosome 2q31.3 and is highly expressed in ~25% of PCa, being more frequently 
expressed in metastatic compared to localized PCa. Its expression was associated with ETS 
gene fusions and PTEN deletions in localized PCa (131). Moreover, SChLAP1 levels 
independently predict poor outcome, including metastasization and PCa–specific mortality 
(131). Knockdown of SChLAP1 dramatically impaired cell invasion and proliferation in vitro 
and, in turn, overexpression of a siRNA-resistant SChLAP1 isoform rescued the in vitro 
invasive phenotype of 22Rv1 cells treated with siRNA. Overexpression of the three 
SChLAP1 isoforms in RWPE cells dramatically increased the ability of these cells to invade 
in vitro but did not affect cell proliferation. In vivo, SChLAP1 depletion impaired metastatic 
seeding and growth. Overall, SChLAP1 seems to control tumor invasion and metastasis by 
influencing cancer cell intravasation, extravasation and subsequent tumor cell seeding (131). 
Using Gene Set Enrichment Analysis of 22Rv1 and LNCaP cells with SChLAP1 knockdown, 
SChLAP1-regulated genes were correlated with the SWI/SNF complex, a multiprotein 
complex know to physically rearrange nucleosomes at gene promoters, thus controlling 
transcription (131). Mechanistically, SChLAP1 co-immunoprecipitates with SNF5 and 
attenuates SNF5 genome-wide localization. Upon knockdown of SChLAP1, 9 of 12 target 
genes disclosed a substantial increase in SNF5 binding. These data sustain that oncogenic 
SChLAP1 overexpression antagonizes the tumor-suppressive role of SWI/SNF complex 
function by attenuating the genomic binding of this complex, thereby impairing its ability to 
properly regulate gene expression (131). 
Prostate cancer antigen 3 (PCA3) is a spliced intronic antisense lncRNA embedded within 
intron 6 of the corresponding sense gene PRUNE2 and upregulated in PCa samples, holding 
promise as biomarker for PCa detection (132). PCA3 controls PRUNE2 levels via a unique 
regulatory mechanism involving formation of a PRUNE2/PCA3 double-stranded RNA that 
undergoes ADAR-dependent adenosine-to-inosine RNA editing (132). Because Drosophila 
behavior human splicing (DBHS) protein P54NRB binds to inosine-containing RNA (RNA-I), 
regulating gene expression, it was found, using RNA-ChIP, that PCA3 and PRUNE2 pre-
mRNA species associate with P54NRB protein, suggesting that DBHS proteins also 
contribute for PRUNE2/PCA3 regulation (132). In vitro stimulation with a synthetic 
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testosterone homolog induced PCA3 expression and decrease PRUNE2 levels [97]. PCA3 
silencing or ectopic PRUNE2 expression decreased cell proliferation and transformation in 
vitro; in contrast, PRUNE2 silencing or ectopic PCA3 expression increased cell proliferation 
and transformation (132). PRUNE2-deficient PC3 cells stably expressing ectopic PRUNE2 
display lower levels of proliferation and transformation in vitro, consistent with the negative 
regulation of PRUNE2 by PCA3 (132). In SCID mice, PRUNE2 silencing and ectopic PCA3 
expression yielded markedly larger tumor xenografts than controls; in contrast, tumor growth 
was significantly diminished compared to controls when PCA3 was silenced, further 
illustrating the oncogenic activity of PCA3 (132). Serum PSA was increased in SCID mice 
injected with LNCaP cells with ectopic PCA3 expression or PRUNE2 silencing, compared to 
controls (132). In human PCa samples, PCA3 and PRUNE2 levels inversely correlate. 
Moreover, A>G/T>C alterations were the most frequent substitutions, indicative of A-to-I 
editing in both PCA3 and PRUNE2 pre-mRNA strands (132). These results establish PCA3 
as a dominant-negative oncogene and PRUNE2 as a tumor suppressor gene in PCa, and 
their regulatory axis represents a putative target for clinical intervention (132). 
 
v. Pseudogenes 
CXADR-ψ, a processed pseudogene on chromosome 15, parental of the tumor-suppressor 
CXADR, was found overexpressed in PCa tissues compared to benign tissue samples (91). 
CDNA cloning from two PCa samples positive for CXADR-ψ showed perfect sequence 
similarity to the pseudogene CXADR-J and only 84% to CXADR wild-type gene (91). No 
correlation was depicted for CXADR and CXADR-ψ. Interestingly, CXADR-ψ expression was 
nearly restricted to PCa lacking an ETS gene fusion, with few ETS-positive samples 
exhibiting expression of this pseudogene (91). On the other hand, CXADR gene expression 
was found in both ETS-positive and ETS-negative samples (91). In the same study, a PCa-
specific readthrough transcript involving KLK4, an androgen-induced gene, and KLKP1, an 
adjacent pseudogene, was identified. KLK4-KLKP1 transcript was highly expressed in 30%–
50% of PCa tissues, and this expression was lineage and cancer specific, with low 
expression detected in benign prostate and other tissues (91). KLK4-KLKP1 transcript was 
previously described in LNCaP as a cis sense-antisense chimeric transcript (91). This 
chimeric transcript is composed of the first two exons of KLK4 and the last two exons of 
KLKP1. It retains an open reading frame incorporating 54 amino acids encoded by the 
KLKP1 pseudogene in the putative chimeric protein (91). Additional studies are needed to 
understand the biological role of the chimeric transcript KLK4-KLKP1 in PCa biology.  
Pseudogene transcription has also been shown to regulate cognate wild type gene 
expression by sequestering miRNA acting endogenous miRNA sponges, or competing 
endogenous RNAs (ceRNAs) (79). ceRNAs communicate and co-regulate each other by 
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competing to bind to a common pool of miRNAs, thus altering miRNA availability and 
stoichiometry (79). PTENP1 pseudogene has been reported to regulate levels of its cognate 
gene, PTEN, by competing for shared miRNAs (79). Both miR-19b and miR-20a (normally 
over-expressed in PCa) suppressed both PTEN and PTENP1 mRNA abundance. Blocking 
miR-17 and miR-19 family increased PTEN/PTENP1 levels, highlighting a shared miRNA-
mediated regulation between these two genes and highlights the role of PTENP1 as a tumor 
suppressor acting as a decoy for oncogenic miRNA-targeting of PTEN (79). Additionally, 
KRAS/KRAS1P transcript levels are positively correlated in PCa and KRAS1P 3’UTR 
overexpression in DU145 cells resulted in increased KRAS mRNA abundance and cell 
growth. These data support a role for KRAS1P in PCa, being targeted by KRAS-targeting 
miRNAs. In silico analysis revealed that KRAS1P maintains the validated binding sites for 
miR-143 and let-7 family previously reported for KRAS [44]. These data provide a framework 
of pseudogenes as natural miRNA decoys in PCa development. 
 
vi. Transcribed ultraconserved region (T-UCR) 
Ultraconserved regions (UCR) are genomic sequences with 100% conservation between 
human and rodent genomes, more than 200 base pairs in length but not harboring any 
known gene (133). Due to the high levels of sequence conservation, UCR must have 
biological functions essential to mammalian cells, although still largely enigmatic. Some UCR 
have been functionally implicated in transcriptional enhancement, alternative splicing, 
nonsense mediated decay mechanisms or miRNA-binding decoys (133). There are 481 
UCRs described, some of which overlap with coding exons, although it is believed that more 
than half of them do not encode any protein. Surprisingly, 68% of UCRs (i.e., 325) are 
transcribed, defining a new class of long non-coding RNA: T-UCRs (134). Many transcripts 
from T-UCRs are polyadenylated and enriched for H3K4me3 at the TSS (135). Although 
UCRs range from 200 to 779 bp in length, the transcriptional units of T-UCRs (the non-
spliced, full-length cDNAs) are usually up to 2 kb for known T-UCRs (134, 136). T-UCRs are 
expressed in normal tissues both ubiquitously or in a tissue-specific pattern.  
The expression profile of the 481 known UCR revealed that particular T-UCRs are 
deregulated in PCa, including uc.106+, uc.477+, uc.363+A, uc.454+A, associating with 
cancer progression, Gleason score, and extraprostatic extension (133). Modulation with the 
epigenetic drugs TSA and 5-AzaC increase uc.283+A expression while treatment with R1881 
increased the expression of uc.287+ and repressed uc.283+A expression, indicating that 
both epigenetic factors and androgens are responsible for regulation of T-UCRs. 
Genomewide expression analysis of LNCaP cells treated with a specific siRNA against 
uc.106+ or sicontrol indicated that uc.106+ might impair cellular transcription of genes 
involved in cell proliferation and cell death, as well as immune response. Although the 
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experimental concept of this work (133) was not the most clear, it showed, for the first time, 
differential expression of T-UCR in prostate tissue samples.  
The SNP rs8004379 in the UCR uc.368 is significantly associated with BCR (137). 
Interestingly, the variant allele, C, for rs8004379 indicates a decreased risk of BCR in a 
dose-dependent manner after adjusting for age, PSA level, pathologic Gleason score, and 
stage (137). RNA secondary structure prediction reveals that rs8004379 has a marked effect 
on uc.368 RNA structure, with a slight reduction in the free energy of the C allele compared 
to the A allele. Moreover, this SNP is located in the intron of NPAS3 gene, and C allele in 
rs8004379 is correlated with increased NPAS3 expression (137).  
More detailed investigation is needed to establish a role for T-UCR in PCa.  
 
 
Table 3. lncRNA manipulation and consequential phenotypes in PCa 
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4. Clinical utility of ncRNA in PCa management 
 
a. Diagnostic and Prognostic Biomarkers 
The emergence of regulatory RNA offers several putative benefits, due to its tissue- and 
cancer-specific expression and involvement in the regulation of PCa hallmarks (Figure 6). 
Serum PSA is currently in widespread clinical use, increasing prostate cancer early 
detection. However, its lack of specificity results in high negative biopsy rate, overdiagnosis 
and overtreatment of PCa (138). NcRNAs may, thus, provide new biomarkes to accurately 
diagnose PCa, improve disease management and reduce overtreatment. Given that 
sncRNAs are resistant to variations in temperature and pH as well as to endogenous RNase 
activity, they offer unprecedented potential to become blood/urine-based biomarkers (139). 
Serum samples from men with low-risk, localized PCa and metastatic CRPC have been 
shown to exhibit distinct circulating miRNA signatures (140). Indeed, miR-21 (141), miR-141 
(139, 140), and miR-375 (140) expression levels are increased in the plasma/sera and 
discriminate patients with advanced PCa from healthy controls, associating with poor 
prognosis. Moreover, miR-21 serum levels are particularly elevated in patients resistant to 
docetaxel-based chemotherapy (141). 
Indeed, miR-21 (141), miR-141 (139, 140), and miR-375 (140) expression levels are 
increased in the plasma/sera and discriminate patients with advanced PCa from healthy 
controls, associating with poor prognosis. Moreover, miR-21 serum levels are particularly 
elevated in patients resistant to docetaxel-based chemotherapy (141). In two independent 
cohorts, promoter hypermethylation of GABRE~miR-452~miR-224 predicted biochemical 
recurrence after radical prostatectomy (142). Moreover, GABRE~miR-452~miR-224 
methylation levels also accurately distinguished non-malignant from PCa samples (AUC: 
0.98), suggesting that this locus might be suitable for urine-based PCa detection. No only 
GABRE~miR-452~miR-224 has biomarker potential, but re-expression of miR-224 and miR-
452 impaired cell viability, migration, and invasion capabilities (142).  
The lncRNA PCA3 is markedly overexpressed in more than 95% of primary PCa (143). Due 
to its PCa-specificity, urinary detection of PCA3 has been developed as a PCa detection test 
with superior tumor specificity compared to PSA (138). FDA approved this test for clinical use 
under the name of Progensa PCA3 with the ultimate goal of aiding in the decision of repeat 
prostate biopsy. However, correlations between PCA3 expression and clinical and 
pathological parameters are conflicting, although some studies reported that PCA3 test is 
negative in men with indolent PCa (144). To improve its performance as a prognostic 
biomarker, PCA3 was combined with other de-regulated genes, such as TMPRSS2-ERG. In 
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two independent prospective, multicentric, evaluations the panel composed of PCA3 and 
TMPRSS2-ERG showed superior PCa specificity over serum PSA. This finding might help 
reduce the number of excessive prostate biopsies (145) and could also have utility for risk 
stratification in an active surveillance setting (146). 
 
 
 
Figure 6. lncRNAs as master regulators of PCa phenotype.  
Alterations in genomic sequence and/or expression levels in PCa cells led to initial 
identification of PCa-associated lncRNAs. Subsequent functional studies directly connected 
some of the identified lncRNAs with prostate carcinogenesis. Those not only control some of 
the hallmarks of cancer but also contribute to androgen-independent growth, transcriptional 
regulation and may be of value for clinical management of PCa patients 
 
 
ncRNAs may also be detected in exosomes secreted into blood stream or urine. Exosomes 
are membranous vesicles containing various biomolecules, including lncRNAs, involved in 
cellular communication and are secreted from many cells, including cancer cells. Combining 
sncRNA-sequencing and qPCR validation in exosomes derived from CRPC patients, 
increased expression of miR-1290 and miR-375 was found in exosomes and associated with 
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decreased overall survival in CRPC patients (147). A multivariate model that included miR-
1290 and miR-375 levels, ADT failure time, and PSA levels at the time of CRPC stage, 
concluded that patients with a high risk score had a 2.58-fold higher risk of death than 
patients with a low-risk score (HR: 2.58; 95% CI, 1.51–4.41) (147). In exosomes purified from 
urine samples either from PCa patients and individuals with benign prostatic hyperplasia 
(BPH), the expression levels of lincRNA-p21 were significantly higher in PCa, discriminating 
from BPH (148). The biomarker performance of lincRNA-p21, however, was disappointing 
(67% sensitivity and 63% specificity). Combination with serum PSA increased specificity to 
94%, but sensitivity decreased to 52%. Testing in larger cohorts is needed to fully disclose 
the biomarker potential of exosomal ncRNAs in PCa.  
 
b. ncRNAs as tools for genomic epidemiology and risk prediction 
Over the last years, genomewide association studies have become a routine tool to identify 
germline SNPs and cancer-associated genetic variations that map to non-coding coordinates 
(149). The vast majority of those SNPs are located whithin enhancers, but others are 
localized within ncRNA-gene body (150). Although PCa risk-related loci were enriched in 
lncRNAs, the SNP density in regions of lncRNA was similar to that of protein-coding regions 
(151). The 8q24 region has been identified as the most important susceptibility region for 
PCa (152). This 1.2 Mb stretch of the genome is enriched for lncRNAs, including PCAT1, 
PRNCR1 and PVT1 and it also harbors the c-MYC gene. The eight SNPs detected at 8q24 
account for approximately 8% of the 2-fold increased risk of PCa in first-degree relatives of 
men with the disease (152). The link between 8q24 SNPs and PCa risk is, however, not clear 
although the proximity to c-MYC oncogene suggests that these SNPs might be involved in 
long-range control of MYC expression, notwithstanding the lack of experimental data to 
support this speculation (152). 
Mapping of DNase I hypersensitive sites identified a variant called rs378854, which is in 
complete linkage disequilibrium with rs620861, as a novel functional PCa-specific genetic 
variant (153). In vitro, the risk allele (G) of rs378854 reduces binding of the transcription 
factor YY1 (a putative tumor-suppressor in PCa). Chromatin conformation capture 
experiments depicted that the region surrounding rs378854 interacts with MYC and PVT1 
promoters. Moreover, expression of the PVT1 oncogene in normal prostate tissue increased 
with the presence of the risk allele of rs378854, whereas expression of MYC was not 
affected (153).  
Collectively, clinical use of some SNPs may help to identify patients at risk for PCa and may 
stratify patient phenotypes (such as clinically aggressive vs. indolent) and outcome. The use 
of specific SNPs may also be useful to predict patients’ response to therapy.  
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5. Discussion & Conclusions 
RNA is not only functional as a messenger between DNA and protein but it is also involved in 
the regulation of genome organization and gene expression, which is extremely elaborated in 
complex organisms. Among the challenges in the coming years, depiction of the crosstalk 
between different types of structural RNAs as well as the hierarchy of RNA- and protein-
mediated regulation of gene expression that contribute to PCa are capital. Additionally, 
characterization of the mechanisms mediating RNA communication between PCa cells and 
mapping the genomic locations of RNA-binding sites (66) are mandatory to further 
understand the how gene expression control and cell state decisions are accomplished in 
PCa. Will ncRNA help on achieving a better definition of PCa as single pathological entity or 
ncRNA profiling may render a subclassifcation of PCa?  
Cellular RNAs contain more than a hundred structurally distinct post-transcriptional 
modifications at different sites (154). These RNA modifications may play an adaptive role 
that can fine-tune the structures and functions of mature RNAs to influence gene expression 
(154). Some post-transcriptional RNA modifications can be dynamic and might have 
regulatory roles equivalent to those of post-translational protein modifications. Therefore 
RNA epigenetics will help determine both mechanisms and functions of these dynamic RNA 
modifications and ultimately define the “prostate cancer epitranscriptome”.  
Genome-editing using CRISPR approaches will offer the capability to dissect ncRNAs 
functions. Moreover, it will provide the ability to directly modify or correct critical PCa-
associated alterations by targeting a genomic locus with an engineered guide RNA, offering 
new therapeutic options for PCa.  
During prostate epithelial transformation, AR cistrome undergoes extensive reprogramming. 
Accordingly, androgen-induced eRNA scaffolds AR-associated protein complexes that 
modulate chromosomal architecture, suggesting that eRNAs are the most critical RNAs 
involved in PCa.  
Translating the developments in RNA biology and technology updates into deeper 
understanding of prostate carcinogenesis may assist in the advance of precision medicine, 
providing not only new and more robust biomarkers (either single or panel ncRNA) but also 
paving the way for patient-tailored RNA-based therapies, as an alternative to currently 
available therapeutic strategies. The age of RNA has come. 
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2.2. Epigenetic regulation of miRNA biogenesis 
Epigenetics represents a new molecular dimension in cancer research and directly controlls 
the key hallmarks of cancer cells (48). These alterations are dynamic in their nature and are 
major determinants of chromatin architecture to allow access of condensed genomic DNA to 
the regulatory transcription machinery proteins, and thereby control gene expression (48). 
MiRNA’s genes can be epigenetically silenced through DNA methylation and due to covalent 
histone modifications (49). 
Cytosine methylation is a DNA modification generally associated with transcriptional 
silencing. The cytosine base in DNA can be methylated to become 5-methylcytosine (5mC), 
and are sometimes referred to as the “5th nucleotidic base”. Approximately, half of the genes 
in vertebrate genomes contain small (around 1kb) CpG-rich regions recognized as CpG 
islands (CGIs), and the rest of the genome is depleted for CpGs (50). Another important 
epigenetic mechanism is histone modifications and chromatin alterations. Alterations in the 
patterns of histone Post-Translational Modifications (PTMs) have been extensively linked to 
cancer, both at the global level across the genome (51). It is clear that histones’ PTM 
mediates a variety of critical biological processes, generally via chromatin modification that is 
conducive to the expression or repression of target genes, including miRNA genes (51). 
Promoter methylation and histone marks represent significant means of silencing various 
tumor-suppressor genes in the cell, an important contribution to gene expression regulation 
(48). Thus, it is now accepted that miRNA genes can be epigenetically regulated through 
epigenetic alterations. Like to other RNA POLII transcripts, miRNA genes have TATA boxes 
and Transcription Factor II B (TFIIB) binding sites upstream of the transcription start site. 
Moreover, the DNA sequence of miRNA genes contains upstream regulatory elements (e.g. 
enhancers), and promoter regions. This is an additional proof that miRNAs are subjected to 
dynamic methylation regulation via DNA methyltransferases or active DNA demethylation, 
histone modifications, or binding of transcription factors to canonical sites within miRNA 
promoters to either promote or repress transcriptional activation (49). Since DNA methylation 
is a tissue-specific trait as well as a tumor-specific one, its potential as a biomarker has also 
been extensively explored. Methylated genes appear to have a higher specificity for cancer. 
DNA methylation is an interesting alteration for laboratory testing since it is far more stable 
and easier to work with than RNA and its isolation and detection is rather straightforward 
(52).  
The book chapter entitled “DNA Methylation Alterations as Biomarkers for Prostate Cancer” 
covers the basic concepts of DNA methylation gene regulation in PCa. Moreover, it 
discusses whether altered epigenetic patterns may serve as useful biomarkers for PCa 
management, and reviews the effectiveness of miRNA’s promoter methylation as novel PCa 
biomarkers for routine clinical practice.  
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Abstract  
Prostate cancer (PCa) is the most common noncutaneous malignancy and a leading cause 
of cancer-related death among men. During prostate cancer development and progression, 
tumor cells undergo abnormal epigenetic modifications, including alterations in DNA 
methylation patterns. DNA methylation, the most studied epigenetic alteration in human 
cancer, is associated with transcriptional repression of both coding and non-coding regions 
of the genome. The relevance of aberrant DNA methylation for cancer risk assessment, 
diagnosis and therapy monitoring in different cancer types, including prostate cancer, is 
increasingly acknowledged. Aberrant DNA hypermethylation, especially at gene promoters, 
is widespread during prostate carcinogenesis, suggesting that restoration of a normal 
prostatic cell epigenome through treatment with demethylating drugs could be clinically 
beneficial. Herein, we discuss the role of DNA methylation changes in PCa and how these 
may translate into the clinical management of PCa patients. 
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Introduction 
Prostate cancer (PCa) is the most commonly diagnosed cancer in men, with an estimated 
250,000 new cases in the United States diagnosed each year, ranking second in cancer-
related mortality. The risk factors for PCa include aging, race (e.g., Afro-American men are 
more prone to develop PCa whereas native Japanese are at low risk for developing PCa) 
and family history of PCa (susceptibility genes may contribute up to 5-10% of all detected 
PCa cases) (1). 
Presently, most patients are diagnosed after detection of elevated serum PSA levels or 
abnormal digital rectal examination, which entail diagnostic prostate biopsy. Clinically 
localized PCa, which is potentially curable, is usually treated with radical prostatectomy or 
radiation, although patients with low-risk disease or short life expectancy may be managed 
expectantly (e.g., through periodic serum PSA measurements and repeat biopsies, if 
required, to assess disease progression). Conversely, patients with locally advanced or 
metastatic (i.e., mostly incurable) disease are initially treated with androgen-deprivation 
therapy (ADT). However, almost all advanced PCa cases, after a period of ADT, progress to 
castration-resistant disease, an aggressive and highly lethal form of PCa (1, 2). 
Prognostication of PCa behavior mostly relies in histological grading, staging and baseline 
serum PSA levels. PCa histological grading is based on the Gleason grading system, which 
combines five simple grades [from grade 1 (most differentiated) to 5 (least differentiated)] 
into 9 combined grades, the so-called Gleason score or sum (ranging from 1+1 to 5+5), a 
feature that incorporates information from the frequent morphological heterogeneity of PCa 
(3). Among putative precursor lesions, the most widely acknowledged is high-grade prostatic 
intraepithelial neoplasia (PIN) which consists of malignant-appearing cells still confined to 
prostate acini, with at least partial preservation of basal layer cells (4). Interestingly, it is 
hypothesized that PCa may originate from either luminal or basal epithelial cells, frequently 
arising as multiple disease foci, thus contributing to wide diversity and heterogeneity at the 
molecular, cellular, and morphological levels (2).  
Prostate carcinogenesis seems to require the acquisition of large-scale genomic 
rearrangements and copy number alterations involving multiple chromosomes. Indeed, 
oncogenic fusions, such as TMPRSS2-ERG, are found in ~50% of all PCa, as well as in 
smaller proportion of high-grade PIN (2). Moreover, loss of tumor suppressor genes PTEN, 
NKX3.1, TP53, and CDKN1B are often identified in PCa and next-generation sequencing is 
providing further evidence for molecular sub-classification of PCa based on CDH1 
alterations, SPINK1 overexpression, ERG rearrangements and SPOP mutations (2, 5-7).  
Given the lack of specific therapeutic targets, high prevalence and the prolonged latency 
period of PCa, the role of chemoprevention has been emphasized. Currently, the most 
encouraging agents are 5-α reductase inhibitors, which prevent the conversion of 
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testosterone to dihydrotestosterone, the most active prostatic androgen. However, early 
development of resistance to ADT with consequent clinical progression due to the acquisition 
of castration-resistant phenotype is a main concern (2). The pathways involved in castration 
resistance are not fully elucidated, but accepted mechanisms include (a) intratumoral 
androgen biosynthesis, (b) androgen receptor (AR) pathway hypersensitivity via AR gene 
amplification, (c) expression of variant AR isoforms that are ligand-independent, (d) selection 
of pre-existing castration-resistant epithelial stem cells, (e) growth factor-mediated increase 
in AR transcription activity and (f) activation of the PI3K-AKT-mTOR pathway (7-9). 
Treatment of castration-resistant PCa (CRPCa) is mostly restricted to taxane-based 
chemotherapy and palliative care. Nevertheless, new drugs that seem to tackle CRPC with 
proven survival benefits, such as abiraterone (blocks androgen production) and 
enzalutamide (inhibition of androgen binding to AR), are able to prolong survival in men with 
metastatic CRPC after docetaxel treatment (7).  
Owing to the importance of early diagnosis of PCa (which is clinically silent at its earliest 
stages) to increase disease survival, there has been an intensive search for specific PCa 
biomarkers. Serum PSA remains the most widely used biomarker but its usefulness has 
been recently questioned due to its lack of specificity and inability to accurately identify 
aggressive forms of PCa, causing overdiagnosis and overtreatment (10, 11). Moreover, 
currently used prognostic parameters, such as the Gleason score are limited in their ability to 
predict disease behavior, in particular for patients with Gleason score 7, which constitutes 
most of diagnosed PCa cases at present. Thus, the discovery of novel biomarkers that may 
identify clinically significant PCa, discriminating these from indolent tumors, is a major 
challenge, which can be met through the study of PCa epigenetics. 
The term “epigenetics” was first used to explain why genetic variations occasionally did not 
lead to phenotypic deviations and how genes might interact with their environment to 
generate a phenotype (12). Currently, epigenetics refers particularly to the study of mitotically 
and/or meiotically heritable changes in gene expression not caused by alterations in the DNA 
sequence (13). In general, epigenetic mechanisms comprise DNA methylation, covalent 
histone modifications and noncoding RNA regulation. Epigenetic homeostasis is fundamental 
to a multitude of biological processes such as transcription, DNA replication, and repair. The 
disruption of these regulatory mechanisms affects an array of shared and specific cellular 
processes, influencing the genomic output, and triggering several diseases, including cancer 
(14, 15). 
Chemical modifications of DNA have been annotated as major players for maintenance of 
the cellular homeostasis and memory. Such DNA modifications include 5-methylcytosine 
(5mC), 5-hydroxymethylcytosine (5hmC) and the less common 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) (16). The addition of a methyl group to a carbon 5 position (5mC) is 
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a common epigenetic mark in many eukaryotes and it is regularly found in the sequence 
context of CpG (cytosine nucleotide-phosphate-guanine nucleotide) or CpHpG (H = A/T/C) 
(17). This is, by far, the most widely studied epigenetic modification in humans (15). In 
mammals, this cis-regulatory alteration is primarily restricted to symmetrical CpG context. 
DNA methylation is dynamic and heritable: methyl groups can be added or removed and can 
remain stable throughout multiple cell divisions. The CpG dinucleotides are predisposed to 
organize in domains called CpG islands (18). These are defined as regions of more than 200 
bp in length, with a GC content of at least 50% and a ratio of observed to statistically 
expected CpG frequencies of at least 0.6. CpG dinucleotides are relatively uncommon in 
mammalian genomes (~1%). There are approximately 28 million CpGs in the human 
genome, 60-80% of which are generally methylated. Only less than 10% of CpGs are found 
in CpG islands. High levels of 5mC in CpG-rich promoters are strongly associated with 
transcriptional repression, whereas CpG-poor regions exhibit a more intricate and context-
dependent relationship between DNA methylation and transcriptional activity. 
Of all human gene promoters about 60% are associated with CpG islands and these are 
often unmethylated in normal cells, although some of them (~6%) progress to a methylated 
state in a tissue-specific manner through early development or in differentiated tissues (19). 
Likewise, CpG nucleotides located in repetitive sequences, inserted viral sequences and 
retrotransposons are also methylated in normal cells (18), to avoid transcription of these 
elements and maintain genomic integrity by obstructing recombination events that may lead 
to gene disruption, oncogene activation, translocations, and chromosomal instability during 
development and differentiation (20). Thus, epigenomic states are established in normal cells 
as result of development (18). This is due to the marks present in DNA and chromatin 
structure and the cell state is maintained through mitosis (18).  
Chemically, 5-methylcytosine is the result of the addition of a methyl group, donated by S-
adenosylmethionine (SAM), to the fifth carbon of the cytosine residue ring, mediated by DNA 
methyltransferase (DNMT) (21, 22). There are five main DNA methyltransferases (23): 
DNMT1 acts on hemi-methylated DNA substrates created during DNA synthesis and 
maintains the existing methylation patterns after DNA replication and mitosis. DNMT3A and 
DNMT3B target previously unmethylated CpGs (23) and are thought to be responsible for the 
establishment of methylation patterns during embryogenesis and are also able to add methyl 
groups at non-CpG sites. DNMT2 shows sequence and structural characteristics of the 
above-mentioned DNA methyltransferases (DNMT1, DNMT3A and DNMT3B) except for a 
putative nucleic acid binding cleft that cannot easily accommodate duplex DNA. It is 
responsible for the methylation of aspartic acid transfer RNA (tRNAASP), specifically at the 
cytosine-38 residue in the anticodon loop, beside its residual DNA methyltansferase activity 
(24). DNMT3L, is structurally similar to DNMTs but do not contain the catalytic domain 
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necessary for methyltransferase activity (23). However, it has the ability to recognize DNA or 
chromatin by specific domains and interact with the unmodified H3K4(23). 
Given the dual and rather unspecific activity of DNMTs (they are able to deposit methyl 
groups at non-CpG sites), whole-genome maps of 5-methylcytosine have revealed 
interesting patterns such as cell state-dependent occurrences of 5mC in contexts other than 
canonical CpGs and in partially methylated domains (PMDs), and conserved regions 
depleted of 5mCs across mouse and human (16). 
Generation and maintenance of non-CpG methylation seems to be strictly regulated, as such 
modifications are enriched in specific cell types (e.g. pluripotent cells and neural progenitors 
in adolescent and adult cortex tissues). It is still unclear if cytosine in non-CpG methylation 
has any functional relevance in normal development and cancer (25).  
PMDs have been mostly found in non-pluripotent cells and non-cortex tissue types. These 
PMDs seem to associate with low transcription rates, lamina-associated domains and late-
replicating domains. Different classes of methylation-depleted regions entitled unmethylated 
regions (UMRs), DNA methylation valleys (DMVs) and DNA methylation canyons (DMCs) 
have been defined, as well (26, 27). These regions tend to be conserved across cell types 
and across mouse and human species. Both methylation valleys and canyons tend to be 
marked with H3K4me3 or H3K27me3 or both, and each can lead to active, inactive or poised 
transcriptional states, respectively. Interestingly, these regions cover most genes important 
for embryonic development (16, 25, 27). 
Nonetheless, there is growing evidence that CpG DNA methylation is augmented at gene 
bodies of actively transcribed genes in mammals (28). It has been proposed that it might be 
related to elongation efficiency and prevention of erroneous initiations of transcription (29). 
The transcriptional repression by DNA methylation is thought to follow two different routes: a 
direct mode in which promoter methylation obstructs the binding of transcriptional activators 
to the target promoter region (30) or an indirect mode through the recruitment of Methyl-
CpG-binding domain proteins (MBD) (31). MBDs can recruit chromatin-remodeling 
complexes to the methylated sequence, resulting in chromatin conformation changes that 
also inhibit gene transcription (32).  
DNA methylation does not occur exclusively at CpG islands. Recently, the concept of “CpG 
island shores” has been defined, referring to regions of lower CpG density that stretch out in 
close proximity (~2 kb) of CpG islands (33). Equally, the methylation of these CpG island 
shores is tightly associated with transcriptional inactivation. Indeed, the majority of the tissue-
specific DNA methylation appears at CpG island shores instead at CpG islands (33, 34). 
Differentially methylated CpG island shores are sufficient to distinguish between specific 
tissues and are conserved between human and mouse. Furthermore, 70% of the 
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differentially methylated regions in reprogramming are associated with CpG island shores 
(34, 35). 
Alterations in DNA methylation equilibrium are hallmarks of human cancer, including Prostate 
Cancer (PCa). Discrimination of driver cancer alterations from those that are merely 
passengers and, thus, not involved in malignant transformation, is a major challenge. During 
oncogenic transformation, dynamic alterations in hypermethylation and hypomethylation of 
DNA arise. Hypomethylation appears to be a global phenomenon, but some data indicate 
that it may take place at specific gene promoters, eventually causing proto-oncogene 
activation (15, 20). Hypermethylation mostly occurs in a gene promoter-context and is one of 
the main mechanisms associated with gene expression disruption due to transcriptional 
repression (15, 20, 36). 
Conventionally, DNA methylation has been associated with protein coding genes. However, 
advances in the postgenomic era revealed a large number of RNA families which were 
thought to be non-functional elements of the genome. These include a plethora of long 
noncoding RNAs (lncRNA) and small regulatory RNAs (37). These are all putative targets for 
DNA methylation, and, among them, microRNAs (miRNA) have often been considered to be 
regulated by DNA methylation (38). MicroRNAs are ~22 nucleotide-long RNA molecules that 
mediate post-transcriptional gene silencing by guiding Argonaute (AGO) proteins to RNA 
targets (39). Following transcription, miRNA are processed in the nucleus by Drosha and 
then exported to cytoplasm by Exportin-5. In the cytoplasm, DICER processes pre-miRNA 
before being loaded into the miRNA-induced silencing complex (miRISC), which contains 
AGO proteins. This complex is involved in translational repression, mRNA decay or both 
(39). DNA methylation disruption of miRNA transcription impairs miRNA processing and 
contributes to tumorigenesis (38). MicroRNAs control the expression of tumor-suppressors 
and oncogenes known to be involved in tumorigenesis, angiogenesis and metastasis. Given 
the tissue-specific expression signatures of miRNAs, they are tightly regulated and DNA 
methylation is a key effector in this process. 
 
The aberrant DNA methylation landscape of prostate cancer 
Altered epigenetic patterns may serve as useful PCa biomarkers for detection, diagnosis, 
prognosis and post-treatment surveillance, advancing on the limitations of currently available 
tools (40). Over the last years, the role of aberrant DNA methylation in the development and 
progression in PCa has been increasingly recognized. Indeed, epigenetic alterations are 
early events in carcinogenesis that may even precede the acquisition of well-defined genetic 
alterations, and persist through invasion, metastasis and life-threatening malignant 
progression. Because they do not directly affect the genome sequence, therapeutic 
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modulation through drugs that can target epigenetic modifications opens new avenues for 
PCa prevention and treatment.  
In theory, prostate cells with anomalous DNA methylation marks arise in non-malignant 
lesions, and due to a "DNA methylation catastrophe", those cells with epigenetically silenced 
genes undergo clonal selection to form a tumor (41). Conversely, during PCa progression, 
there is also a global loss of DNA methylation, probably as a consequence of reduced DNA 
methylation maintenance fidelity, contributing to distinctive cell-to-cell and lesion-to-lesion 
phenotypic heterogeneity (41). Thus, both locus-specific hypermethylation as well as global 
hypomethylation are involved in neoplastic transformation and contribute to tumor 
progression. 
Understanding how epigenetics contributes to the clonal evolution of PCa is also under 
scrutiny. Recent reports suggest that the clonal architecture of aggressive PCa is mediated 
by intratumor DNA methylation heterogeneity given the extensive epigenetic (and genetic) 
heterogeneity observed among different regions of the same tumor (42). This intratumoral 
DNA methylation heterogeneity predominantly occurs at prostate-specific gene regulatory 
elements, with androgen receptor enhancer domains constituting a good example of that 
intratumor variation in methylation patterns. Thus, not only DNA methylation plays a role in 
the regulatory activity of tumor subclones, but it may also be a key element explaining the 
convergent tumorigenic processes and the diversity of metastatic origin (42). The clues to 
understand the lethality of PCa may in fact arise from somatic DNA alterations. These 
aberrations, despite showing marked inter-individual heterogeneity among patients with 
lethal metastatic PCa, seem to be maintained across all metastases within the same 
individual (43). Regions that are frequently hypermethylated across individuals are markedly 
enriched in cancer- and development/differentiation-related genes (43). Hence, DNA 
methylation alterations have the potential to generate selectable driver events in 
carcinogenesis and disease progression (43).  
As previously mentioned, age, diet and environmental factors are thought to be involved in 
prostate tumorigenesis (40, 44), and its effects might be mediated by changes in the 
epigenetic homeostasis. Indeed, some studies pointed out that age, the most important risk 
factor for development of PCa (44), is positively correlated with increased aberrant promoter 
methylation of various genes (40), of which the age-dependent methylation of estrogen 
receptor alpha (ESR1) may represent a mechanism linking aging and PCa (45). Given the 
refined balance between stability and plasticity of DNA methylation patterns, it has been 
proposed that DNA methylation may provide a lifetime record of environmental exposures 
and might be used as a potential source of PCa biomarkers.  
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Promoter hypermethylation in prostate cancer 
The best characterized epigenetic alteration in PCa is promoter hypermethylation (36), and 
both protein coding and noncoding genes are targeted (40). This epigenetic modification is 
associated with silencing of classic tumor-suppressor genes as well as genes involved in 
different cellular pathways such as cell cycle, hormone response, DNA repair and damage 
prevention, signal transduction, tumor invasion and architecture, and apoptosis (15). The 
hypermethylation of those genes in PCa may correlate with pathological grade, clinical stage 
and castration resistance.  
Prostate is an endocrine gland, in which normal cells maintain an appropriated balance 
between sex hormones (androgen, estrogen and progesterone) and their specific receptors 
(2). Several data show that DNA methylation participates in the transcriptional regulation of 
hormone receptors (40). Androgen activity is essential for the development of both normal 
and PCa cells. From its earliest stages, PCa is androgen-dependent, a status that is kept 
during disease progression, until, eventually, tumors are enriched in cells that can grow 
independently of androgens, mostly as a result of ADT (44). The transition to this state 
androgen-independent growth has been associated with genetic alterations including 
mutations and amplifications of androgen receptor (AR) locus (46). Such alterations alter the 
sensitivity of AR to androgens and are thought to play a role in the development of 
castration-resistant PCa (CRPCa) (46). Not surprisingly, CRPCa displays a heterogeneous 
loss of AR that is associated with aberrant methylation of its promoter (47). Up to 28% of 
CRPCa cases show AR methylation (48), whereas about 20% of primary PCa display this 
alteration (49), probably at lower levels that do not significantly impair AR expression. Thus, 
paradoxically, DNA methylation might be an alternative mechanism involved in castration 
resistance in a subset of patients, through abrogation of AR expression, forcing neoplastic 
cells to develop alternative signaling pathways, increasing their biological aggressiveness. 
This may explain the observation that pharmacological reversion of AR promoter 
methylation, using 5,6-dihydro-5-azacytidine, in CRPCa cell lines restores AR activity, turning 
cells (again) sensitive to androgen deprivation therapy (50), and attenuating the more 
aggressive phenotype.  
The hormonal environment of the prostate is also dependent of estrogens and both receptors 
- ESR1 and ESR2 - display low or diminished expression in PCa (51, 52). Although an 
association between ESR1 methylation and tumor progression has been hypothesized (53), 
ESR2 methylation is the main inactivation mechanism accounting for loss of ESR2 
expression in primary PCa (54). However, during PCa progression, especially in metastatic 
PCa, cancer cells can re-express ERS2 (55), which is accompanied by promoter 
demethylation (56). This dynamic reversion of ESR2 expression is epigenetic in nature and 
consequently reversible.  
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Cell cycle is often deregulated in PCa and endows neoplastic cells with increased 
proliferative capabilities. Cell cycle is very strictly regulated, with multiple checkpoints, and all 
genes involved are putative targets for silencing through aberrant DNA methylation. Tumor 
suppressor genes from the cyclin-dependent kinases family are frequently altered in PCa 
due to several mechanisms. CDKN2A has been shown to be dowregulated due to DNA 
methylation (46), although methylation at exon 2 is more frequent than methylation at 
promoter region (57). However, exonic methylation of CDKN2A is not associated with loss of 
gene expression (57), and, thus, further studies are needed to clarify how this may impact in 
prostate carcinogenesis.  
D-type cyclins play a critical role in cell cycle regulation and their abnormal expression has 
been associated with several human malignancies. One of the best studied cyclins is Cyclin 
D2. Promoter methylation levels of CCND2 are significantly higher in PCa compared to high-
grade PIN and non-tumorous prostate tissues (p<0.01), correlating with tumor stage and 
Gleason score (58). Moreover, CCND2 mRNA levels are significantly lower in PCa, inversely 
correlating with promoter methylation, and demethylating treatment induces a substantial 
increase in CCND2 mRNA, in LNCaP cells (58). 
Methylation of SFN promoter methylation is also a frequent event in malignant prostate 
lesions, but it also affects non-tumorous tissue (59). SFN is a putative tumor suppressor 
gene involved in cell cycle regulation and apoptosis following DNA damage (59). Since there 
is a progressive accumulation of neoplastic cells with SFN methylation from HGPIN to PCa, it 
is suggested that this epigenetic event might be relevant for prostate carcinogenesis (59). 
Genes involved in signal transduction pathways are also affected by aberrant promoter 
methylation in PCa. Two of the best examples are endothelin receptor type B (EDNRB) (60) 
and the RAS association domain family protein 1 isoform A (RASSF1A) (61). The protein 
encoded by EDNRB is a G protein-coupled receptor which activates a phosphatidylinositol-
calcium second messenger system(60). Methylation of EDNRB is a frequent event in PCa 
and is associated with decreased mRNA expression (60, 62), being restored after treatment 
with 5-azacytidine (60). EDNRB silencing diminishes the capacity of PCa cells to clean and 
even block the expression the vasoconstrictor ET1, which accompanies PCa progression in 
vivo. Promoter methylation of RASSF1A, a well-known tumor suppressor, is also a common 
event in PCa as well as in high-grade PIN lesions (61, 63), associating with more advanced 
tumor stage (61). These data suggest that RASSF1A promoter methylation occurs early in 
prostate carcinogenesis and increases as PCa progresses, as methylation levels are higher 
in locally invasive tumors compared to those organ-confined (61).  
The maintenance and regulation of normal prostate tissue architecture is based on cadherin-
catenin adhesion systems. In PCa, loss of expression of the cell adhesion molecule E-
cadherin, encoded by CDH1, has been reported in association with promoter methylation of 
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CDH1, which increases with disease progression, suggesting a role in the metastatic 
potential of PCa (64). Moreover, the promoters of genes involved in the cadherin-catenin axis 
are also frequently methylated (APC, CAV1, LAMA3, TIMP3) (40), theoretically contributing 
to tumor invasion and metastization.  
One of the most acclaimed biomarkers in PCa is GSTP1, encoding the intracellular 
detoxification enzyme glutathione S-transferase π. GSTP1 promoter methylation occurs at 
the earliest stages of tumor development and is associated with transcriptional silencing (65). 
Aberrant methylation of GSTP1 is considered a hallmark of PCa, present in about 90% of all 
PCa and in 75% of high-grade PIN lesions (66, 67).  
Disruption of apoptotic pathways is key to PCa development and progression and promoter 
methylation of apoptosis-related genes is common in PCa (68). Aberrant promoter 
hypermethylation of TMS1, a pro-apoptotic tumour suppressor gene, has been reported as 
an early event in prostate carcinogenesis, correlating with higher Gleason score (69). 
Treatment with a demethylating agent restored TMS1 expression in LNCaP cells (69, 70). 
Paradoxically, the oncogene BCL2 (which is anti-apoptotic) is also a common target for gene 
silencing through DNA methylation in PCa (71), a finding that may support a role for 
apoptosis-inducing therapy in PCa. Because promoter methylation prevents the anti-
apoptotic role of BCL2, PCa cells could be more prone to endure apoptosis upon exposure to 
pro-apoptotic drugs. 
MiRNAs are critical regulators of many pathways and are often deregulated in 
carcinogenesis (72). MiRNAs are differentially expressed in PCa and may be targeted for 
downregulation by promoter methylation (73). For instance, the ability to escape apoptosis is 
an important carcinogenic event facilitated by numerous miRNAs in PCa (72).  
 
Table 1. Common microRNA inactivated by DNA methylation in Prostate Cancer 
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Other common pathways disrupted owing to miRNA deregulation include the cell cycle, 
intracellular signaling, DNA repair, and adhesion and migration (74). Table 1 summarizes the 
most relevant information about miRNAs downregulated by promoter hypermethylation in 
PCa. One of the most interesting miRNAs in PCa is miR-132, that controls cellular adhesion 
and directly targets HBEGF and TALIN2, which has been found to be methylated in 42% of 
PCa, with higher methylation levels associating with higher Gleason score and more 
advanced tumor stage (75). Interestingly, re-expression of miR-132 in PC3 cells induced cell 
detachment followed by cell death (anoikis) (75). Furthermore, miR-145 was found to be 
significantly downregulated PCa compared to normal prostate tissues and 5-aza-2'-
deoxycytidine treatment dramatically restored miR-145 expression (76). 
MiRNAs may be putative targets for epigenetic therapy in PCa since they have a role in key 
signaling pathways and are associated with multiple layers of gene regulation. Remarkably, it 
has been demonstrated that about one third of downregulated miRNA loci show a matched 
pattern of DNA methylation and H3K9 acetylation (73). This underlines the cooperation 
between the different levels of epigenetic regulation to accomplish transcriptional block of 
miRNAs.  
 
Hypomethylation in prostate cancer 
Although DNA hypomethylation was the first epigenetic alteration described in cancer, there 
are few reports on this aberration in PCa. Global DNA hypomethylation occurs at both early 
and late stages of PCa and it might serve as biomarker for early detection and 
prognostication (77-79). Global hypomethylation expands the chromatin predisposing to 
genomic instability and promoting deleterious mutations (80, 81). Loss of DNA methylation is 
associated with tumor progression and chromosome instability (80), and global lower levels 
of methylation are more evident in metastatic PCa (82). Genome-wide hypomethylation may 
trigger inappropriate transcription of proviral and retrotransposon sequences, leading to 
disruption of neighboring genes (83, 84). The LINE-1 retrotransposon is hypomethylated in 
50% of PCa samples, especially in cases with lymph node metastases (80). In addition, 
genome-wide hypomethylation is associated with gains or losses of sequences on 
chromosome 8, in localized PCa (80). The progressive genome hypomethylation seems to 
be linked with deficient DNA methylation maintenance fidelity during DNA replication and it 
probably contributes to generate cell and lesion specific phenotypic heterogeneity (41). This 
theory is supported by autopsy studies which showed low levels of DNA methylation and 
high frequency of copy number alterations in lethal PCa(78). 
Gene-specific hypomethylation in PCa has been documented for CAGE (85), CYP1B1 (86), 
HPSE (87), PLAU (88), as well as CRIP1, S100P, and WNT5A (89). Increased expression of 
HPSE, encoding the extracellular matrix degradation protein heparanase which degrades 
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heparan sulfate, has been implicated in tumor invasion and metastasis (87). Interestingly, 
PLAU (urokynase-type plasminogen activator) is associated with the acquisition of castration 
resistance and increases tumorigenesis in both in vitro and in vivo models (88). 
Loss of imprinting is also associated with aberrant biallelic expression of some genes in PCa, 
such as IGF2 (90). Thus, local and tissue-specific patterns of gene expression might prompt 
neoplastic transformation over a long period of time (40). Moreover, IGF2 hypomethylation 
may be a biomarker for early detection of PCa. 
The impact of DNA hypomethylation in overexpression of oncogenic miRNAs in PCa is very 
limited. Thus far, only miR-615 has been reported as epigenetically activated in PCa cells 
due to DNA hypomethylation (73). However, hypomethylation seems to play a role in 
deregulation of the non-coding RNA transcriptome. XIST, a single-copy gene heavily 
methylated in morphologically normal prostate cells, is hypomethylated in PCa, a feature that 
is associated with LINE-1 hypomethylation, suggesting a global hypomethylation rather than 
a promoter specific loss of methylation (91). Moreover, XIST hypomethylation is increased in 
more aggressive tumors (91).  The Melanoma antigen gene protein-A11 (MAGE-11) is a 
coregulator of the AR signaling. During PCa progression and androgen deprivation therapy 
there is increased expression of MAGE-11 mediated by promoter hypomethylation, providing 
an an alternative mechanism for increased AR signaling in castration-resistant PCa (92).  
The available data highlights that hypomethylation changes may not strongly correlate with 
functional gene sets or with cis activation of gene expression. Consequently, in case that 
DNA hypomethylation plays a driver role in PCa, it would most likely be through promotion of 
genomic instability (e.g. through promotion of retrotransposition (93)), rather than through 
direct cis regulation of specific genes. 
 
DNA Methylation-based markers for prostate cancer detection, management and risk 
estimation 
In Western countries, PCa screening is carried out mainly by serum PSA testing. However, 
serum PSA is limited in the ability to specifically detect PCa and it does not discriminate 
between clinically aggressive and clinically indolent PCa. Thus novel and more powerful 
biomarkers are warranted. Because epigenetic alterations are highly prevalent and arise 
early in prostate tumorigenesis, DNA methylation-based biomarkers constitute promising 
biomarkers for PCa detection, diagnosis, assessment of prognosis and prediction of 
response to therapy (40, 94). 
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Table 2. DNA Methylation Alterations as Biomakers for Prostate Cancer Management 
 
 
Cancer detection and diagnosis 
GSTP1 is the best-characterized epigenetic biomarker for PCa. Somatic DNA methylation of 
GSTP1 is nearly universally present in almost prostate cancer cells but is absent or low in 
normal cells (95). Indeed, more than 90% of PCa cases show aberrant promoter methylation 
of GSTP1 (65) and it might be specifically detected using MSP-based approaches in a wide 
range of tissue samples and bodily fluids, mainly blood and urine. Testing for GSTP1 could 
be used for screening or stratification for the need of prostate biopsy (95). GSTP1 
performance methylation displays high specificity (86.8-100%) but low sensitivity, both in 
urine (18.8-38.9%) and serum/plasma (13.0-75.5%) (96-101). This might be overcomed by a 
multigene promoter methylation testing, and several different gene panels have been 
proposed, including GSTP1/ARF/CDNK2A/MGMT (101) and GSTP1/APC/RARB2/RASSF1A 
(102) in urine and GSTP1/PTGS2/RPRM/TIG1 (103) in serum. As a result, the detection rate 
increased significantly to 86% in urine and 42-47% in serum, retaining high specificity: 89-
100% for urine and 92% for serum (101-103). The results gathered allowed for the design of 
a urine-based diagnostic test - the Prostate Cancer Methylation (ProCaM) assay (104) - that 
interrogates the methylation levels of GSTP1, APC and RARB2. The assay displayed 60% 
sensitivity and 80% specificity, with 97% informative rate. ProCaM has been validated in a 
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multicentre prospective study testing samples of men with serum PSA levels of 2.0–10.0 
ng/ml, in which its performance was compared with existing methods based on clinical 
workup and serum PSA levels (104). The ProCaM predictive accuracy was higher than that 
of serum PSA or any of its related parameters (AUC=0.73, p=0.038). Importantly, a positive 
result correlated not only with positive biopsy, but it also associated with increased risk for 
detecting high-grade PCa (Gleason score ≥ 7) with a substantial predictive accuracy 
(AUC:0.79, p=0.001). Indeed, men with positive ProCaM result were 7 time more likely to be 
diagnosed high-grade PCa (104). 
The EGF Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) is a tumor-
suppressor gene epigenetically deregulated in PCa. EFEMP1 methylation seems to be PCa-
specific and accurately discriminates PCa from nonmalignant prostate tissues (AUC=0.98; 
p<0.001), as well as from bladder and renal tumors (AUC=0.986, 96% sensitivity and 98% 
specificity) (105). The high accuracy (96%) of EFEMP1 methylation test shows promise for 
its use as an ancillary tool in diagnostically challenging lesions. Moreover, when compared 
with other frequently methylated genes in PCa (e.g. GSTP1, APC and RARbeta), the 
EFEMP1 assay displays similar performance, even when compared with multigene panels 
(105). 
Using prostate core biopsies, Paziewska et al (106) compared the performance of 
expression and methylation markers to distinguishing cancerous from non-cancerous 
prostate tissues. Although HOXC6, AMACR and PCA3 expression displayed the best 
discrimination between PCa and BPH (AUC: 0.94; 0.92; 0.955), they were not sensitive and 
specific enough to be considered PCa diagnostic biomarkers. However, DNA promoter 
methylation levels of APC, TACC2, RARB, DGKZ and HES5 identified PCa with high 
sensitivity and specificity (AUCs ranging between 0.95 and 1.0)(106). Some overlap was 
observed for DNA methylation levels of PCa-positive and PCa-negative needle biopsies, but 
with minor impact. Combination of methylation levels of RARB, HES5 and C5Orf4 displayed 
the highest performance (AUC=0.909), detecting over 50% of cancer samples with 100% 
specificity (106). Taking into account that problematic prostate core biopsies usually contain 
just a small amount of neoplastic cells, these biomarkers might be of help to pathologists, 
especially in patients with suspected PCa following a negative initial biopsy. 
Fast and accurate DNA methylation analysis of multiple loci in clinical samples with limited 
DNA quantities would provide a clear advantage to patient management. A MethyLight 
multiplex assay combining APC, HOXD3 and TGFB2 has been evaluated in patient samples 
and its sensitivity was sufficient for detection methylation of those genes in formalin-fixed 
paraffin-embedded tissue and urine samples. These encouraging results, however, require 
validation in larger patient cohorts (107). 
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Limitations of sampling during prostatic biopsy raise the concern that cancer might not be 
sampled in high-risk men. This leads to a high frequency of follow-up procedures that are 
needed to ultimately confirm the absence of disease. Partin and collaborators developed an 
assay (DOCUMENT, Detection Of Cancer Using Methylated Events in Negative Tissue) 
aimed to screen, among patients with a negative prostate biopsy, those that are at low risk of 
harboring cancer which were not detected through biopsy due to inaccuracy and might avoid 
unnecessary repeat (108). The assay is based on the quantification of methylation levels of 3 
genes commonly methylated in PCa - GSTP1, APC and RASSF1 – using multiplex 
methylation-specific PCR (108). In a multicenter study, this epigenetic assay was an 
independent predictor of PCa detection in a repeat biopsy thirty months after the initial 
negative results. The performance of the assay displayed 64% specificity, 88% negative 
predictive value and 18% false-negative rate, based on the adjusted cancer prevalence in 
repeat biopsies. In multivariate models corrected for factors with diagnostic potential, the 
assay proved to be the most significant independent predictor of patient outcome (OR 2.69, 
95% CI 1.60-4.51). Owing to the high negative predictive value, the DOCUMENT assay 
combined with other known risk factors may assist in clinical management of PCa suspects, 
reducing the rate of repeat biopsies (108).  
 
Prognosis and prediction of response to therapy 
Current prognostic markers for PCa are suboptimal, contributing to overtreatment of indolent 
PCa patients. A DNA methylation signature that predicts biochemical recurrence after radical 
prostatectomy has been uncovered. Hypermethylation of AOX1, C1orf114, GAS6, HAPLN3, 
KLF8, and MOB3B was shown to be highly PCa-specific (AUC ranging from 0.89 to 0.98) 
and high C1orf114 methylation was significantly associated with biochemical recurrence after 
radical prostatectomy in multivariate analysis, both in the testing and validation sets [hazard 
ratio (HR)=3.10; 95% CI, 1.89 to 5.09; HR=3.27; 95% CI, 1.17 to 9.12, respectively] (109). In 
this multi-cohort approach, a significant three-gene prognostic methylation signature (AOX1-
C1orf114-HAPLN3) was used to classify patients into low- and high-methylation subgroups 
(HR=1.91; 95% CI: 1.26 to 2.90; HR=2.33; 95% CI: 1.31 to 4.13, for cohorts 1 and 2, 
respectively). AOX1-C1Orf114-HAPLN3 and C1Orf114-HAPLN3 panels were evaluated and 
these models successfully predicted biochemical recurrence after radical prostatectomy in 
multivariate analysis including standard clinicopathological variables and in two different 
cohorts, indicating that these methylation-based markers hold independent prognostic value. 
Further testing is needed to evaluate the prognostic potential of these markers in prostatic 
biopsies. 
Hypermethylation of PTGS2 in localized prostate cancer predicted PCa recurrence after 
radical prostatectomy independently of tumor stage and Gleason score (110). The univariate 
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Cox proportional hazards models revealed that high PTGS2 methylation levels significantly 
increased the risk of recurrence (HR=2.82; 95% CI, 1.07-7.44). Moreover, in the multivariate 
Cox proportional hazards model, only high PTGS2 hypermethylation predicted for increased 
risk of recurrence independently of Gleason score and pathological stage (HR=4.26; 95% CI, 
1.36-13.36). 
 A hypermethylation score derived from GSTP1, APC and MDR1 discriminated organ-
confined from locally advanced disease with 72% sensitivity and 67.8% specificity (111). 
Moreover, considering patients with PSA levels <10 ng/mL, the M score had a sensitivity of 
67.1% with 85.7% specificity. The circulating cell-free DNA carrying GSTP1 hypermethylation 
was detected in 12% of men with clinically localized disease and 28% of men with metastatic 
cancer. Additionally, 8 men (15%) who developed PSA recurrence were positive for serum 
GSTP1 hypermethylation, whereas patients who were disease-free tested negative. In 
multivariate analysis, serum GSTP1 hypermethylation was the most significant predictor of 
PSA recurrence (HR=4.4; 95% CI, 2.2-8.8) (112).  
Furthermore, hypermethylation of CD44 and PTGS2 is also predicitive of PSA recurrence 
after radical prostatectomy (HR=8.87, 95% CI, 1.85-42.56). Kaplan Meyer analysis showed 
that combined hypermethylation of CD44 and PTGS2 associated with shorter time to 
biochemical recurrence compared to absence of gene methylation (113). Similar findings 
were reported for promoter hypermethylation of ABHD9 (114). PITX2 hypermethylation is a 
strong marker for biochemical recurrence either in a univariate and multivariate analysis 
(HR=3.4; 95% CI 1.9–6.0; HR=2.1; 95% CI 1.2-3.9, respectively) (115). In survival analysis, 
the estimated 8-year probability of biochemical recurrence free was 79% in the group with 
high PITX2 methylation as opposed to 94% in the low methylation group. Interestingly, PITX2 
hypermethylation seems to be associated with biochemical recurrence in PCa with 
intermediate Gleason score (115).  On the other hand, high methylation levels of APC and 
CCND2 are strong predictors of short time to post-radical prostatectomy recurrence in PCa 
with a Gleason score 3+4=7 (multivariate model, HR=4.33; 95% CI 1.52-12.33)(116), 
whereas in a prospective study, high APC promotor methylation levels predicted poor 
prognosis in prostate biopsy specimens, irrespective of Gleason score (OR=3.5; 95% CI 
1.23-9.96) (117).  
Promoter methylation levels of GABRE/miR-452/miR-224 not only discriminate PCa from 
non-malignant tissues (AUC=0.98; 95.5% sensitivity and 94.3% specificity), but also high 
methylation levels independently predicted early biochemical recurrence after radical 
prostatectomy in two independent cohorts (HR=1.75; 95% CI 1.37-2.23 and HR=2.99; 95% 
CI 1.71-5.21) (118). Interestingly, high methylation was significantly associated with the 
standard clinicopathological parameters, including serum PSA, pathological stage, Gleason 
score and surgical margin status. In a large cohort (407 patients), high HOXD3 promoter 
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methylation levels were strongly associated with shorter recurrence free-survival (high 
methylation = 43.1% vs. low methylation = 34.5%) (119). Moreover, HOXD3 methylation 
levels were associated with higher Gleason score and more advanced tumor stage 
(HR=5.23; 95% CI 1.31-20.96) (119). 
Because miR-205 is epigenetically down-regulated in PCa it may have a prognostic 
biomarker potential (120). Indeed, hypermethylation of miR-205 locus is significantly 
associated with biochemical recurrence in patients with localized PCa and low preoperative 
PSA levels (HR=2.005; 95% CI: 1.109-3.625). Furthermore, on multivariate analysis, low 
miR-205 methylation was a significant predictor of biochemical relapse (HR=2.2; 95% 
CI=0.99- 5.0) (120).  
DNA methylation-based biomarkers might also be useful for prediction of response to 
therapy. In a recent study, detectable baseline methylated GSTP1 in serum was associated 
with poorer overall survival in men with castration-resistant PCa (HR=4.2; 95% CI: 2.1–8.2) 
and a decrease of methylation levels after cycle 1 of chemotherapy was associated with PSA 
response (121). These preliminary findings were further validated in another cohort and the 
results were similar (HR=2.4; 95% CI: 1.0–5.6), thus confirming that assessment of GSTP1 
methylation levels in plasma is a promising predictive biomarker for a subgroup of advanced 
PCa patients undergoing chemotherapy. 
 
Conclusions and Perspectives 
Alterations in DNA methylation patterns are frequent and early events in prostate 
carcinogenesis, enabling its use as tumor biomarkers. These may accurately detect PCa at 
its earliest stages, by means of non-invasive techniques, increasing the likelihood of curative 
treatment. Moreover, the diagnostic performance of several methylated genes in PCa, makes 
them potential ancillary tools of histopathological assessment of prostate biopsies. However, 
discrimination of clinically aggressive from indolent PCa is mandatory and several 
methylation-based biomarkers have demonstrated to be of prognostic value. Finally, the 
predictive value of methylation markers is just starting to be unraveled in PCa, and is likely to 
provide novel tools form clinical management. 
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Figure 1. Clinical applications of DNA methylation analysis in prostate cancer. Urine 
biomarker testing employs a noninvasive approach to detect PCa by collecting voided urine 
samples, isolating DNA from cells in the urine sediment, and quantifying DNA methylation 
levels. The DNA methylation is also an ancillary tool in samples with low cellular content 
such as prostate biopsy. Alternatively, isolation of circulating PCa cells/DNA from patient 
serum and testing for DNA methylation levels might provide predictive information for PCa. 
5mC (5-methylcytosine): quantitative detection of DNA methylation levels using quantitative 
methylation-specific PCR (qMSP). Most accepted panels are suggested for testing in 
prostate samples. ED, early detection; D, diagnosis; P, prognosis. 
 
 
Interestingly, at each stage of the work-up the set of biomarkers differs whereas other remain 
across the algorithm. This may reflect, to the former, the biological stage at which a particular 
epigenetic alteration becomes more relevant to carcinogenesis, whereas for the latter its 
persistence or increase along tumor progression endows a particular relevance for the 
neoplastic process, from transformation, to invasion and dissemination. Importantly, some of 
the biomarkers have been already tested in a clinical-level assay (e.g., ProCaM and 
DOCUMENT), meaning that its translation to routine use might be foreseen for the near 
future. However, it must be acknowledged that a long path lies still ahead for most of the 
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DNA-methylation biomarkers, requiring standardization at methodological level and adequate 
clinical trial design to ascertain whether it represent a significant step forward in the 
management of PCa. 
 
 
 
Figure 2. DNA methylation biomarkers in prostate cancer management.  
Specific panels of methylated genes may be used in the clinical management of PCa 
patients, not only in cancer detection (MethTest 1), but also are putative ancillary tools after 
pathologic assessment (MethTest 2). Additionally, these biomarkers may provide 
prognostic/predictive 
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information of recurrence and progression following clinical decision (treatment or 
surveillance). MethTest, DNA methylation analysis; −, negative test; +, positive test; PSA, 
prostate-specific antigen. 
 
 
Glossary 
CpG island – Regions of more than 200 bp in length, with a GC content of at least 50% and 
a ratio of observed to statistically expected CpG frequencies of at least 0.6. CpG 
dinucleotides are relatively uncommon in mammalian genomes (~1%) but are frequently 
found at promoters. Those CpG islands at promoters are predominantly unmethylated across 
cell types and are very prevalent at transcription start sites of housekeeping and 
developmental regulatory genes. 
Partially methylated domains (PMDs) - Large contiguous regions of the genome (mean 
size ~153 kb) that display intermediate methylation levels (average <70%). 
Unmethylated regions (UMR) - regions constitutively unmethylated that independently 
whether they defined or not as CpG islands. Almost all UMRs are associated with known or 
predicted transcription start sites, and very often packaged with nucleosomes containing 
H3K4me3. 
DNA methylation valleys (DMV) - Large genomic domains (≥ 5kb long) that are methylation 
devoided. Moreover, DMV genes are poised with bivalent states (H3K4me3 andH3K27me3). 
DMVs are uniquely enriched for transcription factors and developmental regulatory genes. 
Developmental regulatory genes are preferentially located in DMVs. Strikingly genes with 
DMVs tend to be hypermethylated in cancer.  
DNA methylation canyon (DMC) - Regions of low methylation covering conserved domains 
that frequently containing transcription factors and are distinct from CpG islands and shores. 
Approximately half of the genes in these canyons are marked with repressive histone marks.  
Gleason score (GS) - Prostate Cancer’s microscopic grading system ranging from 1-5 
based on the glandular architecture and patterns. The combined GS (2–10) is the result of 
the two most prevalent Gleason grade patterns per tumor. GS is a significant prognostic 
indicator: high GS (≥8) is associated with a poorer outcome than an intermediate GS (7), and 
low GS (≤6) is globally associated with a better prognosis. 
Prostate-specific antigen - serine protease produced by prostate epithelial cells implicated 
in seminal fluid liquefaction. Serum PSA levels are used for detection and monitoring of 
prostate cancer. 
Biochemical relapse - when, following radical prostatectomy, PSA levels are higher that 
0.2ng/ml, or when PSA consecutively rises in from the post-operative baseline. It is indicative 
of disease recurrence. 
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Castration-resistant PCa – Highly aggressive and lethal form of PCa characterized by 
disease progression despite androgen deprivation therapy (castrate serum levels of 
testosterone), presenting as one or any combination of a continuous rise in serum PSA 
levels, progression of pre-existing disease or appearance of new metastases. 
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CHAPTER 2 – RATIONAL AND AIMS 
 
 
Rational and Aims 
 
Much progress has been made on Prostate Cancer (PCa) research over the past decade.  
Evidence from computational, biochemical, and genetic experiments have greatly expanded 
our understanding of the mechanism of action and biological properties of miRNAs as a class 
of regulatory molecules.  
PCa is a heterogeneous disease characterized by deregulation of important pathways that 
control normal cellular homeostasis. Due its wide-range interactions, miRNAs are fine-tuners 
of those processes and, thus, “micromanagers” or “microsensors” of aggressive phenotypes 
of PCa. Hence, one of the aims of this research project was to understand which molecular 
mechanisms and interactions of miRNAs may contribute to PCa aggressiveness. 
MiRNAs occupy a unique position in the hierarchy of gene regulators and represent a 
promising avenue for uncovering previously unknown mechanisms of cancer biology. Their 
mechanism of action allows them to act as fine tuners of transcriptional programs, as 
components of complex network motifs, and as post-transcriptional modulators to confer 
robustness to transcriptional programs in the face of environmental and genetic variability. 
MiRNAs can regulate the accumulation of DNA repair proteins at damage sites. Mammalian 
cells have developed an elaborate DNA damage response (DDR) system and DNA repair 
machinery, which play a critical role in development of resistance to DNA damaging agents. 
The precise regulation of DDR and DNA repair is crucial for cell survival and its abrogation 
often results in genetic instability. Metastatic, castration-resistant prostate cancer (CRPC) 
can have genomic abnormalities that affect with DNA repair. The question addressed in this 
Thesis is whether DNA methylation mediates the loss of function of specific miRNAs and 
including the control of DDR-induced senescence in PCa cells.  
Although some examples are described, either functionally characterized and as biomarkers, 
miRNAs are decisive players in PCa development.  
One of the main areas of research in PCa is the discovery of new and more accurate 
predictive and prognostic biomarkers. Indeed, it is clear that current PCa overdiagnosis and 
overtreatment is mainly due to the exhaustive Prostate-specific antigen (PSA) screening. 
Meticulous patient selection for screening and reducing overtreatment are important to 
preserve the benefits and reduce the downstream harms of PSA testing (e.g. incontinence 
and erectile dysfunction). Moreover, when PCa cells metastasize to bone, ¾ of the patients 
die within a period of 5 years. The question we addressed was whether miRNAs’ promoter 
hypermethylation were reliable biomarkers for PCa detection and prognostication.  
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Consequently, the major goal of this Thesis was to understand how the deregulation of 
miRNAs contributes to prostate carcinogenesis and progression, providing functional 
evidence linking miRNAs and PCa and identifying clinically relevant alterations that might be 
useful for clinical management of PCa patients. 
 
Specifically, the aims of this doctoral Thesis were: 
 
1 – MicroRNAs downregulation contribute to Prostate Cancer 
• Characterize the global expression of miRNAs in Prostate samples; 
• Determine which mechanisms trigger PCa downregulation;  
• Evaluate the global response of miRNA expression following DNA demethylation 
treatment;  
• Functionally characterize the role of miR-130a in the prostate cell lines; 
• Identify the molecular pathways controlled by miR-130a in prostate cells.   
 
2 – DNA methylation signature of microRNA deregulation in Prostate Cancer 
• Profile the DNA methylation dynamics underlying miRNA regulation in PCa 
deregulation;  
• Provide evidence of how these miRNAs can contribute to tumorigenesis; 
• In vitro dissection of  the functional relevance of miRNA (miR-130b~301b) 
manipulation; 
• Investigate how these miRNAs modulate DNA repair and cellular senescence. 
 
3 – Integrative analysis of DNA methylation and microRNA expression in Prostate 
Cancer 
• Identification of miRNAs downregulated in PCa targeted by DNA methylation, 
combining expression and methylation data generated aforementioned;   
• Determine if other alterations might account for miR-152 downregulation; 
• Examine the functional significance of miR-152 in PCa cell lines; 
• Discover and characterize the targets of miR-152 and demonstrate their oncogenic 
role in PCa. 
 
4 - Utility of promoter hypermethylation of microRNAs in Prostate Cancer clinical 
management 
• Characterize new miRNAs regulated by promoter methylation in PCa; 
• Describe their potential as PCa biomarkers in tissue samples; 
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• Evaluate their performance as biomarkers for PCa early detection in urine samples; 
• Investigate the prognostic value in biopsy samples. 
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CHAPTER 3 – METHODS 
 
 
Material and Methods 
This section describes the methods used to obtain the results presented in this Thesis. It is 
not structured according to the temporal sequence of papers, but rather attempts to explain 
the reason of using each methodological approach, as well the variety of technics covered. 
The detailed procedure of each method is embedded in the respective manuscripts. 
 
A. Sampling 
Globally, different samples were used to successfully generate the data supporting this 
Thesis. For miRNA profiling and further validation, primary tumors from patients with clinically 
localized PCa (stages T1c and T2, according to TNM staging system, 7th edition) 
consecutively diagnosed and primarily treated at the Portuguese Oncology Institute – Porto 
(IPO-Porto), Portugal, were prospectively collected. For control proposes, morphological 
normal prostate tissue (MNPT) samples were obtained from prostates that did not harbor 
PCa collected from cystoprostatectomy of bladder cancer patients. 
To discover and validate new biomarkers, two different cohorts were selected. Urine samples 
were collected from 95 patients diagnosed with PCa, before being submitted to radical 
prostatectomy, from 1999 to 2002. Control samples were collected from 46 healthy donors. 
This cohort was used to discover new biomarkers for PCa early detection. Furthermore, 
samples from prostatic biopsies from 74 patients were collected from individuals referred to 
IPO-Porto due to elevated PSA levels, from 2001 to 2003. This set, enabled us to identify 
miRNAs whose methylation helped to better prognostication of PCa patients.  
Additionally, to further support the findings in chapters 4, 5 and 6 Prostate dataset from The 
Cancer Genome Atlas (TCGA) was also used.  
For in vitro manipulation, the standard cell lines used in PCa research were also utilized.  
 
B.  microRNA methylation profiling and validation 
Two different platforms were used to profile miRNAs in PCa. First, using miRNA PCR panels, 
the expression of 752 was evaluated in a set of 10 PCa and 5 MNPT (Chapter 4). In parallel, 
the same profiling was performed for PCa cell lines (DU145, LNCaP and PC3) after 
exposure to the demethylating agent, 5-Aza-2’-deoxycytidine (5-Aza-CdR). This strategy 
rendered a global increase in the expression of miRNAs. Using stringent filtering criteria, 
miR-130a was identified as the most promising candidate and selected for validation 
analyses in an independent patient series.  
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The Infinium HumanMethylation450 BeadChip Kit (Illumina) was used to generate a 
comprehensive genome wide profiling of PCa Methylome (Chapter 5). This method 
quantifies methylation levels at specific loci within the genome. The data obtained derived 
from 25 PCa and 5 MNPT samples. This approach was of particular relevance for mapping 
new miRNAs targeted by differential methylation in PCa.  
Then, the candidates selected from the different approaches were validated. In the chapters 
4 and 7, Quantitative Methylation-Specific PCR was used to the assess DNA methylation 
levels, while miRNA expression levels were evaluated using specific primers for each miRNA 
(miRNA LNA PCR primer set, Exiqon, Vedbaek, Denmark). 
In the chapter 5 and 6, the DNA methylation levels were assessed by pyrosequencing.  
MiRNA transcript levels were assessed using TaqMan miRNA Assays specific for each 
miRNA.  
 
C. In vitro validation of selected microRNAs. 
To evaluate the contribution of the previously studied miRNAs, functional, in vitro assays 
were designed. To overexpress miRNAs, miRNA mimics were transfected into the cells to 
simulate naturally occurring mature miRNAs. This increased the proportion of miRISC 
containing the guide strand miRNA. By studying the phenotypic consequences of this 
increased miRNA’s activity it was possible to discover miRNA functions. To silence 
endogenous miRNA, chemically modified, single stranded nucleic acids - miRNA Inhibitors 
(Anti-miR) - were designed to specifically bind to and inhibit endogenous miRNA molecules. 
In Chapters 4, 5, and 6 cell viability (as measured by 3-(4,5-dimethyl-2-thiazolyl)-2,5 
diphenyl-2H-tetrazolium bromide assay (MTT)), apoptosis (determined the translocation of 
phosphatidylserine from the interior to the exterior surface of the mammalian cell 
membrane), cell invasion assay (performed using the Matrigel® Matrix) were applied. In the 
Chapter 5 DNA Damage, the Single Cell Gel Electrophoresis (Comet Assay) was also 
assessed. Herein, the “head” corresponds to intact DNA, whereas the “tail” consists of 
damaged (single-strand or double-strand breaks) or broken segments of DNA. 
Moreover, to support the phenotypes observed, both western blot and real time quantitative 
PCR (RT-qPCR) were performed to evaluate genes directly involved in the pathways altered 
upon in vitro miRNA’s manipulation.  
 
D. microRNA target determination. 
One of the most critical aspects on miRNA research is target’s identification. Although many 
approaches have been proposed for miRNA target detection, there is no consensus to set 
which experimental approach is the most accurate. This is, perhaps, due to the unclear 
definition of how the most appropriate readout of miRNA–target interactions should be. As 
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miRNAs repress the expression of their targets, the gain of miRNA function should lead to 
decreased target expression. Putative transcripts targeted by miR-130a were also assessed, 
using microarray analysis [Affymetrix Human Transcriptome 2.0 Arrays (Affymetrix, Santa 
Clara, CA, U.S.A.)] of scrambled-transfected and miR-130a-overexpressing PC3 cells.  
Validation of selected targets was performed using RT-qPCR and luciferase assays. As in 
genetic screens the identified targets are already linked to a phenotype, the next step 
included in vitro silencing of both DEPD1C and SEC23B, in order to prove their oncogenic 
potential.  
Luciferase assays were also used to provide an alternative mechanistic link between target 
genes and the respective miRNAs (Chapters 4 and 6). 
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Abstract  
MicroRNAs (miRNAs) are small, non-coding RNAs that mediate post-transcriptional gene 
silencing, fine tuning gene expression.  
In an initial screen, miRNAs were found to be globally down-regulated in prostate cancer 
(PCa) cell lines and primary tumors. Exposure of PCa cell lines to a demethylating agent, 5-
Aza-CdR resulted in an increase in the expression levels of miRNAs in general. Using 
stringent filtering criteria miR-130a was identified as the most promising candidate and 
selected for validation analyses in our patient series. Down-regulation of miR-130a was 
associated with promoter hypermethylation. MiR-130a methylation levels discriminated PCa 
from non-malignant tissues (AUC=0.956), and urine samples revealed high specificity for 
non-invasive detection of patients with PCa (AUC=0.89). Additionally, repressive histone 
marks were also found in the promoter of miR-130a. 
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Over-expression of miR-130a in PCa cells reduced cell viability and invasion capability, and 
increased apoptosis. Putative targets of miR-130a were assessed by microarray expression 
profiling and DEPD1C and SEC23B were selected for validation. Silencing of both genes 
resembled the effect of over-expressing miR-130a in PCa cells.  
Our data indicate that miR-130a is an epigenetically regulated miRNA involved in regulation 
of key molecular and phenotypic features of prostate carcinogenesis, acting as a tumor 
suppressor miRNA. 
Key words: miR´s epigenetic regulation, miR-130a, miRNA, Prostate cancer, SEC23B, 
DEPDC1  
 
1. Introduction  
MicroRNAs (miRNAs) are small single-stranded, ~22-nucleotide-long, noncoding RNAs. The 
human genome encodes a large number of miRNAs, each with the potential to target 
hundreds of different mRNAs. By controling the rate of translation of mRNAs into proteins, 
miRNAs coordinate multiple biological processes such as cell proliferation and differentiation, 
cell death, metabolism and invasion/angiogenesis. Dysregulated miRNA expression is linked 
to various human diseases, including prostate cancer (PCa) (1, 2). These molecules may 
have either oncogenic or tumour-suppressive function, depending on the target mRNAs (3, 
4). Similarly to protein coding genes, miRNA transcriptional deregulation may be due to 
genetic and/or epigenetic alterations and this has been implicated in neoplastic 
transformation (1, 2).  
PCa is among the most common adult malignancies in developed countries (5). Although 
most patients with localized disease have slow-growing, non-lethal tumors, a relevant 
number of men experience disease recurrence after first-line treatment, potentially evolving 
to metastasis and death (6). Although locally recurrent disease might be manageable, lack of 
effective treatment for patients which progression to castration-resistant PCa results in a high 
mortality rate (7).  
Epigenetic alterations such as DNA methylation and covalent histone modifications are com-
mon features of PCa pathogenesis (8, 9). Moreover, aberrant DNA methylation and activity 
of chromatin remodeling enzymes is also associated with altered transcriptional states, 
ultimately impairing miRNA expression (10). Because miRNA deregulation is a common 
feature of PCa, driving and coordinating tumor progression (9, 11), we hypothesized that 
deregulated miRNA expression might be due to epigenetic alterations. Expression profiling of 
primary PCa revealed widespread down-regulation of miRNAs. Following exposure of PCa 
cell lines to a demethylating agent the expression level of some miRNAs was restored, 
suggesting that DNA methylation is implicated in miRNA deregulation. We further 
demonstrated that miRNA-130a inhibits PCa malignant phenotype in vitro, partially, by 
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targeting two oncogenes: DEPDC1 and SEC23B. These results indicate that miRNA-130a 
has tumor-suppressive activity in PCa.  
 
2. Material and Methods  
(See Appendix A: Supplementary materials and methods for detailed information.) 
2.1. Tissue specimens and cell lines 
Tissue specimens (n=101 PCa and n=15 morphological normal prostatic tissues) at 
Portuguese Oncology Institute-Porto, Porto, Portugal. This study was approved by the 
institutional review board [Comissão de Ética para a Saúde-(CES-IPOPFG-EPE 205/2013)] 
of Portuguese Oncology Institute of Porto, Portugal. 
The Cancer Genome Atlas (TCGA) prostate cancer dataset was used for validation. 
Human PCa cell lines (LNCaP, DU145 and PC3) were obtained from ATCC (Manassas, VA, 
USA). Culture and treatments were performed accordingly  
DNA and RNA extraction were done using standard methods.  
 
2.2. MicroRNAs global expression and validation 
Expression of miRNAs was assessed in ten PCa and four MNPT using microRNA Ready-to-
Use PCR Human Panel (I + II) v2.R (Exiqon, Vedbaek, Denmark), comprising of 752 
miRNAs. RNA samples were submitted to cDNA synthesis using miRCURY LNA Universal 
RT microRNA PCR (Exiqon, Vedbaek, Denmark) following manufacturer’s instructions. Then, 
data were analyzed using the comparative Ct method (12). Mean value of reference genes 
was used for normalization, and miRNAs with fold change higher than 1.5 were classified as 
overexpressed in PCa compared to MNPT.  
For validation, cDNA was synthesized from 101 PCa, 15 MNPT and four PCa cell lines, as 
previously described. MiRNA expression levels were evaluated using specific primers 
(microRNA LNA PCR primer set, Exiqon, Vedbaek, Denmark). All samples were run in 
triplicates.  
 
2.3. Bisulfite Treatment and Quantitative Methylation-Specific PCR  
One microgram of DNA was use as a template for bisulfite modification using the EZ DNA 
Methylation Gold Kit (Zymo Research, Orange, CA) following the manufacturer's instructions. 
Bisulfite-modified DNA was amplified by quantitative methylation-specific PCR (qMSP) using 
specific primers for miR-130a promoter (Supplementary Table S3).  
 
2.4. MicroRNA and siRNA transfection 
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MiR-130a was transiently transfected in PC3 and DU145 cells with a Pre-miR™ miRNA 
precursor or negative control (pre-miR-130a, PM10506; miR-NC, AM17010, Applied 
Biosystems, Foster City, CA, USA).  
Phenotypic assays (Cell viability, Apoptosis and Invasion assays) were performed according 
Supplementary material & methods  
 
2.5. Gene expression profiling for identification of miR-130a target genes 
To analyse the effect of miR130a over-expression, PC3 cells transfected with miR-130a and 
negative controls, were analyzed for gene expression genome-wide using the Affymetrix 
Human Transcriptome 2.0 Arrays (Affymetrix, Santa Clara, CA, U.S.A.). The microarray data 
have been deposited to the NCBI’s Gene Expression Omnibus, with accession number 
GSE80750. 
 
2.6. Quantitative Real Time-PCR assay 
A total of 300 ng was reverse transcribed and amplified using TransPlex Whole 
Transcriptome Amplification Kit (Sigma-Aldrich, Schnelldorf, Germany) as previously 
described (13). Quantitative real time-PCR (qRT-PCR) reactions were performed Kapa Sybr 
Fast qPCR Master Mix (Kapa Biosystems, Wilmington, MA, USA) (Supplementary Table S3, 
primers sequences).  
 
2.7. Western Blotting 
Cell lysates were separated on 12% polyacrylamide gels and transferred onto nitrocellulose 
membrane using semi-dry transfer. The membrane was incubated for 1 h in blocking buffer 
(5% nonfat dry milk) and incubated overnight at 4 °C with CASP3 (ab90437, 1:500; Abcam, 
Cambridge, UK) and β-Actin (1:8,000, Sigma-Aldrich, CO., St. Louis, MO, USA). Blots were 
developed using Immun-Star WesternC Chemiluminescent kit (Bio-Rad, Hercules, CA, USA).  
 
2.8. ChIP-Seq 
LNCaP ChIP-seq data for the region surrounding the miR-130a locus were downloaded from 
the NCBI GEO website. 
 
2.9. Luciferase assay 
A reporter plasmid containing a binding site at DEPDC1 or SEC23B 3′UTR for miR-130a 
(GeneCopoeia, Rockville, MD, USA) was transfected into HEK293Ta cells using 
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). Luciferase activity 
was assessed with the Secrete-Pair™ Dual Luminescence Assay Kit (GeneCopoeia, 
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Rockville, MD, USA) according to the manufacturer’s instructions. Experiments were 
performed in triplicates at 72 h after transfection.  
 
3. Results 
3.1. Global miRNA expression in prostate tissue samples and prostate cancer cell lines 
To identify differentially expressed miRNAs in PCa compared to MNPT, 752 miRNAs were 
profiled in ten PCa and four MNPT tissue samples. Considering only miRNAs exhibiting more 
than 1.5-fold difference in expression, 64 and 10 miRNAs were found to be down-regulated 
and up-regulated in PCa, respectively (Figure 1A, 1B, Supplementary table S4). Among 
downregulated miRNAs, the highest fold variations were displayed by miR-187 (~3.6 fold), 
miR-224, miR-100 and miR-221-222 (~2.5 fold), miR-205 and miR-145 (~2.0 fold). 
Consistent with previous studies, our data confirmed upregulation of miR-32, miR-141 or 
miR-153, and downregulation of miR-145, miR-205, miR-221-222 and miR-152.  
The relative expression of the same 752 miRNAs was assessed in PCa cell lines (LNCaP, 
Du145 and PC3), either mock or exposed to 1 µM 5-Aza-CdR (Supplementary Figure 1A; 
Supplementary table S5). These results were compared with those of PCa tissues and a set 
of four miRNAs, including miR-130a, miR-145, miR-205 and miR-520g were found to be 
significantly downregulated in both PCa tissues and cell lines, and simultaneously 
reactivated upon 5-Aza-CdR treatment. From this panel, miR-130a had not been previously 
reported to be regulated by promoter methylation and, thus, it was selected for validation 
studies.  
 
3.2. Alterations of the microRNA processing machinery in PCa 
Given that our microRNA profiling revealed that the vast majority of miRNAs is 
downregulated in PCa, we analysed the expression of 4 key genes implicated in the 
biogenesis of microRNAs (Figure 1C). In primary tumors, DROSHA, DGCR8 and DICER 
were significantly downregulated compared to MNPT, and no alterations were found for 
XPO5. As expected, DROSHA/DGCR8 expression levels significantly correlated (Spearman 
r=0.48; p=1x10-8), as well as DGCR8/DICER (Spearman r=0.57; p=1x10-11), and 
DROSHA/DICER (Spearman r=0.33; p=0.00022) (Supplementary Figure 1B, 1C). Thus, 
disruption of the microRNA processing machinery might also contribute to the global 
microRNA dowregulation observed in PCa samples (Figure 1G). Nonetheless, these results 
are not so obvious in the cells lines (Supplementary Figure 1D).  
 
3.3. Validation of miR-130a downregulation in prostate tissue samples 
The expression of miR-130a was evaluated in a larger cohort of prostate tissues (101 PCa 
and 15 MNPT) by qRT-PCR, for validation. The overall expression of miR-130a was 
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significantly lower in PCa compared to MNPT (Figure 1D, p=0.0016). Similar results were 
found for the independent cohort from TCGA. Indeed, miR-130a expression was significantly 
decreased in PCa compared to adjacent normal tissues (p=0.04, Figure 1E), further 
supporting our observations.  
 
Figure 1. miR-130a deregulation in Prostate Samples 
(A) heatmap of the differentially expressed miRNAs in prostate cancer (PCa) compared with 
morphological normal prostate tissue (MNPT). Red: high expression; blue: low expression. 
(B) Principal component analysis (PCA) for the samples analyzed (Red, MNPT; blue, PCa). 
(C) Evaluation of expression levels of the major enzymes involved in microRNA biogenesis in 
primary tumors samples (101 PCa) and controls (15 MNPT). MiR-130a expression 
determined by qRT-PCR (D) and in the TCGA patients (E). (F) MiR-130a promoter 
methylation levels in PCa and control tissue samples. (G) Schematic overview of how 
decreased miRNA levels combined with biogenesis machinery impaired activity contribute to 
prostate tumorigenesis. (Significance level represented as: * = p<0.05; ** = p<0.01; *** = 
p<0.001) 
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3.4. The promoter of miR-130a is methylated in prostate cancer tissues 
Because miR-130a promoter region harbors a CpG island (CGI), we designed a specific 
qMSP assay to detect aberrant DNA methylation. Interestingly, PCa samples displayed 
significantly higher promoter methylation levels compared to MNPT (p< 0.0001, Figure 1F).  
Because 82% of PCa tissues tested positive for miR-130a methylation (Supplementary figure 
2A) we assessed its diagnostic performance using ROC curve analysis of the validation 
cohort. MiR-130a methylation levels accurately discriminated PCa from MNPT with 95.5% 
sensitivity and 94.3% specificity (AUC = 0.956) (Supplementary figure 2C). Furthermore, the 
diagnostic performance of miR-130a promoter methylation was also tested in urine and 
bladder washings (Supplementary figure 2B). Although performance was not as good as in 
tissue samples, PCa was correctly identified with 83.5% sensitivity and 82.3 % specificity 
(AUC= 0.89) (Supplementary figure 2D).  
 
3.5. Promoter methylation mediates silencing of miR-130a 
To confirm the effect of promoter methylation on miR-130a expression, PCa cell lines were 
exposed to 5-Aza-CdR (Figure 2A). Interestingly, miR-130a’s promoter methylation levels 
decreased in all cell lines (DU145, LNCaP and PC3) alongside with increased expression of 
miR-130a, especially in PC3 cells (Figure 2A). These results validate the previous microRNA 
profiling (supplementary figure 1A, supplementary table 5) and implicates DNA methylation 
as a regulatory mechanism for miR-130a expression. 
 
3.6. H3K27me3 repress miR-130a expression 
Considering the role of chromatin remodeling complexes in gene expression regulation, we 
mapped the miR-130a promoter enrichment for H3K4me2, H3K4me3, H3K36me3, H3K27Ac, 
H3K27me3, as well as AR and FOXA1 (Figure 2D). A marked depletion of H3K4me2, 
H3K4me3 and H3K27Ac was found upstream of miR-130a promoter. Conversely, a steady 
enrichment for H3K27me3 at miR-130a and a neighbour gene (YPEL4) was observed, which 
is consistent with both YPEL4 (figure 2C) and miR-130a downregulation. Because 
trimethylation of histone H3 at lysine 27 is catalized by EZH2, we assessed EZH2 transcript 
levels in PCa. Remarkably, high EZH2 mRNA levels were found in all cell lines tested (Figure 
2B).  
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Figure 2. Epigenetic regulation of miR-130a.  
(A) Methylation levels (left panel) and re-expression of miR-130a (right panel) in PCa cells 
treated by vehicle [dimethyl sulfoxide (DMSO)] or 5-aza-dC. (B) Relative expression of EZH2 
in PCa cell lines. (C) Expression of YPEL4 is decreased in PCa samples in the TCGA cohort 
(RNA-Seq). (D) A representative ChIP-seq profiling in LNCaP cells showing K3K27me3 
enrichment at the miR-130a locus. (Significance level represented as: ns – not statistically 
significant, * = p<0.05; ** = p<0.01; *** = p<0.001) 
 
3.7. miR-130a overexpression attenuates the malignant phenotype of PCa cells 
MiR-130a mimics were transfected into PCa cell lines (LNCaP, DU145 and PC3) and 
transfection efficiencies were confirmed by qRT-PCR (Supplementary Figure 3A). In miR-
130a overexpressing PC3 cells, a change in cell morphology was noticed, with the 
acquisition of a less spindled and more polygonal (epithelial) phenotype compared to pre-
miR-NC and anti-miR-130a transfected cells (Figure 3A). 
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Figure 3. Ectopic expression of miR-130a attenuates malignant phenotype in PCa cell 
lines.  
(A) Morphological features of PC3 cells upon transfection. (B) Cell viability posttransfection of 
miR-130a or miR-NC mimics in LNCaP, DU145 and PC3 cells determined by an MTT assay. 
All results are relative to pre-miR-NC miRNA transfected cells. (C) Relative apoptosis in 
LNCaP, DU145 and PC3 cells after miR-130a ectopic expression. (D) Matrigel invasion 
assays performed 48 hours posttransfection. (E) QRT-PCR analyses of genes involved in 
cellular homeostasis after miR-130a overexpression. (F) Western Blot of the effector 
caspase – CASP3. The presented results are representative of a minimum of three 
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experiments performed in triplicate; (Significance level represented as: * = p<0.05; ** = 
p<0.01; *** = p<0.001) 
 
 
Moreover, in PC3 and DU145 cells, miR-130a overexpression caused an inhibitory effect on 
cell viability (p<0.001) (Figure 3B). Increased apoptosis in both DU145 and PC3 cells, as well 
(Figure 3C, p<0.001), and significantly reduced its invasive potential (Figure 3D). In LNCaP 
cells only a modest cell viability reduction and a mild apoptosis increase were achieved 
(Figure 3B, 3C). 
Subsequently, we evaluated the expression of a small panel of genes comprising CASP3 
(effector caspase), KI67 (cellular proliferation), and PARP1 (DNA repair, differentiation) 
(Figure 3E). MiR-130a transfection in LNCaP cells caused an increase in CASP3 expression 
and a decrease of PARP1, implying miR-130a as apoptosis activator and DNA damage 
repair blocker (Figure 3E, left panel). In PC3 cells, miR-130a forced expression significantly 
associated with increased CASP3 and decreased KI67 and PARP1 expression, suggesting 
that miR-130a induction reprograms cell cycle and induces apoptosis (Figure 3E, right panel; 
Figure 3F). In DU145 results were less impressive (Figure 3E, central panel), implying that 
miR-130a-mediated tumor-suppressive activity might be cell-specific.  
 
3.8. DEPDC1 and SEC23B are repressed by miR-130a  
To gain insight into the cellular mechanism through which miR-130a exerts its effect, we 
performed genome-wide expression profile of PC3 cells overexpressing miR-130a (Figure 
4A, Supplementary Table S6). Overall, 1,534 genes were found to be differentially expressed 
from which 667 genes were down-regulated and 867 were up-regulated in the transfected 
cells. The genes were ranked according to differential expression and GSEA was used to 
search for enrichment across the Molecular Signatures Database (MSigDB) (Supplementary 
Table S7). Among the highest ranked concepts in the upregulated genes, we noticed genes 
associated with p53 pathway, unfolded protein response, TNFa signaling via NF-KB, 
apoptosis, hypoxia, and EMT (Supplementary Table S7). For down-regulated genes after 
miR-130a transfection, the highest ranked concepts, we found genes correlated with G2/M 
checkpoint, E2F targets, mitotic spindle, and DNA repair (Supplementary Table S7). 
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Figure 4. Identification of miR-130a putative target genes in PC3 cells. 
(A) A hierarchical cluster of PC3 cells after ectopic expression of miR-130a. (B) Canonical 
pathways most enriched in PC3 cells overexpressing miR-130a. (C) Isolation of miR-130a 
targets among the deregulated genes. (D) qRT-PCR validation of putative targets derived 
from the array after transfection with miR-130a or Anti-miR-130a in PC3 cells. (E) Predicted 
miR-130a MREs in each 3’UTR (seed sequence is highlighted in red). (F) Luciferase reporter 
activity for miR-130a interaction of with DEPDC1 and SEC23B 3’UTR. (Significance level 
represented as: * = p<0.05; ** = p<0.01; *** = p<0.001) 
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Moreover, gene ontology (GO) analysis disclosed that the top cellular processes included 
cell cycle, regulation of apoptosis, mitosis, regulation of cell motion and migration (Figure 4B, 
Supplementary Table S7). Then, we focused on the most variable genes to identify miR-
130a targets, using the following criteria: a) containing at least one predicted miRNA 
response element (MRE); b) being downregulated upon transfection; c) having a known 
function; and d) mRNAs significantly upregulated in PCa samples. Thus, 164 genes were 
selected for further validation (Figure 4C, 5A-B, Supplementary figure 4A-B, Supplementary 
Table S8). GO processes for repressed miR-130a targets included multiple processes such 
as vesicle-mediated transport, protein kinase cascade, angiogenesis, and cell cycle 
(Supplementary table S9). We validated several candidates, involved in different cellular 
pathways (Figure 4D). After this initial screening, DEPDC1 and SEC23B matched all criteria. 
Upon miR-130a transfection in PC3 cells, both microarray and qRT-PCR data revealed a 
significant decrease of DEPDC1 and SEC23B mRNA levels (Figure 4D). Moreover, using 
qPCR, DEPDC1 and SEC23B mRNAs were found upregulated in PCa compared to MNPT 
(Figure 5A and Supplementary Table S8).  
These data were independently validated in the TCGA dataset, in which both DEPDC1 and 
SEC23B were found significantly upregulated in PCa and displayed negative Spearman 
correlations with miR-130a expression (Figure 5C).  
One putative miR-130a MRE was identified at the 3’UTR of SEC23B, whereas DEPDC1 
displayed two MRE (Figure 4E). Using a luciferase reporter system, a statistically significant 
inhibition of luciferase activity in the SEC23B and DEPDC1 MRE1 constructs was observed 
in cells overexpressing miR-130a (Figure 4F), in accordance with our previous observations. 
 
3.9. DEPDC1 and SEC23B are pro-tumorigenic in PCa cells 
To investigate the contribution of individual miR-130a targets, we performed a loss of 
function assay, using RNAi to knock down DEPDC1 and SEC23B in PC3 cells. PC3 cells 
transfected with DEPDC1 or SEC23B siRNAs displayed a significant decrease in cell viability 
at 48h and 72h (Figure 5D; Supplementary Figure 3B), as well as a dramatic increase of 
apoptosis at 72h post-transfection (Figure 5E). These data suggest that the tumor 
suppressive role of miR-130a in PCa might be, at the least partially, mediated by DEPDC1 
and SEC23B downregulation. 
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Figure 5. DEPDC1 and SEC23B are physiologically important in Prostate Cancer. 
(A) DEDPC1 and SEC23B are upregulated in PCa compared to MNPT. (B) Expression of 
DEPDC1 and SEC23B in the TCGA cohort (RNA-Seq). (C) Correlation of miR-130a with 
DEPDC1 or SEC23B expression.  SiRNA-mediated knock-down of DEPDC1 and SEC23B in 
PC3 cells decreases cell viability (D) and increases apoptosis (E). (Significance level 
represented as: * = p<0.05; ** = p<0.01; *** = p<0.001) 
 
 
3.10. miR-130a disrupts critical signaling pathways by overexpressing key genes 
PCa cells exhibit phenotypic plasticity, allowing for adaptation to different tumour 
microenvironments. Much of this plasticity seems to be mediated by miRNAs that fine-tune 
signal transduction networks. In the microarray analysis of miR-130a overexpressing PC3 
cells, several genes implicated in critical signalling pathways were found upregulated. 
Functional enrichment analysis revealed enrichment for critical kinases and transcription 
factors required for both cell cycle progression and checkpoint cascades, including activation 
of the DDR. These genes, including CDKN1B, CDKN2B, PCNA, BIRC5, CCNA2, CCNB2, 
CCNB1, CDK1, CDK2, MAD2L1, Polo-like kinase 1 (PLK1), topoisomerase (DNA) I (TOP1), 
and UBE2C. Notably, many of these proproliferative genes, including Survivin (BIRC5) or 
PLK1 are targeted for pharmacological reduction in a diverse array of cancers (14). These 
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observations suggest that miR-130a may be critical for regulation of an array of 
proproliferative cell cycle and apoptosis genes that have been implicated in cancer (14).  
 
 
 
Figure 6. miR-130a expression induces associates with expression alterations of 
genes involved in critical cellular pathways.  
(A) Apoptosis-related. (B) TP53-related (C) DNA-Damage-Inducible Transcripts. (D) ER-
stress pathway (Significance level represented as: * = p<0.05; ** = p<0.01; *** = p<0.001) 
Among the genes involved in the apoptosis cascade (Figure 6A) we detected an increase in 
TNFRS9 mRNA levels, along with up-regulation of members of the receptor caspases 
network, CASP1, CASP4 and CASP10, which in turn may trigger the activation of effector 
caspases (as previously demonstrated for CASP3). Moreover, TP53BP2 and TP53INP1 
were also upregulated upon miR-130a transfection (Figure 6B). Both TP53BP2 and 
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TP53INP1 are key regulators of apoptosis and cell growth, regulating cell cycle progression 
and inducing cell death by an autophagy and caspase-dependent mechanism.  
In our dataset, we also found DDIT3 and DDIT4 upregulation upon forced expression of miR-
130a, further associating miR-130a with the activation of transcripts known to be stimulated 
by DNA-damage (Figure 6C). As DDIT3 induces apoptosis in response to endoplasmic 
reticulum (ER) stress, we investigated ER-stress pathway genes. QRT-PCR analysis of miR-
130a-overexpressing PC3 cells demonstrated a statistically significant increase of IRE1 
(ERN1) and XBP1spl (a marker of ER stress (15)) transcript levels (Figure 6D). ERN1 
senses unfolded proteins in the ER lumen leading to enzyme self-activation, subsequently 
catalysing the splicing of X-box binding protein (XBP) 1 mRNA, converting it into a potent 
unfolded-protein response transcriptional activator known for triggering growth arrest and 
apoptosis.  
Moreover, GSEA of significant upregulated in miR-130a transfected PC3 cells identified 
several categories associated with senescence-associated secretory phenotype (SASP), i.e 
“cytokine receptor interaction”, “interferon alpha response”, “p53 pathway”. Examination of 
several top-ranked up-regulated SASP genes identified in this analysis demonstrated a 
broad and dramatic deregulation in the expression of canonical SASP genes in PC3 cells 
transfected with miR-130a mimics, and these results were confirmed by RT-qPCR (Figure 
6E). Indeed, CCL20, IL6, MMP1 and MMP10 expression levels were significantly increased, 
whereas the opposite was observed after miR-130a endogenous inhibition. Conversely, 
LMNB1 was downregulated in miR-130a overexpressing cells, but its expression was 
rescued by miR-130a blockade. We also confirmed the overexpression of the cell cycle 
inhibitors CDKN1B and CDKN2B, whereas a decreased expression of PCNA, a DNA 
replication controller, has been observed. These data implicate miR-130a in growth arrest 
phenotype, compatible with cellular senescence.  
 
 
4. Discussion  
Global miR’s downregulation is a common feature of human cancer, although both 
oncogenic and tumor-suppressive functions have been ascribed to miRNAs. Thus, in this 
study, we aimed to identify and characterize the role of miR’s putatively downregulated due 
to aberrant promoter methylation that might be implicated in prostate carcinogenesis. 
Globally, the results of the miRNAs expression profiling, are in accordance with the widely 
accepted view that miRNAs are mostly downregulated in cancer cells (16), which has been 
associated with altered miRNA biogenesis (17). In our dataset, we found evidence that 
miRNA nuclear processing was compromised, through decreased expression of both 
DGCR8 and DROSHA, impacting on pre-miRNA abundance and downstream processing 
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(18). Remarkably, DICER transcript levels were also decreased in PCa, which may cause 
low processing efficiency that coupled with decreased abundance of pre-miRNA to process 
might contribute to global miRNA downregulation.  
Through comprehensive expression profiling analysis of miRNAs downregulated in PCa and 
simultaneously re-expressed after 5-Aza-CdR exposure in PCa cell lines, we were able to 
identify several miR’s putatively regulated by promoter methylation in PCa, of which miR-
130a had not been previously identified (19-21). Indeed, miR-130a methylation levels were 
significantly increased in PCa compared to non-malignant prostate tissues, and an inverse 
pattern was found for the respective expression levels, as demonstrated for other 
epigenetically-regulated miRs (22-24). These results are in accordance with a previous study 
which demonstrated that combined overexpression of miR-130a, miR-203 and miR-205 
repressed oncogenic pathways in PCa (20). That study, however, was limited to the analysis 
of LNCaP cells and neither the molecular basis for miR-130a specific regulation nor other 
specific roles for miR-130a were further investigated (20), contrarily to our study.   
Because quantitative promoter methylation of specific genes has been shown to accurately 
discriminate cancerous from non-cancerous prostate (25), we found that miR-130a 
methylation levels allowed for accurate identification of PCa, both in tissues and biofluids, 
comparing well with other methylation-based biomarkers (25). Eventually, increasing the 
number of urine samples of performing prostatic massage previous to collection (26, 27) may 
improve the biomarker performance of miR-130a methylation. 
In addition to promoter methylation, post-translational histone modifications might also be 
involved in maintaining transcriptional repression (22). Interestingly, we found that miR-130a 
promoter was devoid of activating histone marks such as H3K27ac or H3K4me3, but was 
H3K27me3 enriched, a repressive mark catalysed by polycomb group protein EZH2, known 
to be up-regulated in PCa (28).  
Concerning miR-130a’s implication in prostate carcinogenesis, in vitro data indicates an 
inhibitory effect in cell proliferation and invasion, and promotion of apoptosis. However, 
earlier studies showed the involvement of miR-130a in either repression or stimulation of cell 
viability, apoptosis, migration, invasion and response to therapy in other cancer models, 
depending on the target genes (29-31). Herein, by an integrative bioinformatics and in vitro 
approach, we identified two putative targets, DEPDC1 (a transcriptional co-repressor 
involved in the suppression of apoptosis) and SEC23B (a member of SEC23/SEC24 family 
involved in vesicle trafficking, particularly in ER to Golgi vesicle-mediated transport). 
DEPDC1 has been found upregulated in bladder cancer (32) activating apoptosis and 
regulating vincristine-induced cell death by promoting JNK-dependent degradation of the 
BCL-2 family protein MCL1 (33) whereas SEC23B has been found to be deregulated in 
hepatocellular carcinoma (34). 
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Direct targeting of SEC23B by miR-130a suggested a link with ER-stress pathway. Indeed, 
disruption of SEC23B may impair vesicle trafficking from ER to Golgi, leading to the 
accumulation of unfolded or misfolded proteins inside the ER. This initiates a series of 
adaptive mechanisms known as the unfolded protein response (UPR), and if cell damage is 
sufficiently severe, it results in cell death (35). Interestingly, in GO analysis, we found that 
response to ER-stress was one of the processes in which miR-130a was involved. Indeed, 
other genes critical to ER-stress response would be activated, including XBP1, ERN1 and 
CASP4 (35). In line with those observations, we found that miR-130a induction causes a 
decrease in SEC23B expression and an increase in ERN1 and XBP1 expression, as well as 
that of XBP1spl, a shorter, more stable and active form XBP1. These data is also in 
agreement with a previous report that showed decreased expression of XBP1 in PCa, 
especially in castration-resistant tumors (36). Although current target prediction algorithms 
are based on full complementarity of the miRNA seed to 3’UTR of target genes, CLIP-Seq 
showed AGO binding occurs at sites without perfect seed matches (37). Therefore, non-
canonical miRNA binding sites are prevalent, frequently contain seed-like motifs, and can 
regulate gene expression, generating a continuum of targeting and regulation, amplifying the 
effect of canonical targeting and phenotype observed upon in vitro modulation (37). Thus, we 
are tempted to speculate whether miR-130a non-canonical targets may cooperate in 
activation of different pathways, including ER-stress.  
Remarkably, we found that in vitro overexpression of miR-130a promotes cellular 
senescence, a form of stable cell cycle exit with altered secretory pathway, typified by SASP. 
Senescent cells actively communicate with microenvironment through a plethora of secretory 
factors as part of SASP (38). Moreover, SASP activates immunity to eliminate senescent 
cells, thus removing potentially tumorigenic factors from the microenvironment (39). 
Regulation of SASP is achieved at many levels, from transcriptional regulation to autocrine 
feedback loops, but persistent DNA damage repair appears to be critical for its regulation 
(40). When irreversible cell-cycle arrest is activated by severe or irreparable DNA damage 
(i.e., dysfunctional telomeres or oncogenic stress), the SASP arises in senescent cells (41). 
We observed increase expression of DDIT3 (and other genes related to DNA Damage 
response), which is activated by cellular stress conditions, inducing G1 arrest and apoptosis 
(42). DDIT3 also functions as a dominant-negative inhibitor of gene transcription (43) and 
prevents transcription in response to DNA damage (42, 43), suggesting that miR-130a might 
impair DNA damage response-related genes and thus promoting SASP. We also verified a 
decrease in LMNB1 upon miR-130a transfection. Lamin B1 is specifically downregulated 
during senescence in multiple cell types (38), and its depletion is associated with reduced 
cell proliferation (44), further supporting our observations on cell viability.  
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In summary, we demonstrated that miR-130a is significantly downregulated in PCa. 
Moreover, we unveiled that in addition to microRNA biogenesis disruption, miR-130 
expression might be regulated through the cooperation of aberrant promoter methylation and 
H3K27me3 deposition. We further provided a mechanistic insight into miR-130a’s role in 
prostate carcinogenesis, which is probably mediated through targeting of genes such as 
SEC23B and DEPDC1 involved in cell senescence, cell cycle regulation, apoptosis and 
invasion. Finally, a link between miR-130a and ER-stress response was implied, through 
SEC23B targeting.  
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Abstract 
Background: Numerous DNA-damaging cellular stresses, including oncogene activation 
and DNA-damage response (DDR), may lead to cellular senescence. Previous observations 
linked microRNA deregulation with altered senescent patterns, prompting us to investigate 
whether epigenetic repression of microRNAs expression might disrupt senescence in 
prostate cancer (PCa) cells.  
Methods: Differential methylation mapping in prostate tissues was carried using Infinium 
HumanMethylation450 BeadChip. After validation of methylation and expression analyses in 
a larger series of prostate tissues, functional role of the cluster miR-130b~301b was explored 
using in vitro studies testing cell viability, apoptosis, invasion and DNA damage in prostate 
cancer cell lines. Western blot and RT-qPCR were performed to support those observations. 
Results: We found that the miR-130b~301b cluster directs epigenetic activation of cell cycle 
inhibitors required for DDR activation, thus stimulating the senescence-associated secretory 
phenotype (SASP). Furthermore, overexpression of miR-130b~301b cluster markedly 
reduced the malignant phenotype of PCa cells.  
Conclusions: Altogether, these data demonstrate that miR-130b~301b cluster 
overexpression might effectively induce PCa cell growth arrest through epigenetic regulation 
of proliferation-blocking genes and activation of cellular senescence.  
 
Keywords: miR-130b, miR-301b, microRNA, senescence, senescence-associated secretory 
phenotype, Prostate Cancer.   
 
Background 
MicroRNAs (miRNAs) are small, non-coding RNAs that act as sequence-specific guides for 
Argonaute (AGO) proteins, which mediate posttranscriptional silencing of target mRNA (1). 
MiRNAs are transcribed from individual genes containing their own promoters or are 
originated intragenically from spliced segments of other genes (2). They contain upstream 
regulatory elements and promoter regions, indicating that miRNAs might endure CpG 
promoter methylation via DNA methyltransferase (DMNT), histone modifications, as well as 
other regulatory alterations (1, 3). Importantly, whereas miRNA genes transcription-start sites 
(TSS) are occasionally 5–10kb away from the pre-miRNA sequence (4), promoter regions 
may be up to 50kb apart, which may preclude the elucidation of transcriptional regulation of 
particular miRNAs (1). Functional miRNAs result from sequential processing of pri-miRNAs 
by RNase III family enzymes DROSHA (nucleus) and DICER (cytoplasm). Unlike their 
protein-coding counterparts, however, miRNAs function as guides for identifying target 
mRNAs for repression (5). 
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MiRNAs are involved in development, homeostasis, cell cycle, apoptosis, as well as in 
diverse pathological condition in nearly all vertebrate tissues (6). Importantly, aberrant 
miRNA expression levels have been associated with promotion or arrest of tumorigenesis, 
through its ability to control the expression of a myriad of protein-coding and non-coding 
genes (7). Concordantly, deregulation of miRNA expression has been reported in several 
malignancies, including prostate cancer (PCa) (3). PCa is currently the most common non-
cutaneous malignancy in developed countries and the second leading cause of death from 
cancer in men in the USA and in Europe, accounting for one in nine of all newly diagnosed 
cancers in men (8). Nonetheless, altered miRNA expression patterns in PCa have been 
significantly understudied compared to other cancers, despite evidence suggesting a global 
downregulation of miRNA expression in both tumorigenesis and treatment resistance (9, 10). 
Here, we examined how epigenetic alterations might contribute to miRNAs deregulation in 
PCa, focusing on the role of miR-130b~301b cluster. We found that miR-130b~301b cluster 
displays tumour-suppressive functions in vitro, influencing cell cycle, cell viability, apoptosis 
and invasion. Interestingly, an unprecedented effect of miR-130b~301b cluster on cellular 
senescence, which prevents cancer cell proliferation, was disclosed, suggesting that 
impairment of cellular senescence might underlie the deleterious effects of miR-130b~301b 
cluster downregulation in prostate carcinogenesis. 
 
Methods 
Patients and sample collection 
Primary tumour tissues from 111 patients harbouring clinically localized PCa were 
prospectively collected, after diagnosis and primary treatment with radical prostatectomy at 
Portuguese Oncology Institute of Porto, Porto, Portugal (Supplementary Table S1). A set of 
14 morphologically normal prostate tissues (MNPT) was procured from prostatic peripheral 
zone of bladder cancer patients submitted to cystoprostatectomy and which did not harbour 
concomitant PCa. All tissue specimens were promptly frozen after surgery. Upon histological 
confirmation of tumour or normal prostate tissue, fresh-frozen tissue fragments were trimmed 
to enhance yield of target cells (>70%). Histological slides from formalin-fixed paraffin-
embedded tissue fragments were also routinely obtained from the surgical specimens and 
assessed for Gleason score and TNM stage. Relevant clinical data was collected from 
clinical charts and informed consent was obtained from all participants, according to 
institutional regulations. This study was approved by the institutional review board (Comissão 
de Ética para a Saúde) of Portuguese Oncology Institute of Porto, Portugal (CES-IPOPFG-
EPE 205/2013). 
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Nuclei Acid Extractions, bisulfite conversion and cDNA synthesis 
DNA from fresh frozen tissue samples and cell lines was extracted using phenol:chloroform 
(Sigma). RNA was obtained using TRIzol (Invitrogen, Carlsbad, CA, USA) according to 
manufacturer’s instructions.  
Bisulfite conversion of 1000ng of genomic DNA was accomplished using EZ DNA 
Methylation Kit (Zymo Research), following manufacturer’s instructions. 
Specific-miRNA cDNA was obtained using TaqMan MicroRNA Reverse Transcription Kit 
from Applied Biosystems (Foster City, CA, USA). Total cDNA synthesis was performed using 
high-capacity cDNA Reverse Transcription Kit (Applied Biosystems).  
 
Infinium HumanMethylation450 BeadChip 
All DNA samples were assessed for integrity, quantity and purity by electrophoresis in a 
1.3% agarose gel, picogreen quantification, and nanodrop measurements. All samples were 
randomly distributed into 96-well plates. Bisulfite-converted DNA (200ng) were used for 
hybridization on the HumanMethylation450 BeadChip (Illumina), comprising 25 PCa and 5 
MNPT. 
HumanMethylation450 BeadChip data were processed using Bioconductor minfi package 
(11). The “llumina” procedure, which mimics the method of GenomeStudio (Illumina), was 
performed comprising background correction and normalization taking the first array of the 
plate as reference. Probes with one or more single nucleotide polymorphisms (SNPs) with a 
minor allele frequency (MAF) >1 % (1000 Genomes) in the first 10 bp of the interrogated 
CpG were removed. The methylation level (β) for each of the 485,577 CpG sites was 
calculated as the ratio of methylated signal divided by the sum of methylated and 
unmethylated signals, multiplied by 100. After normalization step, probes related to X and Y 
chromosomes were removed. All analyses were performed in human genome version 19 
(hg19) and data was deposited in GEO repository under accession number GSE52955. 
 
Pyrosequencing 
Specific sets of primers for PCR amplification and sequencing were designed using a 
specific software pack (PyroMark assay design version 2.0.01.15). Primer sequences were 
designed to hybridize, whenever possible, with CpG-free sites, ensuring methylation-
independent amplification. PCR was performed under standard conditions with biotinylated 
primers, and the PyroMark Vacuum Prep Tool (Biotage, Uppsala, Sweden) was used to 
prepare single-stranded PCR products according to manufacturer’s instructions. 
Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q96 
System version 2.0.6 (Qiagen) using appropriate reagents and recommended protocols. 
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Real Time Quantitative PCR (RT-qPCR) 
MiRNA transcript levels were assessed using TaqMan MicroRNA Assays specific for each 
miRNA (miR-130b, assay ID: 000456; miR-301b, assay ID: 002392) and normalized with 
RNU48 (assay ID: 001006; Applied Biosystems). 
RT-qPCR analysis was performed using gene-specific primers (supplementary table S2) and 
normalized to the expression of GUSB housekeeping gene. 
 
PCa cell lines 
LNCaP cells were grown in RPMI 1640, DU145 cells were maintained in MEM and PC3 cells 
were grown in 50% RPMI-50% F-12 medium (GIBCO, Invitrogen, Carlsbad, CA, USA). All 
basal culture media were supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). Cells were maintained in an 
incubator at 37ºC with 5% CO2. All PCa cell lines were routinely tested for Mycoplasma spp. 
contamination (PCR Mycoplasma Detection Set, Clontech Laboratories).  
To reverse DNA methylation effect in the cell lines, we used 1µM of the DNA 
methyltransferases inhibitor 5-aza-2-deoxycytidine (5-Aza-CdR; Sigma-Aldrich, Schnelldorf, 
Germany) alone or in combination 0.5µM histone deacetylase inhibitor trichostatin A (TSA; 
Sigma-Aldrich, Schnelldorf, Germany). After 72h, cells were harvested and RNA extracted. 
 
Pre-miRNA and anti-miRNA Transfections 
To inhibit miR-130b and miR-301b, single stranded nucleic acids designed to specifically 
bind and inhibit endogenous miRNA (miR-130b Inhibitor, product ID: AM10777; miR-301b 
Inhibitor, product ID: AM12929, Ambion) were used. Anti-miR-130b and Anti-miR-301b were 
transfected as follows: in LNCaP, 25nM and 50nM, respectively; DU145, each at 50nM; PC3, 
50nM and 70nM, respectively.  
MiR-130b and miR-301b overexpression were accomplished through commercially available 
synthetic precursor miRNAs (pre-miR-130b, product ID: PM10777; pre-miR-301b, product 
ID: PM12929, Ambion), each transfected at 20nM. Transfections were performed using 
Oligofectamine (Invitrogen), per manufacturer instructions.  
 
Viability assay 
Cell viability was evaluated by MTT assay. Briefly, PCa cells were seeded onto 96-well flat 
bottoned culture plates, allowed to adhere overnight and transfected 24h later (number of 
cells plated before transfection: LNCaP: 10000 cells/well; DU145: 4000 cells/well; PC3: 3000 
cells/well in 96 well plates). At each time point 0.5 mg/ml of MTT reagent [3-(4, 
5dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide] was added to each well, and the 
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plates were incubated in the dark for 1 hour at 37ºC. Formazan crystals were then dissolved 
in DMSO and absorbance was read at 540nm in a microplate reader (FLUOstar Omega, 
BMG Labtech, Offenburg, Germany), subtracting the background, at 630nm. Three replicates 
for each condition were performed, and at least three independent experiments were carried 
out. Measurements were performed 24h, 48h, and 72h post miRNA manipulation.  
 
Apoptosis evaluation 
Evaluation of apoptosis was performed using APOPercentage apoptosis assay kit (Biocolor 
Ltd., Belfast, Northern Ireland) according to the manufacturer’s instructions. PCa cells were 
seeded onto 24-well plates (LNCaP: 50000 cells/well, DU145 and PC3: 30000 cells/well), 
and 24h later were transfected. Apoptotic cells were assessed at the end of day 3 (72h after 
transfection), in a FLUOstar Omega microplate reader at 550nm and the background 
subtracted at 620nm. The results were normalized to number of viable cell determined in 
MTT assay according to the following formula: OD of apoptosis assay at 72h/ OD of MTT at 
72h. 
 
Cell cycle analysis 
Cell cycle distribution of PC3 cells was determined by flow cytometry. Briefly, 72h after 
transfection (150000 cells/well at Day 0, in 6-well plates), 5x105 harvested cells were fixed 
overnight at 4ºC with 70% cold ethanol. After washing with cold PBS, cells were re-
suspended in Propidium Iodide Solution (Cytognos S.L, Salamanca, Spain) and incubated 
for 30 minutes at room temperature. All cells were then measured on a Cytomics FC500 flow 
cytometer (Beckman Coulter, Fullerton, CA, USA) and analysed using Modfit LT (Verity 
Software House, Inc, Topshan, Maine, USA). 
 
Single Cell Gel Electrophoresis (Comet Assay) 
Seventy-two hours after transfection (150000 cells/well at Day 0, in 6-well plates), 50.000 
cells were harvested by trypsinization, washed in PBS and re-suspended in 75μl of low-
melting point agarose (Invitrogen, Carlsbad, CA, USA). This suspension was then applied on 
top of the base layer consisting of normal-melting point agarose in a slide, after which it 
polymerized for 10 minutes at 4ºC. The slides were then immersed in lysis solution (2.5M 
NaCl, 100mM Na2EDTA, 10mM Tris Base and 1% Triton X-100) at 4°C during 2 hours in the 
dark. To allow DNA to unwind, slides were posteriorly incubated in an alkaline 
electrophoresis buffer (300mM NaOH, 1mM Na2EDTA, pH=13) for 40 minutes at 40C. 
Electrophoresis was accomplished on a horizontal electrophoresis platform at 40C for 20 
minutes at 15V. Subsequently, they were incubated in a neutralization buffer (Tris–HCl; 
pH=7.5) for 10 minutes. After fixation with 100% ethanol, slides were stained with Sybr  
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Green® (Life Technologies, Foster City, CA, USA) and DNA damage was evaluated under a 
fluorescent microscope. At least three independent experiments were performed for each 
condition. The DNA damaging effect in terms of DNA fragmentation was determined by 
measuring four parameters, that included tail moment, tail length, percentage of DNA in tail 
of the comet, and 50 DNA-damaged cells were counted at least, for each condition. 
 
Cell Invasion Assay 
Cell invasion was determined using BD BioCoat Matrigel Invasion Chamber (BD 
Biosciences, Franklin Lakes, NJ, USA). Both cell lines were transfected with miRNA 
molecules for 72 hours. Then, 5x104 cells/mL of PC3 cells were added to the upper chamber. 
After 44h (LNCaP) or 20h (PC3), the membrane bottom containing invading cells was fixed in 
methanol, washed in PBS and stained with DAPI (Vector Laboratories, Burlingame, CA). All 
invading cells were counted under a fluorescence microscope. Three independent 
experiments were performed for each condition.  
 
Transcriptomic evaluation of altered genes following cluster miR-130b~301b manipulation 
Cells (LNCaP: 400000 cells/well, DU145: 200000 cells/well, and PC3: 150000 cells/well) 
were plated in 6-well, in the day before transfection. Cells were collected 72h post 
transfection and RNA was extracted and used as template for cDNA synthesis. RT-qPCR 
was performed as previously described.  
 
Western blot 
150000 cells per well were plated before transfection. 72h post transfections, cell lysates 
were separated on 4–20% Mini-PROTEAN TGXPrecast Gel at 120V and transferred onto 
PVDF membrane using semi-dry transfer. The membrane was incubated for 1h in blocking 
buffer (5% non-fat dry milk) and incubated 2h, at room temperature, with primary antibodies 
(Supplementary table S3). Blots were developed using Immun-Star WesternC 
Chemiluminescent kit (Bio-Rad, Hercules, CA, USA).  
 
Morphometric analysis 
Cell morphology was examined 72h after transfection using a digital camera connected with 
Olympus phase-contrast microscope. The cell area and sphericity were determined with the 
Olympus cellSens Dimension software (Olympus Corporation, Shinjuku, Japan) using the 
freehand polygon tool. 
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TCGA data in prostate cancer patients 
Data on mRNA expression and clinical information (when available) from PCa and matched 
normal patient samples, deposited in The Cancer Genome Atlas (TCGA) was retrieved. 
mRNA expression data from samples hybridized at University of North Carolina, Lineberger 
Comprehensive Cancer Center, using Illumina HiSeq 2000 mRNA Sequencing version 2, 
were downloaded from TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp), including 497 PCa and 52 matched normal (12). To 
prevent duplicates, when there was more than one portion per patient, median values were 
used. The provided value was pre-processed and normalized according to “level 3” 
specifications of TCGA (see https://gdc-portal.nci.nih.gov/ for details). Clinical data of each 
patient was provided by Biospecimen Core Resources (BCRs). Data is available for 
download through TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm). 
 
Statistical analysis 
For group comparisons analysis, non-parametric tests (Kruskal-Wallis and Mann-Whitney U-
test) were used. For in vitro assays, comparisons between two groups were performed using 
the Mann-Whitney U-test. Data are shown as mean ± s.d., unless otherwise specified. 
Student’s t-tests were used for invasion assays. All statistical tests were two-sided. Statistical 
analysis was carried out using Graph Pad Prism version 5. Significance level was set at p < 
0.05. 
 
Results 
Identification of a miRNAs subset targeted by DNA methylation in prostate cancer 
We sought to identify specific differentially methylated miRNA loci between PCa and MNPT 
(Supplementary figure 1A). The DNA methylation analysis was conducted using the Infinium 
HumanMethylation450 BeadChip (450k array), a high-density DNA methylation array that 
interrogates ≈485 000 human CpGs. A total of 439 CpG sites located in miRNA gene 
promoter regions were found to be differentially methylated and were clustered separately 
(non-parametric Mann-Whitney and Wilcoxon matched pair test were applied). For all 
analyses, p-values inferior to 0.05, after FDR correction, were considered statistically 
significant (Figure 1A; Table 1; Supplementary Figure 1A). Thus, 51 differentially methylated 
miRNA-promoters in PCa were identified (Figure 1A, Supplementary Figure 1B) and mapped 
to 19 chromosomes. Chromosomes 19 (n=6), 11 and 7 (n=5) and 2 (n=4) were the most 
enriched genomic locations for differential methylation (Supplementary Figure 1C). 
Simultaneously, we identified several hypomethylated candidates, including miR-181c~181d 
and miR-449a~449b clusters. In the hypermethylated branch, our dataset disclosed 
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previously unreported miRNA-promoters, including miR-130b~301b cluster, miR-149, miR-
212, miR-10a, miR-152, miR-210 and miR-129-2. Consistent with previous observations, we 
confirmed hypermethylation of miR-193b, miR-9 family, and miR-34b-34c cluster 
(Supplementary Figure 1B). Gene Ontology (GO, Supplementary table S4) revealed that 
putative targets of this subset of miRNAs dynamically regulated by DNA methylation are 
involved in critical pathways including "sister chromatid segregation", "regulation of double-
strand break repair", "posttranscriptional gene silencing by RNA", "regulation of adaptive 
immune response”, "G1 DNA damage checkpoint" or "DNA-templated transcription”. 
Strikingly, GO analysis also disclosed that the putative targets of this miRNA panel were also 
involved in "hippo signalling" and "prostate gland growth", indicating a critical role in normal 
prostate biology. Based on β-values for DNA methylation levels, miR-130b~301b cluster 
ranked first (Table 1) and was selected for subsequent validation in a larger cohort. 
 
 
Figure 1. Differentially methylated microRNAs in prostate cancer. 
(A) Unsupervised hierarchical clustering of microRNAs’ promoters displaying significant 
alterations in DNA methylation as determined by Infinium HumanMethylation450 BeadChip in 
25 prostate cancer (PCa) and 5 morphologically normal prostate tissue (MNPT) samples. 
Overall, 51 miRNA promoters were differentially methylated in PCa versus MNPT. (B) 
Validation of miR-130b~301b by pyrosequencing and (C) by RT-qPCR in 111 primary PCa 
and 14 MNPT cases, indicated that promoter hypermethylation was associated with miR-
130b~301b downregulation. (D) LNCaP, DU145, and PC3 cell lines retain basal expression 
of miR-130b and miR-301b. (E) Reversal of DNA methylation in LNCaP cells using 5-aza-2-
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deoxycytidine (5-AZA-CdR) increased the expression of miR-130b and, in combination, with 
TSA augmented miR-301b expression. Mann-Whitney U-test: *p<0.05, **p<0.01, ***p<0.001. 
 
Validation of HumanMethylation450 BeadChip by pyrosequencing 
Validation of miR-130b~301b cluster results was accomplished through pyrosequencing, 
which confirmed that promoter methylation levels were significantly higher in PCa compared 
to MNPT (Figure 1B). Likewise, PCa cell lines DU145, LNCaP and PC3 also demonstrated 
miR-130b~301b promoter methylation (Supplementary Figure 1D).  
 
DNA methylation associates with miR-130b~301b cluster expression 
MiR-130b~301b cluster expression levels were evaluated in a series of 125 prostate tissue 
samples, using RT-qPCR, and were found to be significantly downregulated in PCa 
(p<0.0001 for miR-130b; p=0.0014 for miR-301b, Figure 1C) compared to MNPT. Then, the 
effect of demethylating drugs was tested, as the PCa cell lines still displayed endogenous 
expression of miR-130b and miR-301b (Figure 1D). In LNCaP cells, miR-130b was 
significantly upregulated after exposure to 5-Aza-CdR, whereas miR-301b was only re-
expressed upon combined treatment with 5-Aza-CdR and TSA (Figure 1E). 
 
Functional impact of miR-130b~301b cluster expression manipulation in vitro 
The phenotypic impact of altered miR-130b~301b cluster expression was assessed in PCa 
cell lines in which miR-130b~301b cluster expression was detected along with promoter 
methylation: LNCaP, DU145 and PC3 (Supplementary Figure 1D).  The impact of 
endogenous miR-130b~301b blockage was firstly assessed and the efficiency of silencing 
was confirmed by RT-qPCR (Supplementary figure 2). In LNCaP cells, anti-miR-130b 
significantly enhanced growth rate at 72h (Figure 2A, p<0.001), whereas anti-miR-301b 
showed no significant effect. Conversely, at 72h post-transfection, apoptosis was only 
decreased in anti-miR-130b transfected LNCaP cells (Figure 2D, p=0.0043). Importantly, 
decreased CASP3 expression levels (Figure 2F) were consistent with reduced apoptosis. 
Interestingly, in LNCaP cells, miR-301b knockdown significantly increased invasion capacity. 
However, for miR-130b silencing, no significant differences were apparent, suggesting that 
miR-130b is more likely implicated in invasion regulation than miR-301b. In DU145 cells, 
inhibition of either miRNA significantly increased cell viability (Figure 2B, p<0.001 for both). 
Interestingly, the effect of anti-miR-130b was already apparent at 48h upon transfection 
(p<0.0001). Although decreased apoptosis was depicted for both conditions, it only reached 
statistical significance in anti-miR-301b transfected cells (Figure 2D, p=0.0022). A slight 
increase in Ki67 mRNA expression was found upon anti-miR-130b transfection (Figure 2G, 
p=0.026). Thus, in DU145 cells, miR-301b seems to be more critical than miR-130b, 
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although the latter might influence cell viability. MiR-130b or miR-301b inhibition in PC3 cells 
dramatically enhanced cell viability (Figure 2C, p<0.001). Moreover, increased proliferation 
was complemented with a significant decrease in apoptosis after anti-miR-130b or anti-miR-
301b transfection (figure 2D). Remarkably, an apparent effect on cell invasion was observed 
for miR-130b~301b depleted PCa cells, reaching statistical significance in miR-301b-
depleted LNCaP cells (Figure 2E) 
 
 
 
Figure 2. Phenotypic effects induced by blocking endogenous levels of miR-130b or 
miR-301b in PCa cell lines. (A, B, C) Cell viability measured by MTT assay at different time 
points and (D) apoptosis evaluation 72h-post transfection for LNCaP, DU145 and PC3 cells, 
respectively, indicating functional specialization (LNCaP and DU145) or cooperation (PC3) 
among members of miR-130~301b cluster in PCa cell lines. (E) Invasion assay following 
anti-miR knockdown of miR-130b or miR-301b using Matrigel coated Boyden chamber assay 
in LNCaP and PC3 cells, 72h post-transfection. (F-G) Transcript levels of CASP3 and KI67 in 
LNCaP and DU145 cells, respectively, 72h after anti-miRNAs transfection. (H) mRNA 
expression of selected genes involved in cell cycle, apoptosis and invasion in PC3 cells 
transfected with anti-miRNAs, indicating that both miR-130b and miR-301b knockdown 
decreased the expression of Caspases (3, 8 and 9) and critical cell cycle check-point 
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regulators. (I) Representative Western blots for CD44 and p27. All data are presented as 
mean of three independent experiments ± s.d. (*p<0.05, **p<0.01, ***p<0.001). 
 
 
Because phenotypic changes were more apparent in PC3 cells, these were selected for 
evaluation of expression of several genes involved in relevant signalling pathways. Thus, a 
significant decrease in CASP8, CASP9, CDKN1A and CDKN1B expression was depicted, 
whereas CASP3 and Ki67 mRNA levels remained unaltered (Figure 2H). Moreover a 
significant reduction in CD44 and p27 expression was also observed, in line with the invasive 
phenotype induced by anti-miR-130b and anti-miR-301b transfection in PC3 cells (Figures 
2H-I). 
 
MiR-130b~miR-301b overexpression attenuates the malignant phenotype and promotes 
MET 
The phenotypic impact of miR-130b or miR-301b overexpression was tested in PC3 cells. A 
marked reduction in cell viability (Figure 3A) and increased apoptosis (Figure 3B), along with 
increased caspases expression, especially CASP8 (Figure 3E), was observed. Cell cycle 
analysis by flow cytometry depicted a significant arrest at S phase following miR-130b or 
miR-301b overexpression, and at G2/M phase after miR-130b overexpression (Figure 3C). 
These phenotypic alterations were further confirmed by significant decrease in Ki67 
expression and increased CDKN1A (p21) and CDKN1B (p27) expression, both at mRNA and 
protein level (Figure 3E-F).  
 
Figure 3. miR-130b and miR-301b overexpression attenuate malignant phenotype of 
PC3 cells. (A) Cell viability measured by MTT assay indicates that transfection of pre-miR-
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130b and pre-miR-301b significantly decreased cell viability compared to pre-miR-NC 
transfected cells. (B) Either pre-miR-130b or pre-miR-301b significantly increased the relative 
apoptosis levels as determined by the phosphatidylserine-based assay. (C) Cell-cycle 
analysis of PC3 control cells (pre-miR-NC) and PC3 overexpressing pre-miR-130b or pre-
miR-301b, indicate that both miR-130b and miR-301b significantly induce cell cycle arrest at 
S-phase and miR-130b also causes G2/M arrest. (D) Invasion assay in PC3 cells transfected 
with the pre-miRNAs 72h before plating in Matrigel-coated Boyden chambers. (E) mRNA 
expression levels of selected genes involved in apoptosis, cell cycle and invasion, support 
that miR-130b and miR-301b cooperatively reverse the acquisition of malignant features of 
PC3 cells. (F) Western blot for p21, p27 and CD44 in PC3 cells, depicting selected gene 
overexpression upon miR-130b or miR-301b overexpression. All data are presented as mean 
of three independent experiments ± s.d. (*p<0.05, **p<0.01, ***p<0.001). 
 
 
In the TCGA dataset, these findings were confirmed at mRNA level for CDKN1A (p<0.01), 
but not for CDKN1B, (Supplementary Figure 3), whereas Ki67 was strongly up-regulated in 
PCa samples (p<0.0001), as expected. Collectively, these observations indicate that 
decreased cell viability results from a combined effect of cell cycle arrest and increased 
apoptosis.  
We then hypothesized that miR-130b~301b cluster might inhibit epithelial to mesenchymal 
transition (EMT) and/or facilitate mesenchymal to epithelial transition (MET) in PCa cells. 
PC3 cells possess a more mesenchymal-like gene expression profile (13) and phenotype. 
Moreover, the capacity of cancer cells to migrate and invade is an important requirement for 
metastasis formation, and both are EMT hallmarks. With this in mind, the effect of miR-
130b~301b expression on PC3 cells migration was assessed. Restoration of miR-130b~301b 
impaired the invasive capacity of PC3 cells (Figure 3D), whereas the opposite was observed 
following miR-130b~301b depletion (Figure 2E). Moreover, miR-130b~301b overexpression 
was associated with increased CD44 expression, both at mRNA and protein level (Figure 3E-
F), whereas inhibition of miR-130b or miR-301b decreased CD44 expression (Figure 2H-I). 
The expression of other genes implicated in EMT was also assessed (Supplementary Figure 
4) and a differential impact of miR-130b and miR-301b was suggested. 
Moreover, miR-130b or miR-301b overexpression caused a shift in PC3 cell morphology 
towards a more epithelial-like phenotype, compared to wild type PC3 cells or those with miR-
130b or miR-301b depletion, which are more spindled (i.e., more mesenchymal-like, 
Supplementary Figures 4 and 5). These findings suggest that miR-130b and miR-301b 
facilitate MET, impairing cell migration and invasion. 
Cluster miR-130b~301b induces senescence in PC3 cells 
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Cellular senescence is a process by which proliferation-competent cells undergo growth 
arrest, in response to various cellular stresses. Because miR-130b and miR-301b were able 
to induce cell cycle arrest and decreased cell viability, along with CDKN1A and CDKN1B 
overexpression and Ki67 downregulation, a link with cellular senescence was suggested. 
 
 
Figure 4. Modulation of miR-130b and miR-301b induces cell senescence.  
Cell area (A) and sphericity (B), were increased upon miR-130b or miR-301b overexpression 
and compared to the pre-miR-NC transfected PC3 cells; Cell area (C) and sphericity (D) 
decreased with anti-microRNAs knockdown of miR-130b or miR-301b, indicating a more 
fibroblast-like phenotype. (E) RT-qPCR confirms transcriptional signature associated with 
promotion of cellular senescence after forced expression of miR-130b or miR-301b. (F) 
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miRNA. (H) Western blot shows that LMNB1 levels are downregulated when miR-130b or 
miR-301b are overexpressed, concomitantly with locus-specific H3K9me3 increase. All data 
are presented as mean of three independent experiments ± s.d. (*p<0.05, **p<0.01, 
***p<0.001). 
 
 
Because senescent cells undergo cell size increase, this characteristic was evaluated upon 
miR-130b or miR-301b re-expression in PC3 cells. Morphometric analysis (Supplementary 
Figure 5) disclosed a significant increase in cell area (approximately 50%), compared to 
scramble cells (Figure 4A, p<0.0001), with a significant increase in sphericity, as well 
(p<0.0001, Figure 4B). Conversely, a significant decrease in cell area was apparent when 
endogenous miR-130b or miR-301b were depleted (Figure 4C; Supplementary Figure 6), 
whereas a significant decrease in sphericity was depicted for miR-130b only (Figure 4D, 
Supplementary Figure 6). Then, expression of other senescence-associated genes was 
evaluated. Transfection of miR-130b or miR-301b was associated with significant 
upregulation of tumour suppressor genes CDKN2A (p16) and, more dramatically, CDKN2B 
(p15) (Figure 4E), alongside with downregulation of LMNB1, a marker of cellular senescence 
(Figure 4E), which was confirmed at protein level (Figure 4H). Nevertheless, increased β-
galactosidase (GLB1) mRNA levels were only apparent upon miR-130b expression (Figure 
4E). Globally, the opposite trend was observed after endogenous miR-130b or miR-301b 
depletion (Figures 4F-H), although a few exceptions were apparent, including CDK2 
downregulation, at transcript level. 
Formation of senescence-associated heterochromatic foci (SAHF), specifically enriched for 
H3K9me3, has been implicated in cellular senescence. Interestingly, following pre-miR-130b 
transfection, an increase in H3K9me3 was depicted, whereas anti-miR-130b and anti-miR-
301b transfections were associated with H3K9me3 decrease (Figure 4H).  
In TCGA dataset (Supplementary Figure 3), overexpression of LMNB1 (p=3.32x10-10) and 
down-regulation of CDKN2B (p=0.000218) was depicted in PCa tissue samples, mimicking 
to some extent the pattern observed following endogenous miR-130b or miR-301b depletion. 
Nevertheless, whether LMNB1 reduction is caused by senescence or is promoted by a direct 
interaction of miR-130b or miR-301b with LMNB1-3’UTR (Supplementary Figure 7), remains 
unanswered. 
 
miR-130b~301b induces SASP expression 
The secretome of senescent cells is complex, consisting of a range of cytokines, 
chemokines, and proteases, among others. To further confirm our previous findings, we 
sought to analyse some elements of the senescence-associated secretory phenotype 
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(SASP), as these constitute phenotypic and molecular markers of senescence (14). Thus, 
MMP1, MMP10, CCL20, IL1A, IL1B, IL6, and IL8 expression was assessed. Globally, miR-
130b or miR-301b overexpression associated with increased expression of all genes tested, 
whereas anti-miR-130b or anti-miR-301b transfection associated with decreased MMP1, 
MMP10 and CCL20 expression, alongside with IL1A, IL1B and IL6 overexpression, although 
at a much smaller magnitude compared to miR-130b or miR-301b overexpression (Figures 
5A-B). 
In TCGA dataset, PCa tissue samples displayed significantly lower IL1A, IL1B, and IL6 
expression levels compared to normal prostate tissues (Supplementary Figure 3). 
 
 
 
Figure 5. miR-130b and miR-301b overexpression dramatically alters SASP expression 
in PC3 cells. (A) Comparing miR-130b or miR-301b overexpression with pre-miR-NC 
control, a global increase in mRNA levels of most SASP-related genes was depicted. This 
signature suggests that miR-130b or miR-301b-induced SASP reinforces senescence 
through autocrine mechanisms. (B) Comparison of miR-130b or miR-301b endogenous 
blockade with anti-miR-NC control, revealed a decrease (e.g. MMP10) or minimal increase 
(e.g. IL1A) in mRNA expression of some genes. This suggests paracrine activity of SASP 
when miR-130b or miR-301b are inhibited in prostate cancer cells. All data are presented as 
mean of three independent experiments ± s.d. (*p<0.05, **p<0.01, ***p<0.001). 
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In senescent cells, the control of secretome is achieved at many levels, from transcriptional 
regulation to autocrine feedback loops, but persistent DNA damage response (DDR) appears 
to be critical for regulation of SASP (15). We thus hypothesized that miR-130b and miR-301b 
might influence DNA damage responses and genomic instability during senescence. Upon 
pre-miR-130b or pre-miR-301b overexpression in PC3 cells, a significant increase in DNA 
damage was depicted, using the comet assay (Figure 6A-B), especially in tail moment (an 
index of induced DNA damage) and in the percentage of DNA in the tail. Subsequently, 
expression of genes involved in DDR was evaluated and a significant increase in two DNA 
damage inducible transcripts, DDIT3 (that positively regulates IL6 and IL8) and DDIT4 was 
found (Figure 6C). Moreover, ATR, a DNA-damage detector, was also upregulated. 
Strikingly, the growth arrest and DNA-damage-inducible proteins GADD45A and GADD45B 
were significantly overexpressed, as well as RAD9A and RAD17 (Figure 6C). Conversely, 
PCNA (a cell proliferation marker) was among the downregulated genes. 
 
Figure 6. miR-130b and miR-301b impair DNA-damage signalling pathway.  
(A) Comet assay immunofluorescence images of PC3 cells transfected with pre-miRNAs and 
counterstained with Syber Green, depicting DNA-damage associated morphology. (B) 
Graphic representation of parameters analysed in the assay, supporting that both miR-130b 
and miR-301b overexpression induce DNA damage in PC3 cells. (C) RT-qPCR evaluation of 
Tail Moment
0
10
20
30
*** ***
M
e
a
n
 T
a
il
 M
o
m
e
n
t
% DNA in Tail
0
20
40
60
80
***
***
M
e
a
n
 %
 D
N
A
 i
n
 T
a
il
Total Intensity
0
500000
1000000
1500000
***
**
M
e
a
n
 T
o
ta
l 
In
te
n
s
it
y
Tail Lenght
0
20
40
60
80
100 ***
***
M
e
a
n
 T
a
il
 L
e
n
g
h
t
A
TR
G
A
D
D
45
A
G
A
D
D
45
B
D
D
IT
3
D
D
IT
4
R
A
D
9A
R
A
D
17
TO
P
1
0
1
2
3
4
5
10
20
30
40
50
***
***
****** ***
***
***
***
**
**
******
* **
***
*
F
o
ld
 C
h
a
n
g
e
C
C
N
B
1
M
R
E
11
PC
N
A
TO
P
B
P
1
0.0
0.5
1.0
1.5
**
ns
**
*
**
**
* *
F
o
ld
 C
h
a
n
g
e
A
B
C
pre-miR NC pre-miR-130b pre-miR-301b
156 
multiple genes involved in DNA-damage response pathway. All data are presented as mean 
of three independent experiments ± s.d. (*p<0.05, **p<0.01, ***p<0.001). 
 
 
Discussion  
The intense research on the epigenetics field led to the discovery that genes encoding 
miRNAs were epigenetically silenced through DNA methylation (1).  
Because the miR-130b~301b cluster ranked first among all hypermethylated miRNA 
promoters in our dataset and, to the best of our knowledge, had not been previously reported 
in PCa, it was selected for subsequent validation and functional characterization. 
Pyrosequencing of a large number of primary PCa and normal prostate tissues, confirmed 
that miR-130b~301b cluster promoter methylation levels were significantly higher in the 
former, whereas the opposite was apparent for expression levels of both miRNAs, thus 
prompting an association between aberrant promoter methylation and expression 
downregulation in PCa. This was further confirmed in vitro as PCa cell lines disclosed 
increased expression levels after exposure to a demethylating agent, either alone or in 
combination with TSA. Importantly, these findings are comparable to those reported for miR-
193b, miR-34b~34c and miR-23b~27b~24-1 cluster (16-18), confirming that aberrant 
promoter methylation is, indeed, the mechanism underlying miR-130b~301b cluster 
downregulation in PCa. 
Concerning the functional characterization of these findings, it should be emphasized that 
miR-130b and miR-301b are members of a miRNA family which is deregulated in several 
cancer types, acting either as onco-miRs or tumour-suppressive miRs. Indeed, a tumour-
suppressive role for miR-130b in PCa has been proposed (although the mechanism 
underlying its downregulation was not disclosed), counteracting metastasis formation through 
MMP2 downregulation (19). Nevertheless, another report implicated miR-130b in tumorigenic 
reprogramming of adipose tissue-derived stem cells in PCa patients, acting as oncomir (20). 
Furthermore, the role of miR-301b in PCa remains elusive, although it appears to be induced 
under hypoxia and target NDRG2 (21, 22). Interestingly, the functional assays confirmed the 
tumour-suppressive action of miR-130b and miR-301b. In both cases, miRNA 
overexpression reduced cell viability, induced apoptotic cell death and irreversibly activated 
the cell cycle arrest program DNA damage-induced senescence.  
Phenotypic alterations were supported at molecular level, as restored expression of both 
miR-130b and miR-301b significantly increased the expression of genes acting as checkpoint 
sensors, required for effective tumour-suppression. It is not clear whether these alterations 
directly result from miRNA-mRNA interactions at 5’UTR or promoter (23), or from the naive 
output of tumour-suppression. It might be speculated that both miR-130b and miR-301b 
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interact with other regulatory elements and consequently enhance transcription or translation 
of those genes (23). Indeed, it has been hypothesized that many miRNAs have evolved to 
act not as genetic switches of specific pathways or individual targets but rather to modulate 
expression of large gene networks (24). Moreover, it should be recalled that due to the seed 
sequence similarity among miRNAs of the same family, targets from the same miRNAs 
cluster may be shared, although specific targets might also exist, as result of other base 
pairing determinants in addition to seed-sequence (25). This may explain why restoration of 
either miR-130b or miR-301b basically had the same functional impact. Nonetheless, the 
magnitude of the effect may be different, as demonstrated for several target genes, including 
Ki67 and CASP3. Thus, different functional specialization of miR-130b and miR-301b is 
proposed. 
Our data suggest that miR-130b~301b cluster might counteract malignant transformation of 
prostate epithelial cells through impairment of EMT, favouring MET instead. This was 
apparent not only morphologically, as PC3 cells exhibited a more epithelial phenotype upon 
miR-130b or miR-301b overexpression, but also at molecular level, through increased 
expression of several genes, including CD44. Interestingly, CD44 downregulation was 
depicted following transfection with anti-miR-130b or anti-miR-301b. Decreased CD44 
expression has been associated with a more aggressive PCa phenotype, due to its 
association with higher grade and pathological stage, correlating with biochemical recurrence 
and tumour relapse (26). Our observations are in line with these findings, although the 
mechanism by which the miR-130b~301b cluster influences CD44 expression requires 
clarification. Nevertheless, it should be emphasized that the impact of miR-130b and miR-
301b on EMT-related genes seems to differ, as illustrated by the almost opposite expression 
patterns of TGFB3 and WNT5A. Yet, because no double transfection experiments were 
conducted (as all were transient transfections), the net result of miR-130b~301b cluster 
downregulation cannot be determined. 
An interesting and novel finding was the link between miR-130b~301b cluster and cellular 
senescence. This process induces cell cycle and cell growth arrest, and it may counteract 
tumour formation (27). Accumulation of DNA damage is a common basis for senescence, 
preventing genomic instability (28). Senescent cells display cell size increase and a more 
flattened shape, as well as increased p53, CDKN2A (p16), CDKN1A (p21) and CDKN1B 
(p27) expression, and LMNB1 downregulation (29, 30). Remarkably, the same gene 
expression pattern was observed upon miR-130b or miR-301b overexpression, whereas 
miR-130b or miR-301b depletion had the opposite effect, suggesting that miR-130b or miR-
301b downregulation might allow for senescence bypass. Our observations are also in line 
with previous reports correlating LMNB1 reduction (particularly from H3K9me3 regions) and 
spatial repositioning of perinuclear heterochromatin (H3K9me3-enriched) and SAHF 
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formation (31). These findings are further supported by induction of SASP upon miR-130b or 
miR-301b overexpression. Interestingly, in oncogene-induced senescence (OIS), SASP is 
regulated by persistent DDR (32, 33). We found that miR-130b or miR-301b overexpression 
stimulated the expression of genes involved in DDR as well as in DNA repair, suggesting that 
miR-130b~301b cluster downregulation might impair OIS and foster malignant transformation 
of prostate cells. 
 
Conclusions  
In conclusion, we found novel miRNAs deregulated through aberrant promoter methylation in 
PCa. In particular, the miR-130b~301b cluster displays a tumour-suppressive profile and its 
downregulation might fuel malignant transformation and tumour progression through 
facilitation of EMT and bypass of cellular senescence.  
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Abstract 
Prostate cancer (PCa) is a major cause of morbidity and mortality in men worldwide. 
MicroRNAs are globally downregulated in PCa, especially in poorly differentiated tumors. 
Nonetheless, the underlying mechanisms are still elusive. 
Herein, using combined analysis of microRNAs expression and genomewide DNA 
methylation, we aimed to identify epigenetically downregulated microRNAs in PCa. We found 
that miR-152 was underexpressed in PCa and that lower expression levels were associated 
with promoter hypermethylation. These results were validated in our patient cohort and in 
TCGA dataset. Functional in vitro assays suggest that miR-152 suppresses cell viability and 
invasion potential, whereas it promotes cell cycle arrest at S and G2/M phases. Finally, 
TMEM97, which is overexpressed in PCa, was identified as a novel miR-152 target gene.  
Our findings demonstrate the advantages of using a combinatory approach to identify 
microRNAs downregulated due to aberrant promoter methylation. MiR-152 downregulation 
and promoter methylation was found to be prevalent in primary PCa, which impairs its role in 
control of cell viability, cell cycle regulation and invasion.  
 
Key words: miR-152, Prostate Cancer, cell cycle, DNA methylation, NOL4, TMEM97.  
 
Introduction  
MicroRNAs (miRNAs) are a class of small (~22-nucleotide) RNAs that mediate post-
transcriptional gene silencing by guiding Argonaute (AGO) proteins to target mRNAs (1, 2), 
either by repressing translation or by promoting destabilization (3). Target guidance and 
specificity is mainly determined by nucleotides at positions 2–7 of the miRNA (the ‘seed’) (4). 
Such mechanisms are critical for homeostasis maintenance, both under physiological 
conditions and in cell’s response to environment alterations, including stress signals (5). 
Thus, a vast number of biological processes are subject to miRNA-dependent regulation, 
encompassing cell proliferation, signaling, differentiation, stress response, DNA repair, cell 
adhesion and motility, inflammation, cell survival, senescence, and apoptosis (1). 
Interestingly, miRNA’s expression, processing, and functional output are also stringently 
controlled (6). Indeed, miRNAs’ expression and activity are tightly spatially and temporally 
regulated, and its disruption has been extensively linked to human disease, including the 
development of cancer and metastasis formation (1, 7). Globally, miRNAs are mostly 
downregulated in cancer, including that of the prostate (1). Multiple mechanism are known to 
induce miRNA deregulation, including epigenetic alterations, aberrant transcription factors 
binding (e.g., p53, MYC, REST), miRNA biogenesis machinery disruption, RNA editing, post-
transcriptional RNA modifications, Argonaute loading, and RNA decay (7, 8). 
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Prostate cancer (PCa) is the most common non-cutaneous cancer worldwide in men, and a 
leading cause of cancer-related death in developed countries (9). Multiple factors, comprising 
age, family history, genetic susceptibility and ethnicity, contribute to the high incidence of 
PCa (10). Owing to its complexity and heterogeneity, and despite extensive studies, the 
molecular mechanisms that drive prostatic carcinogenesis are still far from complete 
understanding. Because miRNAs regulate a wide range of signaling pathways that are 
frequently deregulated in PCa, this class of noncoding RNAs might be of critical relevance for 
tumor development and progression. Thus, its study may provide novel insights into PCa 
biology and afford innovative tools for patient management, aiding in diagnosis and 
prognosis assessment, as well as the identification of new therapeutic targets (11). 
Here, we attempted to discover new epigenetically regulated miRNA loci in PCa using a 
combinatory approach that compared miRNAs expression profiling with DNA methylation 
patterns. The candidate microRNAs were subsequently validated in two large patient 
cohorts, which included ours and that of TCGA; in vitro assays were performed to 
characterize their role in cancer cell biology, and in silico analysis, followed by in vitro 
validation, allowed for the identification of relevant target mRNAs. Overall, our data extends 
current knowledge about epigenetic deregulation and biological significance of miRNAs in 
prostate carcinogenesis. 
 
Results 
 
Identification of hypermethylated and downregulated microRNAs in prostate cancer 
Global miRNAs expression was assessed using microRNA Ready-to-Use PCR Human Panel 
(I+II) v2.0 (Exiqon, Vedbaek, Denmark). Using a cutoff value of log fold change <-1.5, 40 
miRs were found downregulated in PCa compared to morphologically normal prostate tissue 
(MNPT) (Supplementary Table S1 and Supplementary Figure 1). From these, 10 were 
selected for validation in a larger and independent dataset (miR-10a, miR-23b, miR-27b, 
miR-135b, miR-143, miR-152, miR-187, miR-204, miR-205, miR-221), i.e., the miRNAseq 
expression data from PCa patients and matched normal samples deposited in The Cancer 
Genome Atlas (TCGA) (n = 326 and n = 52, respectively) (Figures 1 A-C and Supplementary 
Figure 2). 
In parallel, DNA methylation profiling by Illumina disclosed 39 hypermethylated promoter 
regions in known miRNA regions, three of which were further validated in TCGA dataset 
(Supplementary Table S1 and Supplementary Figure 3). 
Because gene expression and DNA promoter methylation correlate with gene regulatory 
activity status, we merged the results of the two analytical platforms (expression by Exiqon 
platform and methylation profiling by Illumina) to identify miRNAs with decreased expression 
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associated with promoter hypermethylation in PCa. From this combined analysis, six 
miRNAs emerged as simultaneously downregulated and hypermethylated in PCa: miR-10a, 
miR-23b, miR-27b, miR-34c, miR-152 and miR-335 (Figure 1A; Supplementary table 1). 
 
 
 
Figure 1. Identification of miRNAs downregulated by DNA methylation in prostate 
cancer, using a combinatorial approach.  
(A) Venn diagram of the intersection of the miR expression (Exiqon) versus DNA methylation 
(Infinium HumanMethylation450 BeadChip) for miRNA promoters. Intersection is shown for 
the downregulated miRNAs and hypermethylated miRNAs. The five common miRNAs based 
on expression level and DNA methylation in PCa tissues are miR-10a, miR-23b, miR-27b, 
miR-152 and miR-335. (B) Independent validation using the TCGA Prostate RNA-seq cohort 
for miR-10a, miR-23b, miR-27b and miR-152 in PCa samples compared to NAT samples. 
(C) MiRNA expression analysis of 52 matched normal and PCa samples pairs using TCGA 
cohort. Except for miR-10a, all miRs were significantly downregulated in PCa. (D) DNA 
methylation levels (β-Values) for each probe in specific miRNA loci, comparing normal and 
PCa samples using TCGA Prostate 450K cohort. Overall, DNA methylation gain 
(hypermethylation) was found in PCa samples. NAT: Normal Adjacent Tissue; PCa: Prostate 
Cancer; Mann-Whitney U-test: *p<0.05, **p<0.01, ***p<0.001. 
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In TCGA dataset, all microRNAs, except for miR-335, were confirmed to be downregulated in 
primary PCa compared to noncancerous prostate tissues (Figure 1B). Moreover, and except 
for miR-10a, all displayed significantly lower expression in PCa in comparison with matched 
non-cancerous prostate tissues (Figure 1C). Because miRNA’s promoter methylation status 
was available at TCGA database, these data were also retrieved and it confirmed our finding 
of increased methylation indexes in these miR’s obtained with the Infinium 450K DNA 
methylation profiling platform (Figure 1D). Then, we focused our study on miR-152 as it 
fulfilled the criteria for downregulation associated with promoter hypermethylation in PCa, 
and it had not been previously reported in this cancer model.  
 
MiR-152 expression and promoter methylation analysis in prostate cells  
MiR-152 is located at chromosome 17q21.32, within an intronic region of COPZ2. In TCGA 
dataset, both miR-152 and COPZ2 expression levels were inversely and significantly 
correlated with cg24389730 methylation levels in PCa samples (ρ= -0.331, p<0.0001 and ρ=-
0.561, p<0.0001, respectively).  
To further validate these findings, miR-152 (Figure 2A) and COPZ2 (Figure 2B) expression 
levels were assessed in our cohort of prostatic tissues (PCa=100 and MNPT=14) and 
downregulation of both in PCa compared to MNPT was confirmed (p<0.0001, and p=0.0022, 
respectively). Pyrosequencing analysis demonstrated that the promoter shared by miR-152 
and COPZ2 was aberrantly methylated in PCa (Figure 2C, p< 0.0001). 
 
 
 
Figure 2. COPZ2-miR-152 transcriptional unit’s DNA methylation and expression 
validation in IPO Porto’s cohort of prostate samples.  
(A) Significant miR-152 downregulation in PCa (n=100) compared to morphologically normal 
prostate tissues (MNPT, n=14), as determined by RT-qPCR (p<0.0001). (B) Significantly 
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decreased COPZ2 transcript levels in PCa samples (p=0.0022). (C) COPZ2-miR-152 
promoter hypermethylation in PCa samples determined by pyrosequencing (p=<0.0001). (D) 
MiR-152 expression levels in PCa cell lines compared to benign RWPE cells [expression 
(E):1] assessed by RT-qPCR. Expression is significantly lower in LNCaP (E:~0.13), DU145 
(E:~0.54) and PC3 (E:~0.09) cells. (E) Significantly lower COPZ2 expression levels by RT-
qPCR in LNCaP (E:~0.005), DU145 (E:~0.17) and PC3 (E:~0.12) cells compared to RWPE 
(E:1). (F) Prostate cell lines’s DNA methylation profiling. LNCaP (FC of methylation levels: 
~59) and PC3 (FC: ~7) cells showed increased miR152-COPZ2 promoter hypermethylation 
compared to RWPE (FC:1), 22RV1 and DU145 cells. (G) A 72h 5-Aza-CdR exposure, 
associated with significant decrease in promoter methylation levels of the transcriptional unit 
COPZ2-miR-152 in LNCaP (decreased ~40%) and PC3 (decreased ~68%) cells. (H) LNCaP 
and PC3 cells miR-152 and COPZ2’s expression levels following 72 h exposure to 5-Aza-
CdR associated with increased miR-152 expression levels (FC:1.75; 1.95, respectively) and 
COPZ2 (FC:1.12; 3.98, respectively). Error bars represent the s.d. for three biological 
replicates. Mann-Whitney U-test: *p<0.05, **p<0.01, ***p<0.001. MNPT: Morphologically 
Normal Prostate Tissue; PCa: Prostate Cancer; 5-Aza-CdR: 5-aza-2-deoxycytidine. 
 
 
In DU 145, LNCaP and PC3 cells, miR-152 and COPZ2 expression levels were also 
significantly lower than those found on RWPE cells, which are benign epithelial prostate cells 
(Figures 2D, 2E), whereas promoter methylation levels followed the opposite trend, 
specifically for the latter two cell lines- LNCaP and PC3 (Figure 2F). These findings indicate 
that miR-152 is transcribed in parallel with its host gene, COPZ2. Exposure of PCa cells to 
demethylating agent 5-Aza-2-deoxycytidine (5-Aza-CdR), caused a 38% and 67% reduction 
in COPZ2-miR-152 promoter methylation levels, in LNCaP (p=0.0411) and PC3 cells 
(p=0.0043), respectively (Figure 2G). Nonetheless, the impact in gene expression differed as 
miR-152 re-expression was observed in both cell lines (LNCaP, FC: 1.75; and PC3, FC: 
1.94) (Figure 2 H), whereas COPZ2 transcript levels were only significantly restored in PC3 
cells (FC: 3.98) (Figure 2 H).  
 
MiR-152 attenuates malignant phenotype in vitro  
Using in vitro assays, we found that miR-152 overexpression significantly decreased cell 
viability in both LNCaP and PC3 cells (Figure 3A and D), and promoted a significant 
accumulation of cells in S and G2/M phases (Figure 3B and E). Accordingly, at 
transcriptional level, both cell lines displayed a significant decrease of several cell cycle 
regulators (Figures 3C and F). Conversely, miR-152’s mimic transfection associated with 
increased apoptosis in LNCaP (p=0.0286) and PC3 (p=0.0286) cells (Figure 3G). These 
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results were further supported by the significantly reduced NF-kB expression in both PCa cell 
lines, as well as significantly increased CASP3 expression levels, although only in PC3 
transfected cells (Figures 3H and I). Moreover, miR-152 overexpression significantly reduced 
PC3 invasion ability in PC3 cells (p=0.0286; Figure 3J), and associated with specific 
epithelial–mesenchymal transition genes’ downregulation. Indeed, along with TWIST and 
VIM downregulation, MAPK1, SMAD4 and STAT3 were significantly downregulated after 
miR-152 restored expression in both LNCaP and PC3 cells (Figures 3K and L). 
 
 
 
Figure 3. miR-152 overexpression associated with attenuated malignant features in 
LNCaP and PC3 cells. (A and D) miR-152 overexpression in LNCaP and PC3 cells 
significantly decreased cell viability compared to pre-miR-NC transfected cells (MTT assay at 
24h, 48h and 72h). (B and E) Cell cycle arrest at S and G2/M phases was depicted for 
LNCaP and PC3 cells overexpressing miR-152 (cytometry analysis was performed 72h after 
transfection). (C and F) reduced transcription levels of several cell cycle-promoting genes in 
miR-152 overexpressing LNCaP and PC3 cells. (G) MiR-152 overexpression associated with 
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significant increase in apoptosis compared to cells transfected with negative control miRNA. 
(H-I) Apoptosis-related genes’ expression levels were deregulated in PCa miR-152 
overexpressing cells. Significantly reduced NF-kB levels were found in both miR-152 
overexpressing cell lines. (J) MiR-152 forced expression in LNCaP and PC3 cells associated 
with a significant decrease number of cells invading through the Matrigel coated Boyden 
chamber assay. (K-L) Transcriptional deregulation of EMT and invasion-related genes in 
miR-152 transfected LNCaP and PC3. Differential MET, mTOR and MMP9 results suggest 
cell-specific gene regulation. TGFB3 overexpression and EMT markers STAT3, TWIST, or 
VIM decrease was shared by both miR-152 overexpressing cells. Error bars represent the 
s.d. for three biological replicates. Mann-Whitney U-test: *p<0.05, **p<0.01, ***p<0.001. 
 
 
miR-152 targets NOL4 and TMEM97  
Because the previous results suggested that miR-152 was an onco-suppressor, we sought to 
identify its targets for post-transcriptional regulation, using a combination of multiple in silico 
target prediction tools (putative targets must contain at least one miRNA response element – 
MRE) (Supplementary table S2) and a publicly available gene expression dataset.   
 
 
Figure 4. Identification of putative targets of miR-152 in PCa cell lines.   
(A) Genes selected for validation in our experimental settings: combining in silico prediction 
targets with genome-wide expression using GeneChip® Human Exon ST Array. (B) MiR-152 
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TMEM97	 transmembrane	protein	97	 17q11.2	
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overexpression in LNCaP cells associated with significant decreased levels of BEND4 
(~40%), ELOVL2 (52%) and TMEM97 (40%) as determined by RT-qPCR. (C) PC3 miR-
152’s transfected cells displayed significantly decreased NOL4 expression (approximately 
50%). (D and E) Effect of 5-Aza-CdR treatment in the selected target genes transcript levels 
in LNCaP revealed TMEM97 downregulation (up to 35%), whereas in PC3 cells it associated 
with significantly decreased NOL4 transcript levels (30%). (F) Schematic representation of 
the miR-152’s MRE in NOL4 and TMEM97 (left panel). Luciferase activity in HEK293Ta cells 
co-transfected with reporter constructs containing NOL4 MRE or TMEM97 MRE and either 
pre-miR-152 or pre-miR-NC (Right panel). 3’UTR: 3’ Untranslated Region; MRE: miRNA 
response element Error bars represent the s.d. for three biological replicates. Mann-Whitney 
U-test: *p<0.05, **p<0.01, ***p<0.001. 
 
 
Among the 329 genes predicted as miR-52 targets in silico, only six - BEND4, ELOVL2, 
NOL4, OAS2, SLC7A11 and TMEM97 - disclosed a gene expression log fold change > 1.5 in 
PCa samples (n=368) analyzed by GeneChip Human Exon ST Array (Figure 4A). Moreover, 
forced expression of miR-152 caused a significant downregulation of BEND4, ELOVL2 and 
TMEM97 in LNCaP cells (Figure 4B), whereas in PC3 cells, only NOL4 transcript levels 
significantly diminished following miR-152’s overexpression (Figure 4C). LNCaP cells 
overexpressing miR-152 exposed to 5-Aza-CdR, showed significantly reduced TMEM97 
expression levels (Figure 4D) and NOL4 was downregulated in PC3 cells (Figure 4E). 
Since both NOL4 and TMEM97 3’UTRs contain a MRE for miR-152 (Figure 4F, left panel), 
the functional interaction between miR-152 and NOL4, on the one hand, and miR-152 and 
TMEM97, on the other, was investigated using luciferase assays. Interestingly, a 30% 
reduction (p=0.0022) in luciferase activity for the TMEM97 MRE was found, although only a 
10% decrease was depicted for the NOL4 MRE (Figure 4F, right panel).  
 
TMEM97 and NOL4 expression in primary PCa  
To further confirm the biological significance of our previous findings, NOL4 and TMEM97 
expression levels were assessed in two independent cohorts of PCa patients (the one from 
our institution and that from TCGA). Remarkably, we found that TMEM97 and NOL4 
expression levels were significantly upregulated in PCa cases from both cohorts, compared 
to normal prostate tissues (p= 0.0132 and p=0.0004, respectively, in IPO Porto’s cohort; 
p<0.0001 and p<0.0001, respectively, in TCGA cohort) (Figure 5A-5B). Moreover, no 
associations were found between miR-152 and TMEM97 expression levels and patients’ 
prognosis in IPO Porto’s cohort. However, in TCGA’s cohort, higher TMEM97 expression 
levels (>75 percentile) independently predicted shorter disease free survival (HR= 1.805; 
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p=0.040), whereas miR-152 expression levels did not disclose any association with patients’ 
outcome. 
 
 
 
Figure 5. NOL4 and TMEM97 upregulation in PCa tissues. (A and B) Significantly higher 
NOL4 and TMEM97 expression in PCa tissue samples (n=100) compared with 
morphologically normal prostate tissue (n=14), determined by RT-qPCR. (C and D) 
Expression levels in TCGA Prostate by RNA-seq cohort (NAT: n=52; PCa: n=497). MNPT: 
Morphologically Normal Prostate Tissue; NAT: Normal Adjacent Tissue; PCa: Prostate 
Cancer. Mann-Whitney U-test: *p<0.05, **p<0.01, ***p<0.001 
 
 
Discussion 
MiRNAs are key players in cellular differentiation and homeostasis, being involved in 
regulation of transcriptional programs through the elimination of aberrant transcripts and 
suppression of random fluctuations in transcript copy number (12). Thus, its deregulation 
impairs cellular homeostasis and is involved in the emergence of several pathologies, 
including PCa.  
In this study, we aimed to extend current knowledge on the impact of epigenetic deregulation 
of miRNAs expression in PCa. For that purpose, we used a combined analysis that allowed 
the identification of downregulated and aberrantly methylated microRNAs. Interestingly, only 
TMEM97
MNPT PCa
0
5
10
15
*
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
NAT PCa
0
200
400
600
800
5000
NOL4 
***
N
O
L
4
 e
x
p
re
s
s
io
n
(T
C
G
A
 R
N
A
_
s
e
q
 L
e
v
e
l 
3
)
NOL4
MNPT PCa
0
10
20
30
40
50
300
320
340
360
380
400
***
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
NAT PCa
0
1000
2000
3000
TMEM97 
***
T
M
E
M
9
7
 e
x
p
re
s
s
io
n
(T
C
G
A
 R
N
A
_
s
e
q
 L
e
v
e
l 
3
)
A
B
n=52 n=494 n=52 n=494
n=14 n=100 n=14 n=100
175 
8% of downregulated miRNAs in PCa tissues were found to be simultaneously aberrantly 
methylated. Thus, promoter hypermethylation does not seem to be a prevalent mechanism 
underlying microRNA downregulation in this cancer model, and other causes, whether 
genetic( 13), epigenetic (14) or microenvironment-related (e.g., abnormal AR signaling (15)), 
are likely to be more frequent. Notwithstanding, we have recently shown that aberrant 
microRNA promoter methylation might constitute a clinically useful tool for PCa detection and 
prognostication (16). Although the number of candidate microRNAs was small, the combined 
approach used in this study seems to be more robust and efficient than each strategy (i.e., 
micro-RNA expression analysis and differential methylation mapping) alone, considering the 
significantly higher proportion of validated candidates obtained compared to previous studies 
from our group (17, 18). Moreover, the results also validate this approach as it confirmed 
previous reports on miR-23b and miR-27b (members of the cluster miR-23b/27b/24-1) 
downregulation associated with promoter methylation in PCa (19-21). Remarkably, two novel 
microRNAs within this category were found - miR-10a and miR-152 – although only the latter 
was validated in two independent datasets. 
Interestingly, several miRNAs, including miR-135b, miR-143, miR-187, miR-204, miR-205 
and miR-221 that were commonly downregulated in the Exiqon expression dataset, were 
also downregulated in TCGA dataset. In contrast, the number of putatively downregulated 
microRNAs due to aberrant DNA methylation found in the HumanMethylation450 BeadChip 
and validated in TCGA dataset was much smaller. Thus, our data indicate that miRNA 
expression’s profiling is more likely to identify bona fide miRNA deregulated due to promoter 
methylation compared to DNA methylation profiling, as aberrant DNA methylation might not 
indicate effective transcriptional silencing. Nevertheless, DNA methylation profiling might be 
particularly suitable for integrative analytic approaches (22). 
Because miR-152 fulfilled the criteria for methylation-associated downregulation and it had 
not been previously reported in PCa, we sought to investigate its role in prostate 
carcinogenesis. Our study indicates that miR-152 is a sense-oriented intronic miRNA that 
forms a transcriptional unit (TU) with the respective host gene, COPZ2, being processed as 
part of the host gene mRNA (23, 24). Globally, aberrant promoter methylation associated 
with simultaneous downregulation of COPZ2-miR152 expression. Nonetheless, the results of 
5-Aza-CdR exposure in LNCaP suggest that this is not the only mechanism regulating 
COPZ2-miR152 expression, and we are tempted to speculate whether an independent 
promoter might be located upstream in the host gene, as reported for other genes (25, 26). 
MiR-152 promoter methylation has also been reported in endometrial cancer (27) and in 
MLL-rearranged infant acute lymphoblastic leukemia (28). In similarity with previous reports, 
our data also suggest an onco-suppressor function for miR-152 in PCa. Indeed, in non-small 
cell lung cancer miR-152 suppressed cell proliferation, colony formation, migration and 
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invasion (29), in endometrial cancer miR-152 restored expression prevented tumor cell 
growth both in vitro and in vivo (27), and in ovarian cancer miR-152 was suggested to 
contribute to cisplatin resistance in vitro and in vivo through direct DNMT1 targeting (30). In 
PCa, miR-152 was shown to control cell migration and invasion (31), as well as inhibition of 
cell proliferation (32). Interestingly, in prostatectomy samples, lower miR-152 expression 
levels were significantly associated with higher risk for biochemical recurrence, although only 
in univariate analysis (32). We did not find miR-152 expression levels to be of prognostic 
value in either patient cohort assessed. However, higher TMEM97 expression levels (>75 
percentile) was an independent prognostic marker for biochemical recurrence in PCa 
patients, although only in TCGA cohort. These apparently contradictory results may be 
explained by the existence of other regulatory factors acting on TMEM97, besides miR-152. 
Indeed, it should be recalled that only a 30% reduction in luciferase activity was found for the 
TMEM97 MRE specific for miR-152. 
The gain of function in vitro functional assays demonstrated that miR-152 controls cell 
viability in PCa cells acting as S and G2/M cell-cycle transitions regulator, in both cell lines 
tested, but more expressively PC3 cells. However, these effects might be cell-context 
dependent. In line with functional assays’ results, miR-152 overexpression associated with 
different specific transcript alterations depending on the tested cell line. Our results indicate 
that miR-152 fine-tunes the expression of several genes involved in the MAPK/ERK, TFG-
Beta, JAK–STAT3 and EMT pathways. As these mediate biological processes that are 
critical for cancer progression, an important role for miR-152 in PCa progression might be 
anticipated. 
To better understand the role of miR-152, we attempted to identify putative targets. In silico 
analysis followed by validation in two independent patient cohorts indicated NOL4 (nucleolar 
protein 4) and TMEM97 (transmembrane protein 97) as miR-152 targets. Although no 
information is available for the role of NOL4 in cancer, TMEM97 has been shown to be 
upregulated in several malignancies, including glioma (33) as well as colorectal (34) and 
ovarian (35) cancers. Interestingly, in glioma cells, TMEM97 depletion inhibited cancer cell 
growth and metastasis formation, in parallel with deregulation of EMT-related genes. 
Remarkably, increased TMEM97 expression correlated with shorter survival in glioma (33), 
ovarian (35), non-small cell lung (36) and colorectal (34) cancer patients. Moreover, 
TMEM97 cytoplasmic expression has been positively correlated with PCNA expression (34), 
which acts as a scaffold to recruit proteins involved in DNA replication or DNA repair, being 
required for post-replication repair (37). Remarkably, in our study, miR-152 overexpression 
associated with PCNA downregulation in both cell lines. Therefore, since TMEM97 might be 
functionally associated with PCNA (38), it might suggest that both are controlled by miR-152. 
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Concerning other previously reported miR-152’s targets, we were not able to confirm DNMT1 
as a miR-152’s direct target. (30, 39-40) 
In conclusion, this study uncovered novel miRNAs downregulated by aberrant DNA 
methylation, including a transcriptional unit formed by COPZ2-miR-152. Furthermore, it was 
demonstrated that miR-152 downregulation is a common feature of PCa, favoring the 
acquisition and development of the malignant traits, as in vitro miR-152´s restored 
expression attenuated PCa cell phenotype, by impairment of cell viability, cell cycle 
progression and invasion, through targeting of several genes involved in critical cancer-
related pathways.  
 
Methods 
A flow chart depicting the different steps followed in this study is provided in Supplementary 
Figure 1. 
 
Patient and samples 
PCa tissue samples (n=100) from patients diagnosed and primarily treated with radical 
prostatectomy at Portuguese Oncology Institute of Porto, Portugal were prospectively 
collected. Fourteen normal prostate tissue (MNPT) samples, of peripheral zone of prostates 
without PCa, from patients submitted to radical cystoprostatectomy due to bladder cancer, 
served as controls. All specimens, promptly frozen at -80ºC, were cut for nucleic acid 
extraction. For routine histopathological examination, formalin-fixed and paraffin-embedded 
(FFPE) fragments were also collected. Relevant clinical data was retrieved from clinical 
charts. This study was approved by the institutional review board (IRB-CES-IPOFG-EPE 
215/013). The clinical and pathological data of the patients included in this study is reported 
in Supplementary Table S3.  
 
PCa cell lines and Demethylation treatment 
Prostate cell lines, LNCaP, 22RV1, DU145, PC3 (malignant) and RWPE (benign) were used 
for in vitro studies. LNCaP and 22Rv1 cells were grown in RPMI 1640, whereas DU145 and 
PC3 cells were maintained in MEM and 50% RPMI-50% F-12 medium, while RWPE was 
cultured in Keratinocyte-SFM, containing human recombinant Epidermal Growth Factor 1-53 
and Bovine Pituitary Extract (GIBCO, Invitrogen, Carlsbad, CA, USA), respectively. 
HEK293Ta were maintained in DMEM. All basal culture media were supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). 
Cells were maintained in an incubator at 37ºC with 5% CO2. All cell lines were G-banding 
karyotyped (for validation) and routinely tested for Mycoplasma spp. contamination (PCR 
Mycoplasma Detection Set, Clontech Laboratories). 
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One µM of the DNA methyltransferases inhibitor 5-aza-2-deoxycytidine (5-Aza-CdR; Sigma-
Aldrich, Schnelldorf, Germany) was used for DNA demethylation. Cells were harvested and 
RNA extracted after 72h exposure to the demethylating agent. 
Nuclei acids extraction and bisulfite conversion 
DNA was extracted from fresh frozen tissue samples and cell lines using phenol:chloroform 
(Sigma). RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) according with 
manufacturer’s instructions.  
Bisulfite conversion of genomic DNA (1000 ng) was accomplished using EZ DNA Methylation 
Kit (Zymo Research), following manufacturer’s instructions. 
 
MicroRNA expression profiling  
MiRNAs expression was assessed in ten PCa and four MNPT using microRNA Ready-to-
Use PCR Human Panel (I + II) v2.R (Exiqon, Vedbaek, Denmark), comprising 752 miRNAs 
as previously described (17, 41). Extracted RNAs were submitted to cDNA synthesis using 
miRCURY LNA Universal RT microRNA PCR (Exiqon, Vedbaek, Denmark) following 
manufacturer’s instructions. Data were analyzed using the comparative Ct method and the 
mean value was calculated for reference genes’ expression normalization. MiRNAs with fold 
change of -1.5 in PCa compared with MNPT were considered downregulated. 
 
MicroRNA’s promoter methylation analysis in prostate tissues  
All DNA samples were assessed for integrity, quantity and purity by electrophoresis in a 1.3 
% agarose gel, picogreen quantification, and nanodrop measurements. All samples were 
randomly distributed into 96-well plates. Bisulfite-converted DNAs (200 ng) of 25 PCa and 5 
MNPT were used for hybridization on the HumanMethylation450 BeadChip (Illumina). 
HumanMethylation450 BeadChip data were processed using Bioconductor minfi package 
[54]. The “lllumina” procedure that mimics the method of GenomeStudio (Illumina) was 
performed, including background correction and normalization considering the first array of 
the plate as reference. Probes with one or more single nucleotide polymorphisms (SNPs) 
with a minor allele frequency (MAF) >1 % (1000 Genomes) in the first 10 bp of the 
interrogated CpG were removed. The methylation level (β) for each of the 485,577 CpG sites 
was calculated as the ratio of methylated signal divided by the sum of methylated and 
unmethylated signals, multiplied by 100. After normalization step, probes mapped within X 
and Y chromosomes were removed. All analyses were performed in human genome version 
19 (hg19) and data was deposited in GEO repository under accession number GSE52955. 
TCGA dataset analysis 
Data on miRNA expression and clinical information (when available) from PCa and matched 
normal tissue samples was retrieved from The Cancer Genome Atlas (TCGA) database. The 
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mRNA expression data from samples hybridized at University of North Carolina, Lineberger 
Comprehensive Cancer Center, using Illumina HiSeq 2000 mRNA Sequencing version 2, 
were downloaded from data matrix including 494 miRNA-Seq, 496 RNA-Seq and 498 
Methylation Array for PCa samples and 52 matched normal adjacent tissue samples (NAT). 
To prevent duplicates, when there was more than one portion per patient, median values 
were used. The provided value was pre-processed and normalized according with “level 3” 
specifications of TCGA. Clinical data of each patient was provided by Biospecimen Core 
Resources (BCRs). Data is available for download through https://gdc-
portal.nci.nih.gov/projects/TCGA-PRAD . 
 
Real-Time Quantitative PCR (RT-qPCR) 
MiR-152 transcript levels were assessed using TaqMan MicroRNA Assay (assay ID: 000475; 
Applied Biosystems) and normalized with RNU48 (assay ID: 001006; Applied Biosystems). 
Real-time quantitative PCR analysis was performed using gene-specific primers and 
normalized using GUSB housekeeping gene (Supplementary table S4). Specific-miRNA 
cDNA was obtained using TaqMan MicroRNA Reverse Transcription Kit from Applied 
Biosystems (Foster City, CA, USA). Total cDNA synthesis was performed using high-
capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).  
NOL4 and TMEM97 mRNA levels were confirmed in the same group of tissue samples 
previously indicated. A total of 300 ng was reverse transcribed and amplified using 
TransPlex® Whole Transcriptome Amplification Kit (Sigma-Aldrich®, Schnelldorf, Germany) 
with subsequent purification using QIAquick® PCR Purification Kit (QIAGEN, Hilden, 
Germany), according with manufacturer’s instructions. Expression levels were evaluated 
using TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA, USA), and 
GUSB was used as a reference gene for normalization.  
The expression of each gene or small RNA was obtained using the formula: Relative 
expression = (Target gene mean quantity/Reference gene mean quantity). Ratios were then 
multiplied by 1,000 for easier tabulation. Each plate included multiple non-template controls 
and serial dilutions (10×) of a cDNA obtained from human prostate RNA (Carlsbad, CA, 
USA) were used to construct a standard curve for each plate. All experiments were run in 
triplicates (Supplementary Table S4.). 
 
 
DNA methylation analysis 
DNA methylation analysis was performed by quantitative methylation PCR (qMSP) using 
KAPA SYBR FAST qPCR Kit (Kapa Biosystems, MA, USA) and pyrosequencing. All 
reactions were run in triplicates in 384-well plates using Roche LightCycler 480 II, with β-
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actin (ACTB) as internal reference gene for normalization. Primer sequences 
(Supplementary Table S4) were designed using Methyl Primer Express 1.0 and purchased 
from Sigma-Aldrich (St. louis, MO, USA). 
For pyrosequencing, specific sets of primers for PCR amplification and sequencing were 
designed using a specific software pack (PyroMark assay design version 2.0.01.15). Primer 
sequences were designed, when possible, to hybridize with CpG-free sites to ensure 
methylation-independent amplification. PCR was performed under standard conditions with 
biotinylated primers, and the PyroMark Vacuum Prep Tool (Biotage, Uppsala, Sweden) was 
used to prepare single-stranded PCR products, according with manufacturer’s instructions. 
Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q96 
System version 2.0.6 (Qiagen, Hilden, Germany) using appropriate reagents and 
recommended protocols (Supplementary Table S4). 
 
Pre-miR Transfections 
To overexpress miR-152, synthetic, commercially available, miRNAs’ precursors (pre-miR-
152, ID: PM12269; pre-miR-NC, ID: AM17110; Ambion, Carlsbad, CA, USA) were 
transfected at 30nM. Transfections were performed using Oligofectamine (Invitrogen, 
Carlsbad, CA, USA), per manufacturer’s instructions.  
 
Viability assay 
Cell viability was evaluated by MTT assay. Briefly, PCa cells were seeded onto 96-well flat 
bottomed culture plates, allowed to adhere overnight later (number of cells plated before 
transfection: LNCaP: 10000 cells/well; PC3: 3000 cells/well), and transfected 24h later. At 
each time point, 0.5 mg/ml of MTT reagent [3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide] was added to each well, and the plates were incubated in the dark for 
1h at 37ºC. Formazan crystals were then dissolved in DMSO and absorbance was read at 
540 nm in a microplate reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany), 
subtracting the background, at 630 nm. The number of cells was calculated using the 
formula: [(OD experiment x Number of cells at day 0) / Mean OD at day 0]. Three replicates 
were performed for each condition and at least three independent experiments were carried 
out. 
 
 
Apoptosis evaluation 
Evaluation of apoptosis was performed using APOPercentage apoptosis assay kit (Biocolor 
Ltd., Belfast, Northern Ireland) according with the manufacturer’s instructions. PCa cells were 
seeded onto 24-well plates (LNCaP: 50000 cells/well, and PC3: 30000 cells/well), and 24h 
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later were transfected. Apoptotic cells were assessed at the end of the day 3, in a FLUOstar 
Omega microplate reader at 550 nm and the background subtracted at 620 nm. The results 
were normalized to number of viable cell obtained in the MTT assay according to the 
following formula (OD of apoptosis assay at 72h/ OD of MTT at 72h). 
 
Cell cycle analysis 
Cell cycle distribution of LNCaP and PC3 cells was determined by flow cytometry. Briefly: 
72h after transfections, 5x105 harvested cells were fixed overnight at 4oC with 70% cold 
ethanol. After cold PBS washing, cells were re-suspended in staining Propidium Iodide 
Solution (Cytognos S.L, Salamanca, Spain) and incubated for 30 minutes at room 
temperature. All cells were then measured on a Cytomics FC500 flow cytometer (Beckman 
Coulter, Fullerton, CA, USA) and analyzed using Modfit LT (Verity Software House, Inc, 
Topshan, Maine, USA). 
 
Cell Invasion Assay 
Cell invasion was determined using BD BioCoat Matrigel Invasion Chamber (BD 
Biosciences, Franklin Lakes, NJ, USA). Briefly, 5x104 cells/mL of LNCaP or PC3 cells were 
added to the upper chamber. Both cell lines were transfected for 72 hours with miRNA 
molecules, after which, the non-invading cells were removed with cotton swabs from the 
upper side of the membrane. The membrane bottom containing invading cells was fixed in 
methanol, washed in PBS and stained with DAPI (Vector Laboratories, Burlingame, CA). All 
the invading cells were counted under a fluorescent microscope. Three independent 
experiments were performed for each condition.  
 
Transcriptomic evaluation of altered genes following miR-152 manipulation 
Cells (LNCaP: 400000 cells/well, and PC3: 150000 cells/well) were plated in 6-well, in the 
day before transfection. Cells were collected 72h post transfection and RNA was extracted 
and used as template for cDNA synthesis. RT-qPCR was performed as previously described 
and data analyzed according to the comparative Ct method (42). 
 
Gene Expression Microarrays 
RNA was extracted from tissue samples using TRIzol (Invitrogen by Life Technologies, 
Carlsbad, CA), as previously described (43, 44), and 1 µg of RNA was processed into cDNA 
and hybridized to Affymetrix GeneChip Human Exon 1.0 ST arrays, following the 
manufacturer's recommendations. The Affymetrix Expression Console v1.1 software was 
used to obtain exon-level robust multi-array average (RMA)-normalized expression values for 
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the core probe sets only. The data is freely available in GEO repository under accession 
number GSE42954.  
 
Luciferase assay 
A reporter plasmid containing a binding site at NOL4 or TMEM97 3’UTR for miR-152 
(GeneCopoeia, Rockville, MD, USA) was co-transfected into HEK293Ta cells using 
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). 30nM of synthetic 
pre-miRNA were used. Luciferase activity was assessed with the Secrete-Pair™ Dual 
Luminescence Assay Kit (GeneCopoeia, Rockville, MD, USA) according with the 
manufacturer’s instructions. The ratio of luminescence intensities (RLU, Relative Light Unit) 
of the GLuc (Gaussia luciferase) over SEAP (secreted Alkaline Phosphatase) was obtained 
as follows: GLuc/SEAP, for each triplicate.  
 
Statistical analysis 
Non-parametric tests (Kruskal-Wallis and Mann-Whitney U-test) were used for group 
comparisons analysis for both expression and methylation levels for the two patient cohorts 
(IPO’s and TCGA) and for the in vitro assays.  Correlations between expression levels and 
methylation were evaluated by Spearman’s correlation test.  Data are shown as mean ± s.d., 
unless otherwise specified. Student’s t-test was used for invasion assays. To evaluate the 
prognostic value of mir152 and TMEM97 expression in PCa patients from the TCGA dataset, 
univariable (Log-rank test) and multivariable (Cox regression) analyses of disease-free 
survival were performed, where putative confounding effects (Gleason score, patients’ age, 
and the PSA value) were considered. Disease-free survival was calculated from the date of 
the radical prostatectomy to the date of biochemical relapse, or date of last follow-up or 
death if relapse-free. For the purposes of survival analyses, all cases were coded based on 
the percentile 75 value of expression levels. All statistical tests were two-sided. All 
experiments were run in triplicate. Statistical analysis was carried out using Graph Pad Prism 
version 5. Significance level was set at p < 0.05. 
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Abstract 
Background: Contemporary challenges of prostate cancer (PCa) include overdiagnosis and 
overtreatment, entailing the need for novel clinical tools to improve risk stratification and 
therapy selection. PCa diagnosis and prognostication might be perfected using epigenetic 
biomarkers, among which aberrant DNA methylation of microRNA promoters has not been 
systematically explored. Herein, we identified aberrantly methylated microRNAs promoters in 
PCa and assessed its diagnostic and prognostic biomarker potential.  
Methods: Using HumanMethylation450 BeadChip-based analysis differentially methylated 
CpGs in microRNA promoters were identified. Promoter methylation of six microRNAs (miR-
34b/c, miR-129-2, miR-152, miR-193b, miR-663a and miR-1258) was analyzed by qMSP in 
three sets (180 prostatectomies, 95 urine sediments and 74 prostate biopsies). Biomarkers’ 
diagnostic (validity estimates) and prognostic [disease-free (DFS) and disease-specific 
survival (DSS)] performance was assessed. 
Results: Significantly higher promoter methylation levels in PCa were confirmed for six 
candidate microRNAs. Except for miR-152, all displayed AUC values higher than 0.90, with 
miR-1258 and miR-193b disclosing the best performance (AUC=0.99 and AUC=0.96, 
respectively). In urine samples, miR-193b showed the best performance (91.6% sensitivity, 
95.7% specificity, AUC=0.96). Moreover, higher miR-129-2 independently predicted for 
shorter DSS and miR-34b/c methylation levels independently predicted for shorter DFS and 
DSS. 
Conclusions: Quantitative miR-193b, miR-129-2 and miR-34b/c promoter methylation might 
be clinically useful PCa biomarkers for non-invasive detection/diagnosis and prognostication, 
both in tissue and urine samples. 
 
Keywords: Biomarkers, aberrant miR’s promoter methylation, detection, prognosis, prostate 
cancer. 
 
Background 
Prostate cancer (PCa) is the most incident male cancer in western countries, constituting the 
second most common cause of cancer and the sixth leading cause of death by cancer 
among men worldwide (1). For 2012, it was estimated that PCa alone accounted for 420,000 
newly diagnosed cancer cases and 101,000 of all cancer-related deaths in European men 
(2). PCa is age-related and very heterogeneous, both molecularly and clinically, ranging from 
relatively indolent to highly aggressive. It is typically asymptomatic at its earliest stages, 
when adequate treatment is mostly curative, in contrast with its late diagnosis, which usually 
impairs a curative-intent therapeutic strategy (3). This led to the widespread use of serum 
PSA as screening tool for PCa. However, it is now commonly accepted that this entailed 
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overdiagnosis and overtreatment, justifying the strong recommendation against PCa 
screening and prompting the search for more effective biomarkers (4).  
DNA methylation is a chemically stable and easily quantified alteration (5). We and others 
have previously reported on the use of quantitative promoter methylation of several protein-
coding genes for early diagnosis and prognostication of PCa (6). Although several gene 
methylation panels have been then developed (7, 8), both sensitivity and specificity must be 
perfected to allow for clinical translation. 
MicroRNAs, a class of small (19-25 nucleotides) non-coding RNA, are involved in virtually all 
cellular processes and frequently deregulated in cancer cells (9), although its abrogation due 
to aberrant promoter methylation has been seldom reported (10). Because this epigenetic 
alteration is likely to be highly cancer-specific, it might constitute an effective cancer 
biomarker. Thus, we aimed to explore the potential of microRNA-coding genes promoter 
methylation as diagnostic and prognostic biomarkers in PCa. Therefore, after genome-wide 
screening, a set of putative tumor-suppressor microRNAs (miR-34b/c, miR-129-2, miR-152, 
miR-193b, miR-663a and miR-1258) with increased promoter methylation levels in PCa 
compared to normal prostate tissues was identified and further validated in clinical samples.  
 
Methods 
 
Patients and samples collection 
For the purposes of this study, three independent cohorts of PCa patients were defined. 
PCa tissue samples were prospectively collected from 180 patients with clinically localized 
disease, consecutively diagnosed and submitted to radical prostatectomy (RP) from 2001 to 
2006, at Portuguese Oncology Institute of Porto (Cohort #1). Fifteen control samples were 
obtained from cystoprostatectomy specimens with bladder cancer, not harbouring PCa nor 
prostatic involvement by urothelial carcinoma (morphologically normal prostate tissue, 
MNPT). After collection, tissue samples were fresh-frozen at -80°C and subsequently cut in a 
cryostat for DNA extraction. Prostate biopsy samples were collected from 74 PCa suspects 
(elevated serum PSA), referred to Portuguese Oncology Institute - Porto from 2001 to 2003 
(Cohort #2). In addition to standard diagnostic cores, a core was collected from the most 
suspicious area, fresh-frozen at -80°C and subsequently cut in a cryostat for DNA extraction. 
Voided urine samples from 95 PCa patients were collected from 1999 to 2002 (Cohort #3). 
The control set is composed of urine samples collected from 17 healthy donors and 29 
patients without urological malignancy. Samples were centrifuged at 4,000 rpm for 20 
minutes, washed in PBS 1X and the pellets were frozen at -80°C. 
Clinical data was retrieved from clinical charts. Survival data was collected for patients of 
Cohort #1 and of Cohort #2. Disease-specific survival (DSS) time was calculated as the time 
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elapsed since diagnosis until death or the last follow-up. Disease-free survival (DFS) was 
calculated from the date of the radical prostatectomy or other curative treatment to the date 
of biochemical relapse, date of last follow-up, or death if relapse-free. 
All patients enrolled (Tables 1 and 2) signed informed consent. This study was approved by 
institutional review board (CES-IPOPFG-EPE 019/08 and CES-IPOPFG-EPE 205/2013).  
 
Table 1. Clinical and pathological data of tissue and urine samples used in this study 
 
 
 
Nucleic acid isolation, bisulphite treatment, HumanMethylation 450 BeadChip and 
qMSP analysis 
DNA extracted by phenol-chloroform as described elsewhere(11) was chemically modified 
using sodium bisulfite with EZ DNA Methylation-Gold™ Kit (Zymo Research, CA, USA) 
according to manufacturer’s protocol. 
HumanMethylation450 BeadChip (Illumina, USA) allowed for gene methylation profiling of 
tissue samples (5 controls and 25 tumors), using 500ng of bisulphite-converted DNA, 
according to manufacturer’s instructions. DNA methylation levels were depicted as beta-
values ranging from 0–1. Validation of all candidates was performed by quantitative 
methylation using KAPA SYBR FAST qPCR Kit (Kapa Biosystems, MA, USA). All reactions 
were run in triplicates in 384-well plates using Roche LightCycler 480 II, with β-actin (ACTB) 
as internal reference gene for normalization. 
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Primer sequences (Supplementary Table1) were designed using Methyl Primer Express 1.0 
and purchased from Sigma-Aldrich (MO, USA). 
 
Table 2. Clinical and Pathological data of cohort #2 (prostate biopsies) 
 
 
Statistical analysis  
For HumanMethylation 450 BeadChip data, a threshold intensity with P-value ≤ 0.01 was 
considered for further analysis. To identify consistently differentially methylated CpG sites, 
Wilcoxon rank sum paired test was performed for normalized beta-values. P-values were  
adjusted using false discovery rate, and CpGs with P-values <0.05 were selected. 
In Cohort #1, pathological variables were categorized [Gleason score (GS): <7 and ≥7; 
pathological stage: pT2 and pT3]. Kruskall-Wallis and Mann-Whitney U tests allowed for 
comparisons among three or more groups and between two groups, respectively. For 
multiple comparisons P values were adjusted according to Bonferroni’s correction. Spearman 
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nonparametric correlation was performed to ascertain association between methylation and 
PSA serum levels. 
In Cohort #1 and Cohort #3, receiver operator characteristics (ROC) curves were constructed 
by plotting true positive rate (sensitivity) against false positive rate (1-specificity) and area 
under the curve (AUC) was calculated to assess diagnostic performance. Biomarker validity 
estimates [specificity, sensitivity, positive predictive value, negative predictive value and 
accuracy] were determined using as cut-off the highest value obtained through ROC curve 
analysis [sensitivity + (1-specificity)]. 
In Cohort #1 and Cohort #2, DSS and DFS curves were built using Kaplan–Meier method 
and the prognostic significance of clinicopathological variables (clinical stage, GS and serum 
PSA in both cohorts, and CAPRA Score in Cohort #2) was assessed using log-rank test. 
CAPRA score values were categorized as 0-2 (low-risk), 3-5 (intermediate risk) and 6-10 
(high-risk) (12). To test the prognostic significance of miR-34b/c and miR-129-2 promoter 
methylation, samples were categorized based on methylation levels of each miR (using 
percentile 75 as threshold) (11). A Cox-regression model comprising all variables 
(multivariable analysis) was constructed. SPSS Statistics 20 (IBM, NY, USA) was used for all 
statistical analyses and graphics were assembled using GraphPad 5 Prism (GraphPad 
Software, CA, USA). P values <0.05 were considered statistically significant.  
 
RESULTS 
 
MicroRNA promoter hypermethylation in Radical Prostatectomy samples (Cohort #1) 
Using the 450K array, we screened microRNA loci regulated by DNA methylation in PCa. 
The microarray dataset included 5 MNPT and 25 PCa tissue samples.  
Candidate miRNAs were selected according to adjusted P-values and differences in the 
methylated fraction between MNPT and PCa tissues. CpG sites displaying statistically 
significant differences with adjusted P-values and mean methylation <0.3 in MNPT were 
further considered relevant. Among these, methylation sites located in the promoter region 
and in proximity to transcription start sites (TSS) [1500 and 200 base pairs upstream of TSS 
(TSS200; TSS1500 region)] were identified confirming the results of the array analysis. 
For the validation study, we selected microRNAs in which significant differences (P<0.05) in 
methylation levels were observed at all CpG sites mapped and differences in methylated 
fractions were >0.12. Thus, six microRNAs - miR-34b/c, miR-129-2, miR-152, miR-193b, 
miR-663a, and miR-1258 (Figure 1; Table 3), were selected for large-scale validation in 15 
MNPT and 180 PCa samples (Cohort #1). In this series, overall methylation levels remained 
significantly increased in PCa compared with MNPT (Figure 2).  
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Figure 1. HumanMethylation450 BeadChip results.  
The microRNAs that displayed the most significant differences between normal and 
neoplastic samples were selected for further analysis. All data are presented as mean + 
standard deviation of the samples analyzed in each group. 
 
 
To assess the diagnostic potential of microRNA promoter methylation in PCa we performed 
ROC curve analysis (Figure 2 and Table 4), which revealed AUC values ranging from 0.89 to 
0.99, with miR-1258 (AUC=0.99), miR-193b (AUC=0.96) and miR-34b/c (AUC=0.95) 
demonstrating the best performance. Because AUC for miR-152 was lower than 0.90, it was 
excluded from further analyses. Concerning validity estimates, miR-1258 promoter 
methylation levels displayed the highest values (97.8% sensitivity, 100% specificity) for PCa 
detection. Panels composed by two or more microRNAs did not improve performance (data 
not shown). 
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Table 3. MicroRNA/CpG island probe distribution derived from the Infinium 
HumanMethylation450 BeadChip 
 
 
Table 4. Validity estimates for miR’s promoter methylation as markers for PCa in Cohort #1 
 
 
 
Then, we evaluated whether microRNA promoter methylation levels were associated with 
clinicopathological parameters. MiR-129-2 promoter methylation was associated with higher 
GS and pathological stage (P=0.0248 and P=0.0245, respectively), whereas, miR-34b/c, 
miR-663a and miR-1258 promoter methylation levels were only associated with higher 
pathological stage (P=0.0055, P=0.0386 and P=0.0303, respectively) (Figure 3). 
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Figure 2. Box-plots and ROC curves for miR-34b/c, miR-129-2, miR-152, miR-193b, miR-
663a and miR-1258 promoter methylation levels in morphologically normal prostate tissue 
(MNPT) and malignant (PCa) prostatic tissues from Cohort #1 
 
 
To determine whether microRNA promoter methylation was PCa-specific, malignant and 
benign tissue samples from bladder (43 and 7) and kidney (50 and 9) were analyzed. MiR-
34b/c, miR-193b and miR-1258 promoter methylation levels were significantly higher in PCa 
tissues compared to all other samples tested. Interestingly, miR-129-2 and miR-663a 
showed higher methylation levels in bladder cancer and were, thus, considered unsuitable 
for accurate detection of PCa in urine sediments (Supplementary Figure 1). 
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Figure 3. DNA methylation and Pathological parameters. Distribution of methylation 
levels of microRNAs according to Gleason score and pathological stage in the series of 
patients submitted to radical prostatectomy (Cohort #1) 
 
 
MicroRNA promoter methylation in urine sediments (Cohort #3) 
Best performing PCa-specific microRNAs - miR-34b/c, miR-193b and miR-1258 – were then 
tested in urine sediments, collected without previous prostatic massage, from PCa patients 
(n=95, Cohort #3) and controls (n=46). Higher miR-34b/c and miR-193b methylation levels 
and lower miR-1258 promoter methylation levels were depicted in PCa patients (Figure 4). 
MiR-193b promoter methylation displayed the best performance with high sensitivity (91.6%) 
and specificity (95.7%), providing an overall accuracy of 92.9% (AUC = 0.96). Moreover, the 
panel including both miRs (miR-34b/c, miR-193b) augmented specificity (97.8%) and positive 
predictive value (98.9%) (Table 5). Addition of miR-34b/c promoter methylation did not 
improve biomarker performance. No associations between microRNAs’ promoter methylation 
levels and clinicopathological parameters were depicted in this series. 
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Figure 4. Box-plots and ROC curves of miR-34b/c, miR-193b and miR-1258 promoter 
methylation levels across urine sediments of controls (HD) and prostate cancer patients 
(PCa) from Cohort #3. Receiver operator characteristic (ROC) curves were constructed to 
evaluate the performance of the gene promoter methylation panel (miR-34b/c+miR-193b) 
 
 
Table 5. Validity estimates for miR’s promoter methylation as markers for PCa in urine 
samples (Cohort #3) 
 
 
 
MicroRNA promoter methylation as prognostic biomarker (Cohorts # 1 & # 2) 
Owing to its association with stage and GS, the prognostic value of miR-34b/c and miR-129-
2 promoter methylation was further tested in the set of 180 radical prostatectomy (Cohort #1) 
and in a prospective group of 74 PCa suspects (Cohort #2). 
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Figure 5. Survival Analysis. Disease-free survival (DFS) curves based on pathological 
stage (upper left panel) and Gleason score (upper right panel), and miR-129-2 methylation 
levels (lower panel) in Cohort #1. b - Disease-free survival (DFS) curves based on clinical 
stage (upper left panel) and Gleason score (upper right panel), miR-34b/c (lower left) and 
miR-129-2 (lower right) methylation levels in Cohort #2 
 
 
The median follow-up in Cohort #1 was 110.1 months (range: 2.8–169.1 months). Nine 
patients (5%) had died from PCa and 50 (28%) developed biochemical recurrence. Eighteen 
were never free of disease and were excluded from DFS analysis. In this cohort, pathological 
stage, GS and PSA levels significantly associated with DFS (Figure 5A), whereas, only 
pathological stage and higher GS statistically associated with worse DSS (Figure 6A). 
Remarkably, high miR-129-2 methylation levels associated with shorter DSS. In multivariable 
analysis, only GS and PSA levels for DFS and GS and miR-129-2 methylation for DSS 
retained prognostic value (Table 6). 
Regarding Cohort #2, the median follow-up was 114.9 months (range: 10.3–170.1 months). 
Thirteen patients (17.6%) had died from PCa and 29 (39.2%) developed biochemical 
recurrence. In 3 patients, serum PSA levels >0.2 ng/ml persisted following treatment and 
these were not further considered for DFS analysis. Advanced clinical stage, higher GS, 
higher miR-34b/c and miR-129-2 promoter methylation levels statistically associated with 
worse DFS (Figure 5B). In multivariable analysis only higher clinical stage and high miR-
34b/c promoter methylation levels independently predicted shorter DFS (Table 6). Except for 
serum PSA, all clinicopathological parameters tested, as well as miR-34b/c and miR-129-2 
promoter methylation levels associated with DSS in univariable analysis (Figure 6B).  
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Figure 6. Disease-specific survival (DSS) curves based on pathological stage (upper left), 
Gleason Score (upper right), and miR-129-2 methylation levels (lower) in Cohort #1. B - 
Disease-specific survival (DSS) curves based on clinical stage (upper left), Gleason Score 
(upper center) CAPRA Score (upper left), miR-34b/c (lower left) and miR-129-2 (lower-right) 
methylation levels in Cohort #2. 
 
Similarly to DFS, in multivariable analysis only clinical stage and high miR-34b/c promoter 
methylation levels independently predicted shorter DSS (Table 6). 
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Table 6. Cox regression analysis assessing the potential of clinical and epigenetic variables 
in the prediction of disease-specific survival and disease-free survival in the Cohort #1 and 
Cohort #2. 
 
 
 
 
Discussion 
PCa remains one of the most prevalent neoplasms and a leading cause of morbidity and 
mortality in men. Although PSA screening has decreased the number of men diagnosed with 
metastatic PCa, this was accomplished at the cost of overdiagnosis and overtreatment of a 
sizeable proportion of men carrying indolent/non-life threatening tumors (13). Thus, a strong 
recommendation against serum PSA-based PCa screening has been issued (14), prompting 
the search for more effective biomarkers allowing for better risk stratification of PCa 
suspects. Herein, we aimed to tackle this clinical quest through discovery and preliminary 
validation of novel biomarkers for PCa detection and prognostication, using methylation 
analysis of microRNAs gene promoters. 
Owing to our previous experience in DNA methylation analysis of PCa (6, 11), we searched 
for altered methylation patterns at the promoter regions of microRNAs deregulated in PCa. 
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This information was then used to develop novel biomarkers, instead of microRNA 
expression levels, as previously attempted by other researchers (15). Indeed, DNA 
methylation is easier to assess than microRNA expression, it is more specific and, 
importantly, more stable. Moreover, because microRNAs downregulation in cancer is more 
common than upregulation, it seemed likely that aberrant promoter methylation might 
constitute an underlying mechanism, similar to protein-coding genes (16). Although several 
strategies might be used to identify microRNAs putatively downregulated due to promoter 
hypermethylation, high-throughput technologies such as methylation-array analysis are able 
to simultaneously pinpoint putative candidates (17) and the reliability of the results might be 
readily assessed through analysis of well-known hypermethylated loci. Indeed, results of the 
methylation array experiments confirmed the high prevalence of GSTP1 and APC promoter 
methylation (data not shown), as we previously demonstrated in PCa (18). To increase the 
likelihood of finding robust candidate biomarkers, we used stringent conditions based on high 
fold-variation of methylation levels between cancerous and non-cancerous tissue samples. 
From methylation-array analysis, six candidate microRNAs, putatively deregulated by 
promoter hypermethylation were identified. MiR-1258, miR-193b and miR-34b/c were the 
most promising candidates, displaying substantial PCa-specificity compared with other 
urinary tract tumors, an attractive feature for testing in bodily fluids. MiR-129-2 and miR-663a 
showed modest results and their inability to discriminate PCa from bladder cancer rendered it 
unsuitable for testing in urine samples. 
Association between promoter methylation levels in tumor tissue samples and standard 
clinicopathological variables was also assessed. Higher miR-129-2 promoter methylation 
levels associated with higher GS and stage, suggesting prognostic value. MiR-34b/c, miR-
663a and miR-1258 methylation levels also associated with pathological stage, but higher 
diagnostic performance underscores the potential for detecting PCa at early stages instead 
of prognostication, as we previously reported for EFEMP1 promoter methylation (19). 
Nevertheless, in this series of radical prostatectomies (Cohort #1) higher miR-129-2 
methylation conveyed independent prognostic information, although only for DSS. 
Importantly, these results are in line with previous observations concerning the association of 
higher gene promoter methylation levels with clinicopathological features of more aggressive 
disease (11, 20).  
Urine is a key sample to evaluate DNA methylation biomarkers for PCa, as it is readily 
collected and biomarkers are diluted to a smaller extent than in plasma, providing higher 
sensitivity (21). Nevertheless, the amount of DNA potentially deriving from prostatic cells is 
variable, usually low, entailing the use of a panel with limited number of biomarkers. Thus, 
only miR-34b/c, miR-193b and mir-1258, were tested in urine samples (Cohort #3). From 
these, Mir-193b was previously shown to be aberrantly methylated in PCa cell lines as well 
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as in primary tumors, but no data is available regarding its performance as PCa detection 
biomarker (22, 23). Indeed, Mir-193b performed best, with high AUC, sensitivity, specificity 
and PPV, whereas miR-34b/c performance was more modest.  
Intriguingly, miR-1258, which showed the best performance in tissue samples (Cohort #1), 
displayed a strikingly different result in urines as its methylation levels were higher in controls 
than in PCa patients. The reason for this discrepant result is not immediately apparent, but it 
might be due to high miR-1258 promoter methylation in non-epithelial cells, such as 
leucocytes, which are relatively more abundant in urine than in tumor tissue samples. 
Moreover, median miR-1258 promoter methylation levels in urines from PCa were 
substantially inferior to those of miR-193b, impairing the robustness of the assay. It should 
be recalled that, contrarily to other studies, the urine samples we used were not collected 
following DRE or prostatic massage, which are usually employed in an attempt to increase 
sensitivity. Studies dealing with PCa biomarkers in urine vary in the method of urine 
collection and the real impact of prostatic massage has never been evaluated (24). It could 
be argued that the distance from the peripheral zone to the urinary tract flow may render 
urinary based tests less sensitive, which would be an important issue since most 
malignancies arise from this zone. Nevertheless, studies on PCA3 did not find a difference in 
the levels of this biomarker between patients with peripheral versus transitional zone PCa 
(25, 26). 
Currently, the performance of serum PSA and urinary PCA3, the only biomarkers approved 
for clinical use is rather limited. The reported performance of serum PSA as PCa biomarker 
is somewhat modest, with AUC ranging from 0.54 to 0.70 (27, 28). Even other serum PSA-
derived measurements, like PSA-density, free PSA percentage and PSA-velocity have not 
significantly improved performance (28). Nonetheless, PCA3, which was reported to perform 
better than serum PSA both in urine and ejaculates but has not been approved for 
population-based screening, displays AUCs varying from 0.66 to 0.79 (27-30). Additionally, 
although miRs’ expression has been extensively investigated in liquid biopsies, available 
data for urine samples is rather limited. Nevertheless, an AUC of 0.74 was reported for miR-
107 (31) and simultaneous quantification of miR-107 and miR-574-3p in urine showed an 
AUC of 0.83, for PCa cancer detection (32). We should emphasize that in our dataset, 
urinary miR-193b promoter methylation (AUC = 0.96) outperformed not the only currently 
approved clinical biomarkers, but also the previously mentioned miRs, constituting a 
promising tool for non-invasive PCa detection. 
Because a major goal of this study was to discriminate clinically aggressive from indolent 
PCa, it was critical to test the prognostic value of microRNAs in a pre-therapeutic setting, 
which was accomplished in series of prospectively collected prostate biopsies (Cohort #3). In 
univariable analysis, most standard clinicopathological parameters associated with DFS and 
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DSS, clinically validating this dataset. The same was demonstrated for higher miR-129-2 and 
miR-34b/c promoter methylation levels. The CAPRA score, however, only associated with 
DSS but not DFS. This was unexpected as its determination at diagnosis associated with 
DFS in patients with clinically localized disease submitted to RP (12). Notwithstanding, our 
prostate biopsy series included PCa at diverse clinical stages, submitted to different 
therapeutic modalities (RP, radiotherapy, androgen-deprivation therapy), which might explain 
the apparent flaw of CAPRA score. In multivariable analysis, only clinical stage, amongst all 
clinicopathological parameters, retained independent prognostic value, both for DFS and 
DSS. Remarkably, high miR-34b/c promoter methylation levels also predicted shorter DFS 
and DSS, suggesting that it might constitute a useful PCa prognostic biomarker. These 
results suggest that high miR-34b/c promoter methylation levels identify clinically aggressive 
PCa, irrespective of disease extent at diagnosis. 
It should be acknowledged that in spite of the excellent diagnostic performance of miR-193b 
promoter methylation in urine, additional patient sets must be tested. Furthermore, a larger 
cohort of patients submitted to biopsy and subjected to different therapies is required to 
further validate our observations. Ultimately, we plan to develop a multiplex assay to 
simultaneously assess miR-193b, miR-129-2 and miR34b/c promoter methylation, allowing 
for diagnostic and prognostic assessment of PCa suspects in a single analysis.  
 
Conclusion 
Through genome-wide screening, a set of methylation-based PCa biomarkers was identified 
and validated. MiR-193b demonstrated high sensitivity and specificity for detection of PCa, 
both in tissue and urine, whereas high miR-129-2 and miR-34b/c methylation levels 
independently predicted for shorter DSS and DFS or DSS, respectively. If confirmed in larger 
and independent datasets, quantitative promoter methylation of selected miRs might provide 
useful tools for clinical management of PCa patients. 
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CHAPTER 8 – GENERAL DISCUSSION 
 
 
GENERAL DISCUSSION  
PCa is the second most common cancer in men and the fourth most common tumor type 
worldwide, constituting a major cause of morbidity and mortality (53). Several features, 
comprising age, family history, genetic susceptibility, and race, impact the incidence of PCa 
(54). Due to PSA screening, approximately 90% of PCa are clinically localized at the time of 
diagnosis (55). This led not only to a decrease in PCa-related mortality rates but, also to an 
overdiagnosis and overtreatment of indolent, low grade cancers that, probably, would not be 
clinically apparent during a man’s lifetime (56). The clinical behavior and molecular 
alterations of PCa are highly heterogeneous (57). Clinically, some men will have aggressive 
disease leading to metastasis and death, whereas many others will have indolent cancers 
that are cured with initial therapy or would be suitable for watchful waiting or active 
surveillance (58). Multiple risk stratification parameters have been developed, combining the 
best currently available clinical and pathological parameters (such as Gleason score, serum 
PSA levels, and clinical and pathological staging). These tools, however, still do not 
satisfactorily predict outcome in an individual basis (56) nor help distinguish indolent from 
aggressive PCa.  
MiRNAs have been suggested as important regulators of biologic processes in PCa 
progression (59). An expression profile aiming to characterize each PCa subtype and stage 
has still not been proposed for PCa. One could argue that this task has been hindered by the 
molecular heterogeneity as well as differences in study design and patient selection (60). 
The advance of high-throughput sequencing and comparative genomics studies support that 
a miRNA may target hundreds of sites transversely in the transcriptome (61). Not 
surprisingly, most predicted miRNA targets experience small changes at the mRNA and 
protein levels when miRNA’s expression is disrupted (28, 36, 61). MiRNAs are believed to 
establish thresholds in and confer coherence to the expression of its target genes, as well as 
reduce the cell‑ to‑ cell variability in target gene expression (28, 62). Globally, miRNAs 
control gene expression during developmental and pathological processes. Understanding 
how miRNAs become altered in PCa constituted the main focus of this work.  
Thus, three different aspects have been emphasized: mechanisms driving the deregulation 
of miRNAs; the cellular pathways altered upon miRNA manipulation; and the translational 
potential of miRNAs for PCa detection and prognostication.  
Globally, new concepts were exposed from this Thesis describing: 
• The dynamics of miRNA regulation in PCa;  
• The consequences of miRNA–target interactions; 
212 
• The role of miRNAs in regulation of cell cycle, DDR and senescence; 
• MiR-193b and miR-129-2 promoter methylation potential clinical usefulness as early 
diagnostic and prognostic biomarkers.  
In following section, the most relevant results of the manuscripts previously presented are 
discussed. Altogether, the results obtained disclosed the critical biological significance of 
miRNAs in prostate carcinogenesis and open new perspectives for diagnostic/prognostic 
tools in PCa.  
 
microRNA deregulation in Prostate Cancer 
MiRNA profiling enabled high-throughput analysis of the miRNAome of PCa, identifying a 
global downregulation. Nonetheless, due to the inherent heterogeneity of PCa, sample 
selection and technological platforms used, some inconsistencies are still apparent (59). 
MiRNAs’ expression alterations can be caused by promoter methylation, chromosomal 
rearrangements or transcriptional deregulation (63). Indeed, 20–40% of miRNAs are located 
near CpG islands, confirming their possible epigenetic regulation (63). The miRNAs are 
frequently located within fragile chromosomal sites that exhibit DNA amplifications, deletions, 
or translocations during tumor progression (64). Consequently, miRNAs have been 
characterized either as tumor-suppressors or oncogenes, depending on the expression 
pattern and targeted transcripts (59). Herein, because a significant percentage of miRNAs 
were down-regulated (65), there was a need to characterize the mechanisms underlying the 
regulation of miRNAs in PCa.  
Global miRNA down-regulation might also be caused by miRNA biogenesis machinery 
failure, in addition to genetic and epigenetic alterations. The expression of miRNA biogenesis 
machinery molecules has a major impact in both developmental and tumorigenic processes, 
since they are often deregulated in cancer (66), and specifically in PCa (67). Specifically, 
DROSHA expression levels have been shown to be downregulated in several types of 
cancer, being systematically correlated with invasion, metastasis (68) and reduced patients’ 
survival (65, 69, 70). Conversely, DGCR8 was found to be upregulated in different tumor 
types and correlated with tumor stage (71, 72). However in our dataset, DGCR8 was found 
to be downregulated, and associated with deregulated miRNA expression. Moreover, 
deletion of Dgcr8 impaired tumor progression in a Pten-knockout mouse model of PCa, 
supporting its oncogenic function (73). These results are in sharp contrast with those 
presented herein. Considering that Drosha and DGCR8 regulate each other post-
transcriptionally, downregulation of both DROSHA and DGCR8, depicted in Chapter 4, may 
suggest that a number of mRNAs may be downregulated in a microprocessor-dependent 
way in PCa (74). 
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Finally, Dicer has been considered a haploinsufficient tumor-suppressor gene. Indeed, 
Dicer1 loss diminished survival in a mouse model of lung cancer (75). Therefore, decreased 
DICER1 expression (Chapter 4) may result in global miRNAs downregulation in PCa, 
because precursor miRNA (pre-miRNA) processing is compromised. Notably, DICER1 was 
reported to be upregulated in PCa, causing not only global deregulation of miRNAs but also 
correlating with higher clinical stage, lymph node status, and Gleason score (76). 
The reason underlying deregulation of processing molecules is still not fully understood. One 
may argue that different cancers have different genetic or epigenetic mechanisms controlling 
genes expression of the biogenesis machinery, thus ensuing the abnormal expression of 
oncogenic or tumor-suppressive miRNAs in a given cell type. Although impaired miRNA 
processing enhances cellular transformation and tumorigenesis, it only partially justifies our 
observations.  
Epigenetic alterations, such has DNA methylation and histone modifications, are also 
considered to be of great importance for miRNA gene regulation. They are reported as being 
more prevalent than genetic alterations, to be present in pre-malignant lesions and as driver 
events in PCa development and progression. Tumor-suppressive miRNAs are frequently 
hypermethylated in cancer, thus causing the epigenetic silencing of these miRNAs. However, 
as epigenetic alterations are reversible, pharmacological inhibition of DNA methylation with 
DNA-demethylating agents can reactivate the expression of tumor-suppressive miRNAs.  
In Chapter 4, miRNA profiling combined with reactivation using 5-Aza-CdR, rendered a 
substantial increase of miRNA expression in the cell lines tested. Although this approach is 
an indirect evidence of miRNA repression by DNA methylation, when combined to miRNA 
profiling in primary PCa and in silico prediction of CpG islands, it enabled the identification of 
multiple miRNAs potentially regulated by DNA methylation. As expected, the reactivation 
profile of each cell line differed for expression and regulation. Nonetheless, the expression 
profiling enabled the discovery of new DNA methylation-regulated miRNAs (e.g., miR-130a) 
and validation of previous findings (e.g., miR-145 or miR-205). Regarding miR-130a, 
although previously implicated in several malignancies, its regulation in PCa was never 
dissected. Our data showed that miR-130a is a bona fide tumor-suppressor miRNA and its 
downregulation is both associated with promoter hypermethylation and a repressive histone 
mark enrichment (H3K27me3).  
As DNA methylation is an appropriate indicator for regulatory activity, we aimed to discover 
new miRNA loci targeted for aberrant DNA methylation patterns in primary PCa (Chapter 5). 
The Infinium HumanMethylation450 bead array generated a methylome of 51 miRNA (42 
hypermethylated and 9 hypomethylated). This approach had the advantage to map, in 
clinical prostate tissue samples, miRNAs regulated by DNA methylation, regardless of 
expression status. The validation of this approach was accomplished by the identification of 
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previously reported hypermethylated miRNAs: miR-34b/c, miR-193b and the cluster miR-
27b~23b~24. The data analysis rendered the identification of a new cluster regulated by 
promoter methylation: miR-130b~301b. 
Nonetheless, the intersection between the miRNAs determined as downregulated in Chapter 
4 and those found as hypermethylated in Chapter 5, was rather limited. Indeed, in Chapter 6, 
only miR-10a, miR-23b, miR-27b, miR-34c, miR-152, and miR-335 fulfilled the criteria above 
mentioned. MiR-152 (and its hostgene COPZ2) was found to be at partially regulated by 
5mC, as its expression was restored upon 5-Aza-CdR in both LNCaP and PC3 cell lines 
associated with significantly decreased DNA methylation levels.  
The identification of miRNAs’ functional alterations greatly benefited from the combination of 
comprehensive integration of high-resolution profiling techniques, both at expression and 
regulatory levels (e.g., DNA methylation). Indeed, our data demonstrates that, in PCa, 
miRNAs’ global downregulation is a multilayered controlled process: epigenetic alterations 
impair primary miRNA (pri-miRNA) transcription, the decreased expression of DROSHA and 
DGCR8 (the Microprocessor complex) apparently is associated with defective pre-miRNA 
generation in the nucleus, and ultimately, diminished DICER indicates that cytoplasmic pre-
miRNA processing to generate mature miRNAs is also impaired. Overall, these findings 
highlight the importance of miRNA deregulation in PCa and indicate that miRNA expression 
profile is the most suitable method to identify deregulated miRNA, rather than interrogating 
alterations in regulatory elements, such as promoter DNA methylation.  
 
The functional impact of microRNA downregulation in PCa 
In addition to discover new miRNA downregulated in PCa, it was also our goal to uncover 
molecular pathways targeted by miRNAs deregulation that might decisively contribute for 
prostate tumorigenesis. In Chapter 4, miR-130a was selected for further analysis, whereas in 
Chapter 5, cluster miR-130b~301b’s role was addressed. Strikingly, these miRNAs are 
members of the same highly conserved miRNA family: miR-130. Both share the same seed 
sequence (AGUGCAA) and are, thus, expected to target the same pathways and have 
affinity for common targets (28). This reinforces the network-regulating roles of these 
miRNAs. MiRNAs from the same family often target the same or similar subsets of genes or 
the same pathway or process. These observations are supported by previously reported 
polycistronic miRNAs and /or family-related miRNAs that control critical pathways such as 
epithelial-to-mesenchymal transition (EMT) (suppressed by the two polycistronic genes that 
encode the five members of the miR-200 family) (77, 78) or EMT and metastasis activation 
by the coordinated actions of miR-96, miR-182 and miR-183 (79).  
Due to the capacity of miRNAs to control multiple-target genes, they are emerging as 
regulators of the hallmarks of cancer (33). Both miR-130a and the cluster miR-130b~301b 
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were found to be functionally relevant for PCa development, functioning as tumor-suppressor 
miRNAs. Indeed, these miRNAs proved to reduce cell viability, induce cell death by 
apoptosis and impair invasion ability. MiR-130a and cluster miR-130b~301b have already 
been implicated in multiple cancers, both as onco-miRNAs or tumor-suppressive miRNAs. 
MiRNAs may, indeed, have different, or even opposite, functional outcomes in different 
contexts. These discrepancies likely reflect the differential expression of target genes 
between tissues and serve both as a reminder of the complexity associated with miRNAs 
and as a cautionary note for the rigid assignment of any given miRNA to one specific role or 
function (80). 
As miR-130a and cluster miR-130b~301b are parolog miRNAs, the data presented in this 
Thesis suggests a functional specialization and cooperation that may coexist among 
members of the same family. The phenotypic impact of each miRNA is very similar, however, 
each miRNA had the ability to trigger different signaling pathways. It is worth to mention that, 
due to the seed sequence similarity in a given miRNA family, it is expected that the miRNAs 
from the same cluster might also have additional specific targets, as a result of other base 
parings determinants besides seed-sequence. In a cooperative network, restoration of both 
any parolog miRNA will ultimately have the same functional impact (80). Nonetheless, we 
showed that the magnitude of fold change differs, and in common genes tested in both 
Chapter 4 and Chapter 5, there was a different gene expression modulation, reinforcing the 
functional specialization of each miRNA. Moreover, miRNA activity is cell-type specific, as 
described for the endogenous inhibition and functional output of each miRNA in the different 
cell lines tested in Chapter 5. Overall, it is clear that miRNAs exert their effects in the context 
of complex regulatory networks. 
Although in Chapter 4, specific targets for miR-130a were found (among which SEC23b and 
DEPDC1 were validated), the genome-wide data following pre-miR-130a overexpression, 
revealed a large number of genes upregulated upon transfection. In Chapter 5, some of 
these genes were also validated showing the same trend (e.g. MMP1, MMP10). Thus, 
restoration of miR-130a, miR-130b or miR-301b significantly increased the expression of 
genes acting as checkpoint sensors needed for tumour-suppression. Moreover, the 
simultaneous miRNA targeting of multiple genes may facilitate specific fine-tuning through 
the regulation of distinct pathways (80). Nonetheless, indirect effects caused by miRNA 
deregulation are also observed, as miRNAs can initiate indirect effects on gene expression 
through the downstream activities of miRNA-targeted transcription factors (80, 81). Most 
changes in mRNA level after miRNA manipulation may actually be due to altered 
transcription and not as direct transcript-destabilizing effects of miRNAs per se (81). This is 
well documented for miR-200 family concerning repression of the master EMT regulators 
ZEB1 and SNAIL1 (82). 
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Whether these alterations are a direct measure of miRNA-mRNA interactions in the 5’UTR or 
promoter (83), or the naive output of tumor-suppression activities, it is still unclear. 
Furthermore it is tempting to speculate that miRNAs might interact with other regulatory 
elements and, consequently, enhance transcription or translation of those genes (83). 
Globally, many miRNAs have evolved not acting as genetic switches of specific pathways or 
individual targets, but rather as modulating the expression of large gene networks (47).  
One major finding of this Thesis was ability of these parolog miRNAs to induce growth and 
stable cell cycle arrest by cellular senescence. Senescence may counteract tumor formation 
in different contexts and tissues (84). This biological phenomenon causes a permanent cell 
proliferation arrest as a strategy to prevent genomic instability (85). Senescence is induced 
by multiple mechanisms, such as progressive shortening of telomeres during cellular 
replication and DNA damage. Senescent cells are characterized by expression of a diversity 
of indicators that reveal irreversible proliferation arrest, including an increase in cell size and 
a more flattened shape, increased levels of p53 and of the cell cycle inhibitors CDKN2A 
(p16), CDKN1A (p21) and CDKN1B (p27) or Lamin B1 downregulation (86, 87). However, 
the senescent phenotype was more evident when miR-130b or miR-301b were modulated. 
The genome-wide study depicted in Chapter 4, demonstrated that miR-130a overexpression 
induced secretion of a diversity of growth factors, cytokines, and proteases, known to be part 
of the senescence-associated secretory phenotype (SASP). SASP seems to be a common 
feature of different types of cellular senescence responses that in oncogene-induced 
senescence (OIS) is regulated by persistent DDR (88, 89). Indeed, in Chapter 5 it was 
demonstrated that both senescence and SASP are related with DNA damage. 
Induction of SASP markers by miR-130b or miR-301b was more impressive than that by 
miR-130a. SASP can act non-cell autonomously to suppress tumorigenesis by promoting an 
antitumor microenvironment, in part through secreted factors that modulate prostate immune 
response (90). Overall, it may be assumed that miR-130b and miR-301b regulate DDR and 
may, thus, mediate OIS. Nonetheless, other types of senescence responses present display 
SASP in the absence of DDR, suggesting additional mechanisms for SASP regulation (91), 
such as NF-KB (92) or STAT3. SASP factors have been reported to reinforce the 
senescence program (93) and, tumor clearance (94) in an autocrine manner and to promote 
aggressiveness in a paracrine mode (95). SASP factors can also promote immune 
surveillance of senescent cells, leading to its elimination both from tumors and normal 
tissues (94, 96). Nevertheless, the impact of SASP on cancer initiation and progression is 
still controversial, and several studies strongly suggest that, at least in some contexts, SASP 
may fuel inflammation and exert pro-proliferative activity, thus contributing to tumorigenesis 
(97). Overexpression of those parolog miRNAs induces alterations in SASP factors, such as 
IL1A, IL6 or MMP1. Overall, these findings supports that miR-130a, miR-130b or miR-301b 
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overexpression induces autocrine SASP signaling, whereas endogenous blocking of these 
miRNAs is possibly involved in paracrine signaling. This observation is based on a slight 
increased expression of IL1A, IL1B, and IL6. Therefore, cellular senescence constitutes a 
barrier against tumor progression but, if senescent cells are not quickly removed, they may 
become deleterious because different SASP signaling may reinforce tumorigenesis (86).  
Thus, cluster miR-130b~301b seems to be intimately associated to senescence by 
controlling DNA damage response-related genes, but miR-130a might have a broader action. 
The miR-130a target SEC23B is involved is endoplasmic reticulum (ER)-stress response, a 
form of stress caused by the accumulation of unfolded proteins in the ER. The ER-stress 
may induce multiple adaptive mechanisms that constitute the Unfolded Protein Response 
(UPR). UPR activation is able to restore protein-folding homeostasis. However, in case of 
severe impairment, UPR signaling triggers cell death by apoptosis. Interestingly, not only 
miR-130a overexpression increased apoptotic levels, but also SEC23B knockout increased 
the apoptosis rate in PC3 cells. These observations suggest that inactivation of miR-130a 
circumvents apoptosis induction by ER-stress, due to the upregulation of SEC23B.  
Interestingly, sustained UPR activation in response to continued ER-stress causes death of 
premalignant cells to prevent neoplastic progression (98). For instance, HRAS induces UPR-
mediated cell senescence in premalignant cells (99). It would be a selective advantage for 
malignant PCa cells harboring miRNA alterations (e.g., miR-130a) that suppress UPR-
induced apoptosis or senescence.  
Lastly, it has been showed that induction of senescence by LMNB1 depletion in human 
diploid fibroblasts (HDFs) triggers large-scale the formation of chromatin domains enriched 
for H3K4me3 and H3K27me3 (termed mesas) and depleted for H3K27me3 (entitled 
canyons) in senescent HDFs (100). These were correlated with the expression of key 
senescence-associated genes (100). It was also detected a redistribution of LMNB1 along 
the genome: LMNB1 is specially reduced from regions enriched for H3K9me3 rather than 
H3K27me3, but there are small regions (~2% of the genome) where LMNB1 accumulates 
(101). Genes within these LMNB1-increased regions, which include some cell cycle genes, 
tend to be repressed during senescence, with increased H3K27me3 across the gene bodies. 
LMNB1 reduction (particularly from H3K9me3 regions) and spatial repositioning of 
perinuclear heterochromatin (H3K9me3-enriched) and SAHF formation (101). Overall, these 
studies suggest that alteration of LMNB1 might also contribute to senescence through gene 
regulation in some specific regions. Thus, the cluster miR-130b~miR-301b may act as an 
indirect player in the regulation of chromatin in prostate cells, as it overexpression causes 
LMNB1 downregulation and might trigger LMNB1-mediated chromatin reorganization. 
In Chapter 6, restoration of miR-152 was shown to attenuate the malignant phenotype in 
both LNCaP (Androgen Receptor (AR) sensitive) and PC3 (AR castration resistant) cells. 
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Moreover, TCGA data analysis confirmed that this miRNA is downregulated in primary PCa. 
The most persistent effect of miR-152 restoration was the ability to control cell cycle 
progression in the two cell lines tested. Indeed, miR-152 induced cell cycle arrest in two 
different checkpoints: S and G2/M. This indicates that miR-152 may control same signaling 
pathways depending on the cellular and molecular context. As previously demonstrated, the 
miR-152’s overexpression caused a significant attenuation of the PCa cells malignant 
phenotype: decreased invasion and augmented apoptosis levels. Interestingly, a specific 
target of miR-152 was found, TMEM97, a conserved integral membrane protein.  
Cumulatively, there is a co‑ regulation of common biological processes by different miRNAs 
in PCa (47). 
Overall, the data gathered in this Thesis demonstrates that miRNAs occupy a very particular 
position in the hierarchy of gene regulation. In contrast to the diversity of transcription factors 
and genetic switches, miRNAs in most cases do not seem to act as major regulators of gene 
expression. Their mechanism of action allows them to act as fine tuners of transcriptional 
networks, and as ‘post-transcriptional buffers’ that, ultimately, present robustness to 
transcriptional programs in the face of environmental and genomic variability (39).  
 
MicroRNAs promoter methylation as potential biomarker for PCa 
Finally, the last topic addressed in this Thesis was the potential of miRNA deregulation to be 
translated into clinical application. DNA methylation data gathered in Chapter 7 was then 
used for development of novel PCa biomarkers, instead of miRNA expression levels, as 
previously attempted by others [91-93]. Indeed, DNA methylation is easier to assess than 
miRNA expression, not only because it is more specific, but, importantly, because it is more 
stable. In fact, DNA methylation analysis uncovered valuable detection biomarkers for this 
disease, based on protein coding genes such as GSTP1, APC, RARβ2 and RASSF1A [69]. 
We attempted to extend these observations for miRNAs. Thus, from methylation-array 
analysis, six miRNAs loci emerged as promising candidates and were further tested. MiR-
34b/c, miR-193b and miR-1258 showed very high sensitivity, specificity and accuracy in 
tissue samples. Additionally, they demonstrated significant PCa-specificity compared with 
other tumors from the urinary tract, a feature that would make it the most promising 
candidate to be tested in bodily fluids. Indeed, urine samples analysis entails a huge 
potential for clinical implementation. It is minimally-invasive clinical material in which 
biomarkers are diluted to a smaller extent than in plasma, providing higher sensitivity. In a 
cohort composed of healthy donors and patients harboring PCa, miR-193b displayed the 
best results in this assessment, with high area under the curve (AUC), sensitivity, specificity 
and positive predictive value (PPV), whereas miR-34b/c performance was modest. Of note, 
the urine samples utilized were not collected following digital rectal examination (DRE) or 
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prostatic massage, which are usually employed in an attempt to yield a more representative 
sample to increase sensitivity. MiR-34b/c and miR-193b showed higher methylation levels in 
urine samples from PCa patients, as would be expected, showing better results than GSTP1, 
RARβ2 and APC. GSTP1, RARβ2 and APC promoter methylation levels assessed in urine 
samples collected after DRE showed deceptive performance as biomarkers for PCa 
detection (AUCs varied from 0.63 to 0.68) (102). In another study using urine samples 
following prostatic massage, Rouprêt et al. assessed methylation levels of several genes. Of 
these GSTP1, RASSF1A, APC and RARβ2 were those that best discriminated malignant 
from non-malignant cases, with AUC values ranging from 0.74 to 0.86. The combination of 
these four genes yielded the greatest discriminatory power of 86% sensitivity and 89% 
overall accuracy [101].  
Moreover, when compared to serum PSA and urinary PCA3, the performance of miR-193b is 
far better. The performance of serum PSA as PCa biomarker is rather modest, displaying 
AUC ranging from 0.54 to 0.70 [53, 100]. PCA3, which is currently the most widely used non-
PSA based first-line test, performed better than serum PSA, both in urine and ejaculates, 
with AUC varying from 0.66 to 0.79 [53, 100, 102, 103]. These data emphasize that miR-
193b performance compares well with those two PCa biomarkers and might constitute a 
promising tool for early non-invasive detection of PCa. Essentially, the diagnostic 
performance of miR-193b in urine compares positively with the abovementioned biomarkers, 
but it is mandatory to test it in larger and independent datasets.  
Strikingly, miR-130a promoter methylation was also found to be a specific PCa biomarker 
(Chapter 4). Although performance was not as good as in tissue samples, PCa was correctly 
identified with 83.5% sensitivity and 82.3 % specificity (AUC= 0.89) in urine. However, this 
performance is rather limited when compared with miR-193b promoter methylation levels, 
although larger cohorts of urine samples or performing prostatic massage before collection 
might increase the detection potential of this miRNA. 
Because miR-129-2 higher promoter methylation levels associated with higher Gleason 
score and stage and miR-34b/c correlated with pathological stage, a putative prognostic role 
was investigated. The major objective was to discriminate clinically aggressive from indolent 
PCa, and to test the prognostic value of the miRNAs in a pre-therapeutic setting, using 
prostatic biopsies.  
In a cohort 180 radical prostatectomy pathological stage, Gleason score and PSA levels 
significantly associated with DFS, whereas, only pathological stage and higher GS 
statistically associated with worse DSS. Remarkably, high miR-129-2 methylation levels 
associated with shorter DSS. In multivariable analysis, only GS and PSA levels for DFS and 
GS and miR-129-2 methylation for DSS retained prognostic value.  
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In a prospective group of 74 PCa suspects – cohort 2 - advanced clinical stage, higher GS, 
higher miR-34b/c and miR-129-2 promoter methylation levels statistically associated with 
worse DFS. In multivariable analysis only higher clinical stage and high miR-34b/c promoter 
methylation levels independently predicted shorter DFS. Except for serum PSA, all 
clinicopathological parameters tested, as well as miR-34b/c and miR-129-2 promoter 
methylation levels associated with DSS in univariable analysis. Similarly to DFS, in 
multivariable analysis only clinical stage and high miR-34b/c promoter methylation levels 
independently predicted shorter DSS. Interestingly, in the radical prostatectomies series 
higher miR-129-2 methylation presented independent prognostic information, although only 
for DSS. Importantly, support previous observations concerning the association of higher 
gene promoter methylation levels with clinicopathological features of more aggressive 
disease. 
Nonetheless, the major goal was to classify clinically aggressive from indolent PCa, in a pre-
therapeutic set. In univariable analysis, the standard clinicopathological parameters 
associated with DFS and DSS, clinically validating this dataset. The same was demonstrated 
for higher miR-129-2 and miR-34b/c promoter methylation levels. The fact that CAPRA score 
failed to predict DFS might be intimately related to the heterogeneity of prostate biopsy 
series included PCa at diverse clinical stages, subjected to different therapeutic approaches 
(RP, radiotherapy, androgen-deprivation therapy).   
However, in multivariable analysis, only clinical stage retained independent prognostic value, 
both for DFS and DSS. Curiously, high miR-34b/c promoter methylation levels also predicted 
shorter DFS and DSS, suggesting that it might constitute a useful PCa prognostic biomarker. 
These results indicate that high miR-34b/c promoter methylation levels identify clinically 
aggressive PCa, irrespective of disease extent at diagnosis. 
However, the validation in additional independent cohorts it is still required. To ascertain the 
real value of miR-193b, miR-129-2 and miR-34b/c as new and powerful biomarkers for PCa. 
If a multiplex assay capable to simultaneously assess miR-193b, miR-129-2 and miR34b/c 
promoter methylation is designed and validated, this would allow for diagnostic and 
prognosis assessment of PCa suspects in a single analysis.  
Finally, in Chapter 6 we found that TMEM97 expression levels (>75 percentile) 
independently predicted shorter DFS. Although, miR-152 methylation or expression levels 
did not associate with patients’ prognosis, this suggests TMEM97 as a useful biomarker for 
PCa management, being as well a potential therapeutic target for PCa. Further studies are 
required to further confirm the function and the prognostic value of TMEM97 in PCa patients.  
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CHAPTER 9 - MAIN CONCLUSIONS  
 
 
Conclusions 
In the previous sections, it was attempted to outline a coherent sequence of the rationale and 
the main findings of this Doctoral Thesis, integrating them with earlier and later published 
results in this research area. Therefore, the conclusions of this Thesis are both depicted in 
each manuscript and then integrated in the General Discussion. Nonetheless, and taking the 
risk of being redundant by enumerating the main conclusions, it seems to be important to 
provide a synopsis of the background behind this Doctoral Thesis. 
 
Consequently, the main conclusions of this Doctoral Thesis are summarized in this section: 
 
1 – Prostate Carcinomas and Morphological Normal Prostate Tissues have distinct miRNA 
profiling, towards a global down-regulation of miRNAs in Prostate tumours; 
2 – The global miRNAs down-regulation is a multilayer process, resulting of both decreased 
expression of the core miRNA’ biogenesis machinery – DROSHA, DGCR8 and DICER - and 
aberrations in the epigenetic landscape; 
3 – Prostate malignancies show distinct DNA methylation dynamics causing alterations in the 
expression of miRNAs; 
4 – In vitro reversal of DNA methylation dramatically restores the global expression of the 
miRNAnome; 
5 – DNA methylation contributes to the silencing of newly discovered PCa tumor-suppressor 
miRNAs: miR-130a, miR-130b~301b, and miR-152; 
6 – MiR-130a targets the proto-oncogenes SEC23B and DEPDC1, whose loss of function 
phenotype overlaps miR-130a over-expression; 
7 – MiR-130a fine-tunes multiple signaling pathways, including DNA apoptosis, cell cycle, 
cell migration and the response to endoplasmic reticulum stress; 
8 - MiR-130a methylation levels discriminated PCa from non-malignant tissues (AUC=0.956) 
and its assessment urine samples showed high specificity for PCa detection (AUC=0.89); 
9 - MiR-130b~301b restoration significantly reduces malignant phenotype, by arresting the 
cells at S phase (both miR-130b and miR-301b), or at G2/M arrest (miR-130b) and promotes 
mesenchymal to epithelial transition; 
10 – Overexpression of cluster miR-130b~301b causes senescence bypass, repressing Ki67 
and LMNB1 or overexpressing of CDKN1A, CDKN1B, CDKN2A, and CDKN2B; 
11 – The cluster miR-130b~301b dramatically fosters the secretome of senescent cells, 
known as SASP; 
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12 - The cluster miR-130b~301b induces DNA damage and DNA-Damage-Inducible 
Transcripts (DDIT3, DDIT4, GADD45A, or ATR); 
13 – MiR-130b and miR-301b are part of a complex signaling network that in PCa causes 
DNA damage and, subsequently, senescence; 
14 – There is a coexistence of functional cooperation and specialization among these 
parolog miRNAs, identifying miR-130a as multiple pathways fine tuner, whereas cluster miR-
130b-301b is implicated in DNA damage and senescence; 
15 – MiR-152 and its host gene COPZ2 are downregulated and hypermethylated in Prostate 
tumours; 
16 - MiR-152 attenuates malignant phenotype of PCa cells, mainly by triggering cell cycle 
arrest in S and G2/M checkpoints; 
17 – MiRNAs do not only exhibit cell-specific activity but also can generate thresholds in 
target gene expression and mediate feed-forward and feedback loops in gene networks; 
18 - MiR-193b was shown to be a very promising diagnostic biomarker in a urinary test for 
early detection of PCa (AUC 0.96; 91.6% sensitivity and 95.7% specificity); 
19 – Higher miR-129-2 methylation levels independently predicted for shorter DSS in radical 
prostatectomy specimens; 
20 - miR-34b/c and miR-129-2 promoter methylation levels associated with DSS in 
univariable analysis in prospective group of 74 PCa suspects; 
21 - High miR-34b/c or miR-129-2 promoter methylation define subsets of clinically 
aggressive tumors.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART IV - FUTURE PERSPECTIVES 
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Future perspectives 
The rapid discovery of ncRNA species by high-throughput technologies has accelerated 
current conceptions of transcriptome complexity. MiRNAs are the most well characterized 
family of ncRNAs widely recognized and defined as critical actors of numerous cellular 
processes. The clinical translation of some miRNAs might be related with its usefulness for 
PCa biomarker development, and, in the future, RNA-based therapies may be a feasible 
alternative in clinical oncology.  
Although this Thesis provides a mechanistic view of how miRNA deregulation promote PCa 
progression, and their eventual clinical potential, there are some interesting questions and 
hypothesis that derived from these results. 
 
The role of the prostate microenvironment in microRNA homeostasis 
Androgens are a male sex steroid hormone that binds to and activates the androgen 
receptor. In addition to epigenetic and miRNA machinery biogenesis aberrations, studies on 
the impact of AR in the miRNA regulation may contribute to a broader understanding of how 
miRNAs become deregulated in prostate carcinogenesis. Moreover, it would be of great 
interest to investigate the function of AR in miRNA regulation and its synergistic role in the 
establishment of the of CRPC phenotype. Since miRNAs might be implicated in a diverse 
range of resistance mechanisms in CRPC, it might present new options for disease 
management. Thus, combining miRNA-based therapeutics with classical drugs such as 
abiraterone and enzalutamide might be envisaged.  
 
Use of miRNAs in the clinic as diagnostic/prognostic tools for PCa  
DNA methylation is easier to assess than miRNA expression: it is more specific and, 
importantly, more stable. This Thesis revealed that quantitative assays for specific miRNA 
promoter methylation (miR-193b and miR-129-2) might constitute important diagnostic and 
prognostic ancillary tools for clinical decision making. To further confirm these results, 
additional studies, preferably involving multi-institutional cohorts of patients, are required.  
Additionally, liquid biopsies might be used for detection, monitoring or prognostication of 
PCa, using extracellular nucleic acids, primarily by exosomes isolation from patients’ 
peripheral blood or/and urine. MiRNAs in extracellular vesicles or stably bound to proteins in 
patient biofluids opens unique possibilities for using such circulating RNAs as easily 
accessible molecular biomarkers. The main question is whether DNA or RNA is the most 
suitable template for clinical use. The development of such tests requires an extensive 
characterization of the miRNA and DNA methylation profile in these liquid biopsies coupled 
with high-throughput next-generation sequencing techniques to unravel the complete 
exosomal small RNA landscape.  
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Opportunities and challenges for microRNA-based therapeutics  
Deregulation of miRNAs’ activity has been frequently implicated in the development and 
progression of PCa, thus constituting attractive molecules for drug discovery. Conventional 
PCa therapy is generally unsuccessful at advanced stages of disease. An alternative 
strategy would be miRNA modulation by using oligonucleotides that can either mimic a 
miRNA (thus, inducing gene silencing), or bind to a target miRNA (thus, blocking it intrinsic 
activity). An example of this strategy to restore the tumor-suppressor miRNA-34 is using the 
liposome-based miR-34a mimic (MRX34) (103). This MRX34 is currently in Phase I clinical 
trials to test its safety for patients with primary liver cancer or liver metastasis 
(NCT01829971), as well as pharmacodynamics and pharmacokinetics of the liposomal 
injection in Melanoma patients (NCT02862145). In this Doctoral Thesis some miRNAs 
emerged as having growth suppressive activities. It would be interesting to test in vivo 
whether any of these miRNAs retain such tumor-suppressor capabilities. However, delivery 
of oligonucleotides to patients or animal models is an obstacle. Nonetheless, this can be 
partially overcome by encapsulation in liposomes or polymer-based nanoparticles and 
through addition of chemical modifications. Following determination of which alteration is 
more likely to render full activity for these miRNAs, in vivo experiments may be conducted. 
Moreover, combining any of these miRNAs with other chemical compounds may prove 
greater efficacy to target PCa.  
A major drawback of miRNA-based therapeutics is hybridization-associated off-target effects. 
The lack of target specificity and the potential off-target effects of miRNA therapeutics are a 
major concern, as they may cause toxic phenotypes. Thus, it will be critical to evaluate the 
full range of effects of miRNA manipulation at the transcriptomic and proteomic level in vivo 
to limit the eventual damaging effects of miRNA-based therapeutics.  
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